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Abstract 
The human skin surface is covered with a lipid film that forms the interface between the viable 
epidermal layers and outer environment, and influences the colonisation of bacteria. Hydrolysis 
of the epidermal lipid ceramide via ceramidase yields sphingosine, an antimicrobial lipid that is 
able to kill staphylococci rapidly. Studies of patients with atopic dermatitis have indicated a 
correlation between levels of sphingosine and S. aureus colonisation of human skin, yet the 
contribution of sphingosine to the composition of the human skin microbiome and microbiota 
colonisation is unclear. This study investigates the effect of the host epidermal antimicrobial 
lipid D-sphingosine on S. aureus and S. epidermidis, with a focus on discovering components that 
contribute to survival of the former. 
The methods RNA-Seq and qPCR were used to dissect the transcriptional responses of S. aureus 
Newman and S. epidermidis Tü3298 after challenge with D-sphingosine. S. aureus displayed a 
large set of differentially expressed genes (1331), which contrasted with a smaller set for S. 
epidermidis (340). There was a clearly defined stimulon that was common between the species 
that included pathways for energy maintenance, amino acid and ion transport and metabolism, 
and protein repair. Previously reported transcriptomic responses to multiple cell wall and 
membrane-targeting antimicrobials shared commonalities with the response to sphingosine 
that supports its reported mode of action at the cell surface with membrane damage.  The VraSR 
cell wall stress stimulon was upregulated in both species.   
Each species displayed pronounced upregulation of a putative phosphate-specific ABC 
transporter system encoded by the pstS-pstCAB operons.  Experiments identified a contribution 
of this transport system to sphingosine survival and phosphate supplementation was shown to 
markedly increase sphingosine survival. 
Previous studies by the Horsburgh group identified experimentally evolved S. aureus strains 
with high levels of D-sphingosine resistance after serial passage with increasing concentrations 
of the lipid. SNPs associated with increased resistance were determined by genome 
resequencing and some of these were localised to the farER genes encoding a FarR-regulated 
FarE (mmpL) lipid efflux transporter. An isogenic farR SNP mutant of S. aureus was generated 
using molecular genetics approaches and showed a 10-fold higher MIC for D-sphingosine 
compared with the wild type Newman strain, indicating that the purported FarER fatty acid 
efflux system may have the capacity to mediate transport of sphingosine.  The study findings of a 
link between sphingosine challenge and phosphate metabolism indicates future research 
potential to study host spingosine-1-phosphate in staphylococcal lifecycles, during health and 
disease. 
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Chapter 1: Introduction 
 
1.1 Staphylococci 
Species of the genus Staphylococcus are Gram-positive cocci, which are non-
flagellate, non-motile, and non-spore forming, facultative anaerobes (Ray, 2004). 
There are at least 40 recognised species of staphylococci, of which S. aureus and 
S. intermedius are coagulase-positive, with the remainder being coagulase-
negative (Foster, 1996). Most species of staphylococci are harmless colonisers 
of the skin and mucosa of human and other mammals and birds (Cogen et al., 
2008; Costello et al., 2009; Taylor et al., 2003; Nagase et al., 2002). More than 
one dozen species are frequent colonisers of humans, including the coagulase-
negative S. epidermidis, S. capitis, S. cohnii, S. haemolyticus, S. hominis, S. 
saprophyticus, S. simulans, S. warneri and S. xylosus (Kloos and Schleifer, 1975; 
Kloos and Musselwhite, 1975; Coates et al., 2014). In contrast, the coagulase-
positive S. aureus is a transient skin coloniser (Kluytmans and Wertheim, 2005; 
Moss and Squire, 1948; Cho et al., 2010). 
 
1.1.1 Staphylococcus aureus 
Staphylococci that secrete coagulase to clot blood are associated with disease 
(Kloos and Musselwhite, 1975) and the coagulase-positive S. aureus is an 
important human pathogen. The species name aureus was assigned due to the 
golden colour it produces when grown on solid media, while the coagulase-
negative (CoNS) species such as S. epidermidis, S. capitis, and S. hominis, form 
translucent, white to pale yellow colonies (Howard and Kloos, 1987).  
S. aureus has a protective cell wall ~20-40 nm thick that is relatively amorphous 
in appearance (Shockman and Barrett, 1983). Peptidoglycan together with 
teichoic acids makes up 90% of the cell wall mass (Knox and Wicken, 1973, 
Waldvogel, 1990). Teichoic acids bind to the peptidoglycan covalently or insert 
in the lipid bacterial membrane and provide a negative charge for the 
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staphylococcal cell surface, which assists in the acquisition and localization of 
cations as well as autolytic enzyme activities (Wilkinson, 1997). The remaining 
10% cell wall mass is composed of peptidoglycan hydrolases (autolysins), 
surface proteins and exoproteins, some of which are virulence determinants. 
This integral tight multi-layered cell wall network contributes to withstanding 
environmental challenges, such as osmotic pressure (Wilkinson, 1997). Over 90% 
of clinical strains of S. aureus are found to produce polysaccharide (poly-β-1,6-
N-acetyl-d-glucosamine) that protect bacteria from phagocytosis, in addition to 
capsular polysaccharide that is more variably produced by strains (Thakker et 
al., 1998). Adhesins with specificity for a range of host components, including 
fibrinogen, fibronectin, vitronectin, collagen and laminin are expressed on the S. 
aureus surface (Foster and McDevitt, 1994). These cell wall-associated surface 
proteins play a key role in S. aureus attachment to plasma and extracellular 
matrix (ECM) proteins. 
The most important site of S. aureus colonisation is the nose (Williams, 1963), 
which is considered its primary niche, though it can also be found in the 
perineum, axillae, pharynx and on the skin (especially on the hands, chest and 
abdomen where it is considered to be a transient member of the skin flora) 
(Wertheim et al., 2005). S. aureus nasal carriage among the general adult 
population shows global variation, with the carrier percentage varying from 9.1% 
in Indonesia to 41.7% in French Guiana (Sollid et al., 2013).  
S. aureus can cause local infections of the skin, nose, gastrointestinal tract, 
urethra and vagina (Shulman and Nahmias, 1972). The most frequent pathology 
of S. aureus is an abscess lesion when it enters the underlying tissue of the 
human body (Elek, 1956), which will cause septicaemia if it reaches the blood or 
lymphatic channels (Waldvogel, 1990). A range of extracellular toxins such as 
enterotoxin A-E, exfoliative toxins A and B, and toxic shock syndrome toxin-1 
(TSST-1) can be produced by S. aureus (Projan and Novick, 1997). TSST-1 is 
responsible for the toxic shock syndrome (TSS) that is commonly associated 
with menstruating women. The exfoliative toxins can cause staphylococcal 
scalded skin syndrome (SSSS) and will damage the epidermal layer of the skin. 
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When enterotoxin is produced in contaminated food its subsequent ingestion 
may cause food poisoning (Howard and Kloos, 1987).  
 
1.1.2 Staphylococcus epidermidis  
Those coagulase-negative staphylococcus species that are normal commensals 
colonise the skin, anterior nares, and ear canals of human. S. epidermidis is the 
best characterised and most frequently isolated Staphylococcus species on skin 
and is isolated from up to 100 % of healthy tested individuals (Foster, 2009; 
Roth and James, 1988). Healthy individuals can possess up to 24 strains of S. 
epidermidis. Approximately 65-90% of all staphylococci isolated from human 
aerobic flora were found to be S. epidermidis, and can survive under desiccation 
stress for long periods. (Nilsson et al. 1998). 
Whilst being a very common skin commensal, S. epidermidis can also be invasive 
and cause hospital-acquired infections. But it is a true opportunistic pathogen, 
as it requires a major breach in the host’s innate defences, which typically 
occurs by colonising in-dwelling medical devices, e.g. catheters or heart valves 
(Uckay et al., 2009). Once attached, the organism produces an 
exopolysaccharide matrix that assists adherence to plastic and cells, and 
contributes to defence against phagocytosis by the host immune system, and 
antibiotics. The biofilm of S. epidermidis consists of cells embedded in this 
extracellular polymer that can be up to 160 μm thick. These disease-causing 
strains of S. epidermidis are now leading pathogens of nosocomial infections 
(Villari et al., 2000). Diagnosis can be difficult since these infections are often 
indolent and chronic with few obvious symptoms, due to the smaller array of 
virulence factors and toxins compared with those produced by S. aureus (Foster, 
1996). 
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1.2 Human skin 
Skin is a vital barrier, resisting penetration by microorganisms and potential 
toxins while retaining moisture and nutrients inside the body (Proksch et al., 
2008; Elias, 2007; Segre, 2006). Resident bacteria of the skin microbiome can 
survive and thrive within this hostile and demanding environment. The 
microbiota, including certain species of staphylococci, bestows a barrier 
function to the host epidermis by competing with overt skin pathogens such as S. 
aureus and inhibiting their colonisation (Cogen et al., 2008).  
 
1.2.1 Structure of human epidermis 
Sebaceous units comprise human epidermis and enable thermoregulation and 
protection activities of the skin. Each unit contains a hair follicle (HF), sebaceous 
gland, and interfollicular epidermis (IFE).  Forming the epidermis, the skin 
layers can be classified into four categories in order of least to most 
differentiated as: basal (stratum basale); spinous (stratum spinosum); granular 
(stratum granulosum); and stratified (stratum corneum) (Figure 1.1) (Candi et 
al., 2005; Proksch et al., 2008). The skin is a continuously self-renewing organ. 
Cell numbers of the skin are maintained due to stem cells that progressively 
differentiate and migrate towards the outermost layer (Segre, 2006). 
Suprabasal cell division occurs during formation of the epidermis. These 
progeny cells differentiate into suprabasal spinous keratinocytes, then granular 
cells and finally corneocytes to complete development of the stratified skin 
structure (Blanpain and Fuchs, 2009).  
Migration of keratinocytes is accompanied by a series of morphological changes, 
such as the round shape changed into flattened or polygonal and the plasma 
membrane becomes permeable (Coates et al., 2014). The majority of changes 
with terminally differentiated keratinocytes occur between the granular layer 
and the stratum corneum (Candi et al., 2005). Development ends with 
enucleation and maturation of a cornified envelope (Rice and Green, 1977). The 
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cornified envelope is a protein layer cross-linked by isopeptide bonds and is 
extremely resistant to common proteolytic enzymes (Proksch et al., 2008).   
 
 
 
Figure 1.1 Structure of human skin. (Coates et al., 2014) 
 
Ceramides and free fatty acids are produced by hydrolysis of phospholipids and 
glucosylceramides released from the lamellar granules (Madison, 2003; Drake 
et al., 2008). These granules are extruded during the transition between the 
granular layer and the stratum corneum. Keratin is bound into tight bundles by 
fillagrin and results in flattening of the keratinocytes (Candi et al., 2005). The 
plasma membrane disintegrates and the cell’s organelles are degraded under 
apoptosis (Candi et al., 2005).  
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The terminally differentiated cells are known as cornified cells or corneocytes 
(Candi et al., 2005; Proksch et al., 2008). Cornified envelope, which is a protein 
layer self-associated by isopeptide bonds, forms beneath the plasma membrane. 
The bonds are so tight as to make this layer resistant to common proteolytic 
enzymes (Proksch et al., 2008). In addition, this cornified envelope is also linked 
to a lipid envelope, which contains ω-hydroxyceramides, via covalent bonds 
(Proksch et al., 2008; Candi et al., 2005; Madison, 2003). The lipid matrix that 
surrounds corneocytes consists of ceramides (45-50 %), cholesterol (25 %), 
free fatty acids (10-15 %) and other lipids (< 5 %) (Madison, 2003), and is 
maintained by non-covalent interaction with intercellular lamellae. This lipid 
matrix forms both gel phase domains, which are highly ordered and relatively 
impermeable, and liquid crystalline phase domains, which are more fluid and 
provide flexibility (Madison, 2003). Corneodesmosomes differ from 
desmosomes that are found in lower layers of the epidermis and bind 
corneocytes together. Proteolytic degradation of corneodesmosome proteins 
results in shedding of the stratum corneum, which is known as desquamation 
(Jonca et al., 2011). The keratinocye cells in the basal layer proliferate at a rate 
matched by the rate of desquamation and a complete turnover occurs every 14 
days (Candi et al., 2005; Roth and James, 1988).   
The stratum corneum extracellular matrix (ECM) comprises mostly skin lipids 
with ceramides, cholesterol and free fatty acids at a ratio of 1:1:1 in a stacked 
bilayer organization (Iwai et al., 2012). This matrix plays an important role in 
tissue organisation, wound healing and ageing (Watt and Fujiwara, 2011). 
 
1.2.2 Human skin microbiome 
As the largest organ of the human body, skin is an ecosystem composed of 1.8 
m2 of diverse habitats, where approximately 102-107 microorganisms can be 
found in every cm2 of human skin (Schroder and Harder, 2006). The skin, being 
an interface with the outside environment, has abundant folds, invaginations 
and specialised niches that support a wide range of microorganisms, including 
bacteria, fungi and viruses (Chiller et al., 2001; Fredricks, 2001; Cogen et al., 
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2008). Most of these microorganisms are harmless or even benefit their host by 
providing vital functions that cannot be expressed by the human genome. 
Symbiotic microorganisms occupy a wide range of skin niches; they can prime 
and educate the skin T cells to respond to similar pathogenic factors and they 
may also assist in protection against invasion of pathogenic or harmful 
organisms through nutrient competition (Grice and Segre, 2011). 
The microenvironment and the variability of skin microbial flora can be 
influenced by host factors such as age (Leyden et al., 1975; Somerville, 1969), 
gender (Marples, 1982; Fierer et al., 2008; Giacomoni et al., 2009), genotype, 
immune system variation (including previous exposures and inflammation), 
pathobiological conditions, such as diabetes, as well as environmental factors 
such as lifestyle, climate and usage of antibiotics. 
Most skin bacteria can be classified into four phyla: Actinobacteria, Firmicutes, 
Bacteroidetes and Proteobacteria, according to metagenomic sequencing of 16S 
ribosomal RNA genes. Actinobacteria represent the dominant colonisers of skin, 
while Firmicutes and Bacteroidetes are more abundant in the gastrointestinal 
tract (Grice and Segre, 2011). 
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Figure 1.2 Topographical distribution of bacteria on skin. (Figure from Grice and Segre, 
2011, data from Grice et al., 2009) 
 
Molecular analysis has indicated that colonisation of bacteria is dependent on 
the physiology of the skin site (Figure 1.2), with taxa being associated with 
moist, dry and sebaceous microenvironments. Temporal variation is also 
dependent on the skin site and the most consistent populations are at sites that 
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are partially occluded, including the external auditory canal (inside the ear), the 
nares (inside the nostril) and the inguinal crease (Grice et al., 2009). The skin 
microbial variation is more dependent on the site than on the individual, since 
intrapersonal variation in microbial community membership and structure 
between symmetric skin sites is less than the interpersonal variation, as 
determined by 16S rRNA gene-based metagenomic sequencing (Gao et al., 2007; 
Grice et al., 2009; Costello et al., 2009).  
 
 
1.3 Staphylococcal skin survival 
The acidic pH, high salt and low moisture conditions of the skin limit bacterial 
colonisation (Roth and James, 1988; Coates et al., 2014). Microbes must firstly 
adhere to the skin to colonise, and must be able to evade components such as 
antimicrobial peptides and antimicrobial lipids of the innate immune system to 
persist on the skin (Coates et al., 2014). Moreover, for microbes to outcompete 
other skin bacteria they have to survive their antimicrobial peptides and target 
them through various mechanisms (Cogen et al., 2008; Cogen et al., 2010a; 
Cogen et al., 2010b). S. epidermidis has a better adaptation to these challenges 
than S. aureus (McEwan et al., 2006; Cho et al., 2001; Melnik, 2006; Ong et al., 
2002; Arikawa et al., 2002; Takigawa et al., 2005; Ishikawa et al., 2010), but 
insufficient information is known about what determinants lead to the 
differences in skin colonisation observed between S. epidermidis and S. aureus.  
  
1.3.1 Colonisation and persistence 
A primary requirement for skin colonisation is to adhere to the flattened, 
cornified keratinocytes, then being able to attach to the new layers before cells 
are shed through desquamation. Adhesins mediate strong attachment to specific 
receptors on the skin and minimise loss (Brooker and Fuller, 1984; Zeeuwen et 
al., 2012; Grice et al., 2009).  
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There are three groups of staphylococcal adhesins: non-proteinaceous adhesin, 
microbial surface components recognising adhesive matrix molecules 
(MSCRAMMs), and secretable expanded repertoire adhesive molecules 
(SERAMs) (Heilmann, 2011). Non-proteinaceous adhesins that are usually 
embedded in the membrane lipids act through non-covalent bonds; MSCRAMMs 
covalently bind the staphylococcal cell wall and adhere to one or more host 
factor; SERAMs non-covalently bind to the staphylococcal surface and provide 
both adhesive and enzymatic functions adhesion (Heilmann et al., 2003; 
Bowden et al., 2002).  
Different adhesins facilitate S. aureus nasal colonisation at distinct stages. The 
non-proteinaceous adhesin, wall teichoic acid (WTA) is found to be important in 
the initial stages of nasal colonisation (Burian et al., 2010a; Burian et al., 2010b; 
Weidenmaier et al., 2004) since WTA mutants with disruption of WTA 
biosynthesis are unable to colonise (Weidenmaier et al., 2008). The MSCRAMMs 
IsdA and ClfB are important in long-term colonisation of the nose (Burian et al., 
2010a; Burian et al., 2010b). 
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Table 1.1 Staphylococcal adhesins with known receptors for skin. (Coates et al., 2014) 
Host receptor Adhesin 
Adhesin 
(abbreviations) 
Species Reference 
Collagen type I 
Collagen adhesin Cna S.aureus (Snodgrass et al., 1999) 
Extracellular adhesive protein/Major histocompatability complex type II 
analog protein 
Eap/Map S.aureus (Hansen et al., 2006) 
Extracellular matrix protein-binding protein Emp S.aureus (Hussain et al., 2001) 
Glycerol ester hydrolase D GehD S.epidermidis (Bowden et al., 2002) 
Serine aspartate repeat family protein F SdrF S.epidermidis (Arrecubiete et al., 2007) 
Serine aspartate repeat family protein I SdrI S.saprophyticus (Sakinc et al., 2006) 
Cytokeratin-10 
Clumping factor B ClfB S.aureus (O’ Brien et al., 2002) 
Iron-regulated surface determinant protein A IsdA S.aureus (Clarke et al., 2009) 
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Table 1.1 Continued 
Host 
receptor 
Adhesin 
Adhesin 
(abbreviations) 
Species Reference 
Fibrinogen 
Autolysin/Adhesin of S. aureus Aaa S.aureus (Heilmann et al., 2005) 
Autolysin Atl S.aureus 
(Hirschhausen et al., 
2010) 
Clumping factor A ClfA S.aureus (McDevitt et al., 1994) 
Clumping factor B ClfB S.aureus (Ni Eidhin et al., 1998) 
Extracellular adhesive protein/Major histocompatability complex type II analog 
protein 
Eap/Map S.aureus (Hussain et al., 2001) 
Extracellular matrix protein-binding protein Emp S.aureus (Hussain et al., 2001) 
Fibrinogen binding protein of S. epidermidis/serine aspartate repeat family 
protein G 
Fbe/SdrG S.epidermidis (Hartford et al., 2001) 
Fibrinogen binding protein of S. lugdunensis Fbl S.lugdunensis (Nilsson et al., 2004) 
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Table 1.1 continued 
Host receptor Adhesin 
Adhesin 
(abbreviations) 
Species Reference 
Fibrinogen 
Fibronectin binding protein A FnbpA/FnbA S.aureus (Wann et al., 2000) 
Fibronectin binding protein B FnbpB/FnbB S.aureus (Burke et al., 2011) 
Iron-regulated surface determinant protein A IsdA S.aureus (Clarke et al., 2004) 
Uro-adherence factor  UafB S.saprophyticus (King et al., 2011) 
Fibronectin 
Autolysin/Adhesin of S. aureus Aaa S.aureus (Heilmann et al., 2005) 
Autolysin/adhesin of S. epidermidis Aae S.epidermidis (Heilmann et al., 2003) 
Autolysin/adhesin of S. saprophyticus Aas S.saprophyticus (Hell et al., 1998) 
Autolysin Atl S.aureus (Hirschhausen et al., 2010) 
 
 
 
 
14 
 
Table 1.1 Continued 
Host receptor Adhesin 
Adhesin 
(abbreviations) 
Species Reference 
Fibronectin 
Autolysin of S. caprae AtlC S.caprae (Allignet et al., 2002) 
Extracellular adhesive protein/Major histocompatability complex type II analog 
protein 
Eap/Map S.aureus (Hussain et al., 2001) 
Extracellular matrix binding protein Embp S.epidermidis (Williams et al., 2002) 
Extracellular matrix protein-binding protein Emp S.aureus (Hussain et al., 2001) 
Fibrinogen binding protein of S. epidermidis/serine aspartate repeat family 
protein G 
Fbe/SdrG S.epidermidis (Nilsson et al., 1998) 
Fibronectin binding protein A FnbpA/FnbA S.aureus (Flock et al., 1987) 
Fibronectin binding protein B FnbpB/FnbB S.aureus (Jonsson et al., 1991) 
Iron-regulated surface determinant protein A IsdA S.aureus (Clarke et al., 2004) 
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Table 1.1 continued 
Host receptor Adhesin 
Adhesin 
(abbreviations) 
Species Reference 
Fibronectin 
Serine aspartate repeat family protein I SdrI S.saprophyticus (Sakinc et al., 200) 
Uro-adherence factor  UafB S.saprophyticus (King et al., 2011) 
Involucrin Iron-regulated surface determinant protein A IsdA S.aureus (Clarke et al., 2009) 
Keratinocyte lipids/glycolipis Plasmin sensitive protein Pls S.aureus (Huesca et al., 2002) 
Loricrin 
Clumping factor B ClfB S.aureus (Mulcahy et al., 2012) 
Iron-regulated surface determinant protein A IsdA S.aureus (Clarke et al., 2009) 
Undetermined receptor on 
desquamated epithelial cell  
Accumulation associated protein Aap S.epidermidis (Macintosh et al., 2009) 
Undetermined receptor on 
desquamated nasal cells 
Clumping factor B ClfB S.aureus (Corrigan et al., 2009) 
Iron-regulated surface determinant protein A IsdA S.aureus (Corrigan et al., 2009) 
 
 
 
16 
 
Table 1.1 continued 
Host receptor Adhesin Adhesin(abbreviations) 
Speci
es 
Reference 
Undetermined receptor on 
keratinocyte cell line 
Serine aspartate repeat family protein C SdrC 
S.aure
us 
(Corrigan et al., 2009) 
Serine aspartate repeat family protein D SdrD 
S.aure
us 
(Corrigan et al., 2009) 
Serine aspartate repeat family protein G SasG 
S.aure
us 
(Corrigan et al., 2007) 
Coagulase 
 
S.aure
us 
(Mempel et al., 1998) 
Clumping factor A ClfA 
S.aure
us 
(Mempel et al., 1998) 
Fibronectin binding protein A FnbpA/FnbA 
S.aure
us 
(Mempel et al., 1998) 
Fibronectin binding protein B FnbpB/FnbB 
S.aure
us 
(Mempel et al., 1998) 
Staphylococcal protein A Spa  
S.aure
us 
(Mempel et al., 1998) 
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Known staphylococcal adhesins to the human epidermis and their receptors are 
displayed in table 1.1. The S. epidermidis  Rp62a genome encodes 12 MSCRAMMs, 
whereas S. aureus strains expresses up to 20 MSCRAMMs (Heilmann, 2011).  
Binding to different layers of the stratum corneum due to receptor variation 
between skin layers could affect long-term colonisation and survival. Studies of 
S. epidermidis identified three patterns of adhesion to layers of the stratum 
corneum: binding to superficial, fully differentiated corneocytes and hairs; 
binding to deeper, less differentiated epithelia at cell-cell junctions; and 
universal binding to all layers across the entire surface of the cell (Brooker and 
Fuller, 1984). 
Variation in repertoire may result in colonisation differences between S. aureus 
and S. epidermidis (Ben et al., 2008). For example, Aap of S. epidermidis  binds 
buccal epithelial cells and desquamated corneocytes, while the Aap homologue 
SasG, expressed by S. aureus, binds desquamated nasal cells, but not buccal 
epithelial or keratinocyte cells (Roche et al., 2003; Macintosh et al., 2009). It is 
suggested that the receptor for Aap and SasG is the same, but Aap binds the 
receptor better than SasG, since recombinant Aap could block SasG adhesion 
(Roche et al., 2003).  
 
1.3.2 Osmotic stress and resistance 
Osmotic stress that affects bacterial colonisation of the skin environment can be 
divided into three classes: low relative humidity (RH), matric water stress 
(desiccation) and ionic stress (salts or ions) (Potts, 1994). On skin, the relative 
humidity is low while the ionic stress is often high (Grice and Segre, 2011). Skin 
bacteria also face the additional stress of a sudden increase in water availability 
caused by sweating or washing. Although Staphylococcus species are one of the 
most abundant organisms colonising moist areas (Grice et al., 2009; Costello et 
al., 2009), their transmission and survival are still threatened when the relative 
humidity (RH) is below the threshold for growth.  
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It was shown that S. aureus can grow at 87% RH and S. epidermidis was tolerant 
of 81-84% RH, while Escherichia coli, Bacillus subtilis and Pseudomonas 
fluorescens required 92-94.5% RH for growth (de Goffau et al., 2009). The lower 
RH that S. epidermidis can tolerate compared with S. aureus may be a reason for 
its enhanced survival on the skin. This hypothesis was supported by the finding 
that S. epidermidis was inhibited by Pseudomonas fluorescens at high RH, but 
gains competitive advantage at lower RH (de Goffau et al., 2009).  
To tolerate desiccation conditions, S. aureus and S. epidermidis undergo 
morphology changes that are probably controlled by autolysin activity (de 
Goffau et al., 2011). As a result, the cells become larger in size, forming thicker 
walls and cuboidal packs of eight cells, instead of their typical grape-like 
clusters (de Goffau et al, 2009; de Goffau et al., 2011). Through these 
morphology changes, the bacteria reduce their surface area to volume ratio to 
prevent water loss and maintain turgor pressure (de Goffau et al., 2011). 
Further work has indicated that staphylococci grown at low RH also become 
more hydrophilic to increase water acquisition (de Goffau et al., 2011). 
The ability of staphylococci to produce the polysaccharide intercellular adhesin 
(PIA) might contribute to desiccation resistance through buffering activity, 
similar to exopolysaccharide (EPS) that protects Pseudomonas spp. (Roberson 
and Firestone, 1992). S. epidermidis strain Rp62a is a PIA producer (McKenney 
et al., 1998) that was found to be the most low RH tolerant S. epidermidis strain 
tested by de Goffau et al (2009). Potentially, this tolerance of Rp62a to low RH 
could result from its ability to form biofilms, which would further reduce the 
ratio of surface area to volume (de Goffau et al., 2009). 
Poly-γ-glutamic acid (PGA) forms a capsule around S. epidermidis ubiquitously 
and was reported to assist in protection from high NaCl concentration (2M) 
(Kocianova et al., 2005). Genomes of S. epidermidis and some other coagulase-
negative staphylococci, including S. capitis, S. caprae, S. haemolyticus, S. warneri 
and S. hominis, encode the PGA biosynthesis genes pgsBCAD/capBCAD while S. 
aureus do not (Kocianova et al., 2005). 
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Membrane zwitterionic phospholipids decrease in conditions of increasing 
salinity, and cardiolipin (CL) is known to play a role in osmotic stress responses 
in various bacteria. CL can stiffen membrane to reduce its permeability and 
prevent loss/gain of small solutes (Nagamachi et al., 1992). CL also interacts and 
regulates expression of the mechanosensitive channel MscL and the 
osmosensory transporter ProP (Romantsov et al., 2009). S. aureus encodes two 
CL synthase genes, one responsive to stress and the other is a housekeeping 
gene maintaining biosynthesis. Mutation of both genes leads to a decrease in 
long-term survival in high salinity media (Tsai et al., 2011).  
Other gene products that were identified to be important in osmotic stress 
resistance include proteases, ClpX and YjbH that assist in ionic and matric stress 
resistance, and extracellular matrix binding protein homologue (Ebh) that 
increases survival in high salt conditions (Kuroda et al., 2008). Ebh 
(extracellular matrix-binding protein homologue) which is only found in S. 
aureus and S. epidermidis and absent from S. haemolyticus and S. saprophyticus is 
a cell wall and membrane-associated protein. Invaginated vacuoles along their 
septum were observed within 30 min when ebh mutants were exposed to high 
salt conditions, suggesting that this protein contributes to initial ionic stress 
resistance (Kuroda et al., 2008 ), however a specific role for Ebh during the cell 
cycle of S. aureus remains unknown. 
 
1.3.3 Acid stress and resistance 
Acid stress contributes to innate defence against microbial colonisation on the 
surface of skin. Across the skin layers there is an acidic gradient, increasing 
throughout the stratum corneum from pH 7.4 in the stratum granulosum to pH 
4-5 at the skin surface (Rippke et al., 2002, Matousek and Campbell, 2002, 
Schmid-Wendtner and Korting, 2006). This acidic gradient is established by 
several components, including lactic acid and free amino acids from sweat, free 
fatty acids from sebum, the filaggrin degradation products urocanic acid and 
pyrrolidone carboxylic acid, and cholesterol sulphate (Rippke et al., 2002, 
Matousek and Campbell, 2002).  
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The acid gradient is important in the maintenance of the cohesion and integrity 
of the stratum corneum, as well as permeability homeostasis of the outer layers 
of the skin (Hachem et al., 2003). The acid gradient also facilitates regulation of 
skin enzymes such as β-glucocerebrosidase and serine proteases, dependent on 
their location within the stratum corneum to ensure timely differentiation and 
desquamation of keratinocytes. Change of pH is considered as a causal factor for 
skin diseases, such as atopic dermatitis and ichthyosis (Rippke et al., 2002; 
Matousek and Campbell, 2002; Schmid-Wendtner and Korting, 2006).  
The more acidic pH of the human skin surface relative to most other mammals 
may contribute to the difference between the flora of each (Matousek and 
Campbell, 2002). Low pH can cause direct damage to bacterial proteins and 
DNA by denaturation and, additionally, acidic conditions increases activity of 
cationic antimicrobial peptides (CAMPs) and antimicrobial fatty acids (AFAs) 
(Walkenhorst et al., 2013; Cartron et al., 2014). 
Gram-positive bacteria respond to acid stress by increasing resistance 
mechanisms that raise pH inside the cell, change architecture of the cell surface, 
and repair protein and DNA damage (Cotter and Hill, 2003). The most direct 
approach to keep the internal pH at an acceptable level is the use of proton 
pumps, which move protons out of the cell. Acidification of the cytoplasm is 
counteracted by increasing the concentration of alkaline compounds within the 
cell (Cotter and Hill, 2003). Genes encoding urease subunits A, B and C (ureA, 
ureB and ureC), as well as ureF encoding the urease accessory protein UreF, are 
all strongly upregulated in S. aureus by acid shock (Matforsk et al., 2007). In 
comparison, urease is expressed at a very high level in Helicobacter pylori, and 
this organism has adapted itself to colonise the strongly acidic environment of 
the human stomach. Urease activity is the major acid-resistance mechanism of H. 
pylori, and the enzyme neutralises acid by producing NH3 and CO2 (Valenzuela 
et al., 2003). 
In addition to its membrane lipid synthesis role mentioned above, CL synthase 
contributes to acid shock resistance by changing membrane structure. CL 
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production under normal conditions synthesised by Cls2, is changed to Cls1 
under acute acid stress (Ohniwa et al., 2013).  
 
1.3.4 Antimicrobial fatty acids and resistance 
Antimicrobial fatty acids (AFAs) are abundant on healthy mammalian skin. The 
majority of skin fatty acids originate from the sebum and the lamellar granules, 
and some can be released from the hydrolysis of triglycerides and biglycerides 
(Kohler et al., 2009; Madison, 2003; Drake et al., 2008). Fatty acids facilitate the 
maintenance of skin homeostasis by reducing inflammation and promoting 
wound healing (Brogden et al., 2012; Huang et al., 2014; Lai et al., 2009), and 
they contribute to the acid mantle of the skin together with lactic acid and 
amino acids in sweat (Fluhr et al., 2001). The free fatty acids on skin that are 
antimicrobial include sapienic acid, linoleic acid and oleic acid (Drake et al., 
2008). 
AFAs are proposed to limit staphylococcal colonisation (Costello et al., 2009; 
Lampe et al., 1983). While S. aureus is isolated from less than 5% of individuals 
with healthy skin, it is routinely isolated from atopic dermatitis patients who 
have lower AFA levels (Noble et al., 1967; Leyden et al., 1974; Breuer et al., 
2002). There is also an inverse relationship between sebaceous (and thus AFA 
rich) regions and frequency of staphylococcal isolation from skin (Grice and 
Segre, 2011; Grice et al., 2009) (Figure 1.2). These correlations support AFAs as 
potentially important contributing factors in differential survival of S. 
epidermidis and S. aureus on human skin. 
AFAs are able to disrupt bacterial membranes. The insertion of AFA molecules 
increases membrane fluidity and permeability that results in leakage of low 
molecular weight (<20 kDa) compounds, such as ATP and amino acids from the 
cell, as well as alteration of pH within the cell (Greenway and Dyke, 1979; 
Cartron et al., 2014; Parsons et al., 2012). Whilst there is evidence to support 
membrane insertion by AFAs, membrane insertion was not essential to inhibit 
growth (Greenway and Dyke, 1979; Cartron et al., 2014). AFAs are able to 
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uncouple oxidative phosphorylation as protonophores and lead to inhibition of 
respiration, disruption of the electron transport chain and collapse of the proton 
gradient (Cartron et al., 2014; Parsons et al., 2012; Jezek et al., 1998). 
S. aureus possesses several mechanisms for AFA defence. Wall teichoic acids 
(WTA) and MSCRAMM IsdA reduce hydrophobicity of the bacterial surface to 
limit AFA interaction (Parsons et al., 2012; Kohler et al., 2009; Clarke et al., 
2007). Transcription of capsule and peptidoglycan genes increases after AFA 
challenge (Kenny et al., 2009) and might contribute to the reduced 
hydrophobicity in response to AFAs. Moreover, S. aureus synthesises carotenoid 
staphyloxanthin to maintain membrane integrity (Chamberlain et al., 1991). 
Staphyloxanthin also contributes to antioxidant defences and counteracts AMP-
mediated membrane fluidity (Clauditz et al., 2006; Mishra et al., 2011).  
Staphylococci produce enzymes to detoxify AFAs. Myosin-cross reactive antigen 
(McrA) protein of S. pyogenes is a fatty acid hydratase and a homolog is encoded 
by S. aureus (Volkov et al., 2010; Moran et al., 2017). The McrA family of cell 
wall-anchored proteins includes the S. aureus surface protein F (SasF) (Kenny et 
al., 2009) and the S. saprophyticus surface protein F (SssF), and homologues of 
these proteins were found in all sequenced staphylococci by King et al. (2012). 
Both S. aureus and S. epidermidis secrete the exoenzyme fatty acid modifying 
enzyme (FAME) that esterifies lipids with cholesterol or primary alcohols to 
reduce their cellular toxicity (Chamberlain and Brueggemann, 1997; Kapral et 
al., 1992). The gene for this enzyme remains to be identified. Most skin isolates 
of staphylococci encode lipases that hydrolyse triglycerides and diglycerides 
releasing free fatty acids as substrates for FAME (Kapral et al., 1992). 
The arginine catabolic mobile element (ACME) encoding arginine deiminase 
(AD) activity improves survival of S. aureus on the skin in community acquired 
MRSA isolates (Diep et al., 2006). Genes encoding deiminase pathway enzymes 
such as those in the oligopeptidepermease operon (opp) and the arcABDC 
operon are upregulated by challenge of AFAs. An arcA mutant is more 
susceptible to AFAs than wild type strain (Kenny et al., 2009). Induced arginine 
deiminase activity is proposed to counteract acidity from lactic acid in sweat 
23 
 
(Thurlow et al., 2013) and may similarly contribute to AFA defense (Kenny et al., 
2009; Moran et al., 2017). 
FarRE (fatty acid resistance regulator and effector), which belongs to the 
multidrug pumps superfamily was identified as an exporter pump that 
facilitates resistance to linoleic acid and arachidonic acid (Kenny et al., 2009; 
Alnaseri et al., 2015). Linoleic and arachidonic acids strongly induce expression 
of farE in an farR-dependent manner, and inactivation of farE resulted in 
significant increased susceptibility of S. aureus to linoleic and arachidonic acid 
(Alnaseri et al., 2015). 
 
1.3.5 Antimicrobial peptides and resistance 
Antimicrobial peptides (AMPs) are part of the innate immune system on human 
skin. A variety of AMPs are effective against a wide range of pathogens like fungi, 
bacteria and viruses (Giuliani et al., 2008). They are synthesized as pre-forms 
and need to be activated to mature peptides, when needed. Most AMPs are 
positively charged and amphipathic with common structural motifs. The 
cationic AMPs bind to the commonly anionic bacterial surface and form 
channels or pores in the cytoplasmic membrane (Otto, 2010). Many cell types of 
the human immune system are able to produce CAMPs, including mast cells, T 
cells, and neutrophils where the antimicrobial peptides are secreted within 
phagosomes that kill ingested microorganisms (Faurschou and Borregaard, 
2003). Keratinocytes are the most important source of AMPs on the skin, while 
sebocytes and hair bulb cells also contribute to AMP production.  
Human skin produces dermcidin, adrenomedullin, lysozyme, RNase7 and skin-
derived antileukoproteinase as common AMPs. Dermcidin is secreted from 
sweat glands (Schittek et al., 2001; Rieg et al., 2004) and it inhibits synthesis of 
staphylococcal RNA and protein (Senyurek et al., 2009) via formation of ion 
channels in the bacterial membrane (Paulmann et al., 2012; Song et al., 2013). 
Adrenomedullin is a 52 amino acid peptide and functions in hormone regulation, 
vasodilatation and neutransmission (Richards et al., 1996). Although it is 
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effective against many bacteria, particularly Propionibacterium acnes (Allaker 
and Kapas, 2003), its effect on S. aureus and S. epidermidis is moderate (Allaker 
et al., 1999). The enzyme lysozyme is active against both Gram-positive and 
Gram-negative organisms (Neu et al., 1968) and can be found in many body 
fluids, such as tears and mucosal secretions. It cleaves the β-1,4 glycosidic bond 
in bacterial peptidoglycan between the N-acetylmuramic acid (MurNAc) and N-
acetylglucosamine (GlcNAc) residues (Chipman and Sharon, 1969). Pathogenic 
species of staphylococci, including S. epidermidis and S. aureus, are resistant to 
lysozyme due to activity of a transferase that O-acetylates MurNAc in 
peptidoglycan (Bera et al., 2006). The cationic RNase7 acts upon a wide range of 
bacteria, including S. aureus (Zhang et al., 2003), and is expressed in many tissue 
types such as keratinocytes on the skin. Keratinocytes also produce skin-
derived antileukoproteinase that controls inflammation by inhibiting neutrophil 
elastase; it is not bactericidal but inhibits growth of bacteria, including S. aureus 
(Williams et al., 2006). 
The skin-colonising and pathogenic bacteria have evolved resistance 
mechanisms for CAMPs, with an important approach being to modify the cell 
surface with positive charge that repels CAMPs. S. epidermidis encodes a two-
component sensor-regulator ApsSR that is activated by CAMPs (Li et al., 2007; 
Matsuo et al., 2011). Sensor protein ApsS has a negatively charged extracellular 
loop domain that binds the CAMPs, and gene deletion apsS mutants have 
reduced survival to hBD3 (Li et al., 2007). The dlt operon that is regulated by 
ApsSR plays an important role in staphylococcal resistance to CAMPs, 
cathelicidins and defensins via encoding enzymes for covalent attachment of D-
alanine to wall teichoic acids (Herbert et al., 2007; Peschel et al., 1999). In 
addition, expression of the MprF flippase that modulates cell surface charge by 
addition of lysine to membrane lipid via lysyl-phosphatidylglycerol synthetase 
activity is similarly regulated by ApsSR (Ernst and Peschel, 2011; Peschel et al., 
2001).  
 S. aureus has a homologue of the Aps system, GraRS (Yang et al., 2012). 
Mutation of the genes for GraRS increased sensitivity to CAMPs and reduced S. 
aureus virulence in a mouse infection model (Kraus et al., 2008; Herbert et al., 
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2007; Yang et al., 2012). The GraRS system requires the contribution of GraX 
and the VraFG ABC transporter for sensing and resistance to CAMPs (Herbert et 
al., 2007; Meehl et al., 2007; Falord et al., 2012; Yang et al., 2012). GraS has a 
substitution of a serine for a proline residue in the extracellular loop, compared 
with the S. epidermidis ApsS sensor, accounting for altered expression of dlt and 
mprF, which might contribute to the different responses to AMPs by S. aureus 
and S. epidermidis (Li et al., 2007). 
Production of proteases is another key defence for AMPs in staphylococci. The 
extracellular neutral metalloprotease SepA of S. epidermidis contributes to 
dermcidin resistance by degradation (Lai et al., 2007). Metalloprotease 
aureolysin produced by S. aureus disables the human cathelicidin LL-37 and 
assists in skin persistence and contributes to disease by limiting phagocytosis 
via complement inhibition (Kubica et al., 2008; Garzoni and Kelley, 2009; 
Laarman et al., 2011). 
 
1.3.6 Competitive exclusion 
Microbe interactions on the skin include bacterium-bacterium, virus-bacterium, 
and fungus-bacterium interactions. Correlated species distributions relative to 
staphylococcal colonisation were observed with skin and the nasal cavity. 
Infrequent co-isolation of S. epidermidis and S. aureus was shown in several 
studies (Frank et al., 2010), with S. epidermidis considered to associate with 
competitive exclusion of S. aureus from the nasal epithelium (Iwase et al., 2010). 
Other competing species from the nasal cavity correlated with absence of S. 
aureus include, S. haemolyticus, S. hominis, Finegoldia magna, Corynebacterium 
accolens, and Micrococcus spp. (Libberton et al., 2014; Wos Oxley et al., 2010; 
Iwase et al., 2010). Several Corynebacterium spp. were found to inhibit 
staphylococcal colonisation of the nasal cavity, presumably by competition for 
nutrients or adhesin receptors (Uehara et al., 2000). 
There are several mechanisms to circumvent colonisation inhibition by other 
species: interference via adhering to a range of receptors; resistance to 
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competitor antimicrobials similar to AMP resistance described in section 1.3.5, 
and production of inhibitory compounds targetting competitors.  
The skin commensal S. epidermidis is proposed to also protect the skin from 
pathogens by producing AMPs, such as phenol-soluble modulins (PSMs) 
(Schommer and Gallo, 2013). The phenol-soluble modulins (PSMs) δ and γ of S. 
epidermidis are amphipathic, α-helical staphylococcal proteins that, interact 
with lipid membrane, similarly to mammalian AMPs. These PSMs show 
antimicrobial activity against S. aureus, Group A Streptococcus (GAS), and 
Escherichia coli, via their insertion into membranes that leads to lipid vesicle 
leakage (Periasamy et al., 2012; Cogen et al., 2010b). S. epidermidis produces the 
serine protease Esp that was proposed to inhibit biofilm formation and nasal 
colonisation of S. aureus (Iwase et al., 2010). Esp-secreting S. epidermidis cleared 
S. aureus colonisation when applied intranasally (Iwase et al., 2010; Park et al., 
2011). Esp stimulated production of the AMPs, human beta defensins 2 and 3 
(hBD2 and hBD3) act upon S. aureus, but not S. epidermidis (Lai et al., 2010; 
Iwase et al., 2010). Separately, the frequency of S. epidermidis consistently 
increases, together with S. aureus, during the dysbiosis of atopic dermatitis (AD) 
when no treatment is applied, suggesting that S. epidermidis may not only 
benefit its eukaryotic host, but could also share a mutualistic or commensal 
relationship between staphylococci (Kong et al., 2012). 
Bacteriophages are potential competitors of staphylococci on the skin and 
staphylococcal phages were isolated from mammalian skin (Slanetz and Jawetz, 
1941). Phages capable of infecting S. epidermidis were also found in the anterior 
nares at low levels (Aswani et al., 2011). 
Clustered Regularly Interspaced Palindromic Repeats (CRISPRs) and their 
associated Cas proteins that provide phage resistance have been described in 
some staphylococci (van der Oost et al., 2009; Vale and Little, 2010; Marraffini 
and Sontheimer, 2008; Ramia et al., 2014). The Cas proteins process phage 
derived-DNA and store them as short repeat regions within CRISPR regions in 
the genome. These repeat regions in association with Cas proteins then lead to 
sequence-specific interference and degradation of phage genetic material in 
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subsequent infections with a similar phage or reactivation of a prophage within 
the cell (Vale and Little, 2010).  
 
1.3.7 Two-component systems 
Bacteria rely on sensory elements within their cell envelope to trigger adaptive 
responses to wide-ranging environmental conditions. The large family of signal 
transducers called two-component systems (TCS), consist of a membrane-
bound sensor kinase that responds to environmental signals and then activates 
a cognate response regulator to induce or repress specific sets of target genes. 
(McCallum et al., 2010; Stock et al., 2000). Phosphorylation of the response 
regulator (RR) by the sensor histidine kinase (HK) regulates differential 
expression of the regulon (Mascher et al., 2006). The CAMP defence TCS, ApsSR 
and GraSR were described above. VraSR, SaeRS and LytSR are three further 
well-studied TCS of S. aureus that have cell surface and survival roles (Belcheva 
and Golemi-Kotra, 2008; Liu et al., 2016; Patel and Golemi-Kotra, 2015). 
S. aureus VraSR (vancomycin resistance associated sensor/regulator) was 
shown to mediate resistance to cell wall synthesis inhibitors, such as 
vancomycin and β-lactams (Bae and Schineewind, 2006; Belcheva and Golemi-
Kotra, 2008). VraSR TCS is activated following exposure to a variety of cell wall-
targeting antibiotics, or the depletion of essential cell wall synthesis enzymes, 
and regulates expression of a cell wall stress stimulon (CWSS) (Gardete et al., 
2006; Kuroda et al., 2003; Sobral et al., 2007; Utaida et al., 2003).  Induction of 
the VraSR-dependent CWSS protects S. aureus against cell envelope damage 
through upregulation of cell wall peptidoglycan biosynthesis genes, including 
pbpB (bifunctional staphylococcal penicillin binding protein PBP (Pinho et al., 
2001)), fmtA (an accessory PBP with low affinity for β-lactams (Fan et al., 
2007)), murZ (a redundant MurA isozyme (Blake et al., 2009)), and sgtB (a 
soluble transglycosylase (Wang et al., 2001)) (Kuroda et al., 2003; McAleese et 
al., 2006; Utaida et al., 2003). Inactivation of VraSR results in decreased 
resistance of S. aureus to most VraSR inducing cell wall antibiotics (McCallum et 
al., 2010). 
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SaeRS (S. aureus exoprotein expression regulator/sensor) is an important 
virulence regulator, demonstrated using various animal models of S. aureus 
infection (Goerke et al., 2005; Liang et al., 2006; Voyich et al., 2009; 
Montgomery et al., 2010; Cho et al., 2015; Zhao et al., 2015). SaeRS regulates 
transcription and expression of an innate immune evasion regulon of genes, 
including hla, hlb, hlgABC, lukED  and coa (Giraudo et al., 1999; Liang et al., 2006; 
Rogasch et al., 2006; Nygaard et al., 2010). Inactivation of SaeRS leads to 
impaired cytotoxicity and ability of S. aureus to adhere to and invade epithelial 
and endothelial cells (Liang et al., 2006; Steinhuber et al., 2003). 
 
 
 
Figure 1.3 Organisation of the sae operon. Two angled arrows represent the P1 and P3 
promoters, respectively. Two vertical lines in the P1 promoter region indicate the SaeR binding 
sequences. 
 
The sae operon consists of four genes (saeP, saeQ, saeR and saeS) transcribed 
from two promoters, P1 and P3 (Figure 1.3) (Novick and Jiang, 2003; Jeong et al., 
2011; Steinhuber et al., 2003). P1 upstream of the first gene saeP is a strong 
promoter, due to two SaeR binding sequences, that direct transcription of all 
four genes (Novick and Jiang, 2003; Steinhuber et al., 2003). The P3 promoter 
within saeQ that only directs transcription of saeR and saeS (Novick and Jiang, 
2003; Jeong et al., 2011) is weaker than P1, yet transcription of saeRS from P3 is 
sufficient for activation of the sae regulon (Jeong et al., 2011). 
There are three well-described S. aureus SaeS polymorphisms: SaeSP, SaeSSK, 
and SaeSSKT (Liu et al., 2016). The SaeSP variant was originally identified in the 
strain Newman, with a L18P substitution mutation (T53C) in the first 
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transmembrane helix (Steinhuber et al., 2003; Adhikari and Novick, 2008). 
Kinase activity of SaeSP is highly increased due to the substitution mutation (Sun 
et al., 2010). An altered signal response was determined for SaeSP with 0.006% 
SDS (sodium dodeceyl sulfate) treatment, where for SaeSP the response was 
increased while wild type SaeS was inhibited (Schafer et al., 2009). SaeSP is 
unstable in the absence of SaeQ, which indicates that SaeSP is subject to 
proteolytic degradation in the membrane, from which SaeQ protects SaeSP 
(Jeong et al., 2011). SaeSSK has two substitution mutations (N227S and E268K) 
and is found in the strains MW2, Mu50 and USA600 (Olson et al., 2013). SaeSSKT 
is a SaeSSK variant with one more amino acid substitution at the last position 
(S351T) and is found in ST30 and ST36 lineages of S. aureus (Ramundo et al., 
2016). SaeSSK does not show altered enzymatic activity of SaeS (Olson et al., 
2013) while SaeSSKT  shows highest activity in the exponential growth phase and 
reduced activity in the stationary phase (Ramundo et al., 2016), while the wild 
type Sae reaches maximal activity at the post-exponential growth phase (Novick 
and Jiang, 2003; Steinhuber et al., 2003).  Thus, SaeS appears to be under 
genetic selection, potentially reflecting its role in immune evasion. 
LytSR TCS is associated with signal transduction of cell membrane electrical 
potential perturbation and is involved in the adaptation of S. aureus to cationic 
antimicrobial peptides (CAMPs) (Patton et al., 2006; Sharma-Kuinkel et al., 2009; 
Yang et al., 2013). LytSR can participate in two signal transduction pathways 
through two phosphorylation processes: phosphorylation of LytR by LytS; and 
phosphorylation of LytR by acetyl phosphate (Patel and Golei-Kotra., 2015). 
LytR regulates the expression of lrgAB and cidABC operons to control 
programmed cell death and lysis during biofilm formation (Rice et al., 2007; 
Bayles, 2007; Rice and Bayles, 2008). Upregulation of cidABC operon 
contributes to increased activity of murein hydrolysis and antibiotic tolerance 
(Rice et al., 2003), while lrgAB inhibits these processes (Groicher et al., 2000). 
Both lrgAB and cidABC operons were also found to be induced by excess of 
glucose metabolism (Patton et al., 2006). Phosphorylation of LytR by acetyl 
phosphate was found to be associated with regulation of lrgAB operon under 
high levels of glucose in vivo (Lehman et al., 2015). 
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1.4 Sphingosine and staphylococci 
The epidermal lipids in the stratum corneum comprise a 1:1:1 ratio of ceramide, 
fatty acids and cholesterol. The hydrolysis of ceramide yields fatty acids and 
sphingosine (Pruett et al., 2008; Shirakura et al., 2012). A sphingosine 
concentration of approximately 270 μM of is observed on healthy skin, whilst 
only 140-160 μM is present on atopic skin that becomes typically heavily 
colonised by S. aureus (Arikawa et al., 2002). Sphingosine is able to kill S. aureus 
rapidly with a similar action mode to AFAs (Parsons et al., 2012), however 
resistance mechanisms and transcriptional responses of staphylococci have not 
been characterised. 
 
1.4.1 Atopic dermatitis: sphingosine defence against S. aureus colonisation 
Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterised by 
dry, flaky skin lesions (Bieber, 2008). The skin stratum corneum of AD patients 
has increased bacterial colonisation, and is particularly susceptible to infections 
with S. aureus, and viruses such as herpes and vaccinia (Leung, 2013; Kim et al., 
2013). The frequency of bacterial colonisation in non-lesional skin of patients 
with AD is significantly higher than that of other types of dermatitis (Akiyama et 
al., 1996). Around 80% of AD skin of patients can be colonised by S. aureus, and 
high levels of S. aureus colonisation were also observed on their non-lesional 
skin (Roth and James, 1988; Takigawa et al., 2005; Kong et al., 2012; Higaki et al., 
1999).  
The constitutive barrier disruption of the stratum corneum seen with AD 
patients, including decreased levels of sphingolipid metabolites such as 
ceramide, was considered to be associated with the increased susceptibility to S. 
aureus colonisation (Arikawa et al., 2002; Imkawa et al., 1991). Studies that 
compared the stratum corneum of AD patients with age-matched normal 
controls detected no significant difference in the activities of major ceramide-
generating and degrading enzymes: sphingomyelinase (SMase); β-
glucocerebrosidase (GlCDase); and alkaline ceramidase (CDase) (Hara et al, 
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2000; Jin et al, 1994). Further work identified a sphingomyelin (SM) deacylase, 
which degrades SM at its acyl site to produce sphingosylphosphorylcholine 
instead of ceramides (Murata et al., 1996). SM deacylase is overexpressed in the 
epidermidis of AD patients, being at least three to five times higher than in the 
epidermis of healthy controls (Hara et al., 2000). These studies supported the 
hypothesis that overexpression of SM deacylase competes with SMase for their 
common substrate SM and may account for the ceramide deficiency in the 
epidermidis of AD patients (Murata et al., 1996; Hara et al., 2000).  
Altered sphingolipid metabolism in AD patients suggests that ceramide or its 
metabolite sphingosine may be involved in defence from S. aureus colonisation 
(Bibel et al., 1992; Bibel et al., 1993). The amount of sphingosine is reduced by 
approximately 2-fold in the upper three layers of the stratum corneum of AD 
patients compared with healthy controls, and this decreased level of 
sphingosine results in an approximately 200-fold increase of S. aureus 
colonisation (Arikawa et al., 2002). Other factors associated with AD and S. 
aureus skin colonisation include reduction of AFAs and AMPs in the epidermis 
of AD patients (Cho et al., 2010; Schafer and Kragballe,1991).  
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1.4.2 Sphingoid bases and antimicrobial activities 
Sphingoid bases, including free sphingosine and dihydrosphingosine derived 
from epithelial sphingolipids via hydrolysis, are present in the stratum corneum 
and are proposed to contribute to the permeability and innate immunologic 
barriers of the skin (Brogden et al., 2012; Jungersted et al., 2008). 
 
 
 
Figure 1.4 Structure of sphingosine, dihydrosphingosine and phytosphingosine (Sigma-
Aldrich). 
 
 
D-sphingosine, dihydrosphingosine and phytosphingosine are all similar in 
structure (Figure 1.4). D- Sphingosine is the natural isomer of sphingosine (2-
amino-4-octadecene-1,3-diol), which is an 18-carbon chain unsaturated amino 
alcohol with a single trans double bond between C4 and C5, two hydroxyl 
groups on C1 and C3, and an amino group on C2 (Fischer et al., 2013). 
Dihydrosphingosine is the saturated analog of sphingosine, and 
phytosphingosine is structurally similar to dihydrosphingosine with the 
exception of a hydroxyl group at C4. Both sphingosine and dihydrosphingosine 
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inhibit protein kinase C (PKC) that can modulate many biochemical actions 
(Darges, 1997) and play a role in a variety of cellular processes (Bu et al., 2006; 
Shi et al., 2007; Saba and Hla, 2004; Spiegel and Milstien, 2003; Spiegel and 
Milstien, 2011). Phytosphingosine is abundant in plants and fungi and present 
in animals. Phytosphingosine has anti-inflammatory and anti-proliferative 
properties (Kim et al., 2006; Pavicic et al., 2007). 
Sphingoid bases: D-sphingosine, dihydrosphingosine, and phytosphingosine all 
show antimicrobial activity against a variety of Gram-positive and Gram-
negative bacteria, including E. coli, S. aureus, Corynebacterium bovis, C. striatum, 
C. jeikium, Streptococcus sanguinis, Strep. mitis, and Fusobacterium nucleatum 
(Drake et al., 2008; Bibel et al., 1992a; Klee et al., 2007; Bibel et al., 1992b; Bibel 
et al., 1993; Fischer et al., 2011). Kinetic assays showed that sphingosine and 
phytosphingosine were capable of killing S. aureus, Strep. sanguinis, Strep. mitis, 
and C. striatum within 0.5 to 6 h (Fischer et al., 2011). 
Electron microscopy revealed cell wall lesions, membrane disruption and 
leakage of cellular content for sphingoid base-treated S. aureus, supporting that 
the activity site of sphingoid bases is the cell wall (Bibel et al., 1993). In a study 
by Bratt et al (2010), fragments of the lysed cell wall were found after sphingoid 
base treatment of S. aureus. Obvious disruption with loss of cell wall and 
membrane by sphingoid bases in S. aureus was also by observed by Fischer et al. 
(2013), who showed sphingoid bases induced ultrastructural damage of E. coli 
and S. aureus treated with 10 times MIC concentration of D-sphingosine, 
dihydrosphingosine or phytosphingosine. These three sphingoid bases induce 
intracellular inclusions and they accumulate in both E. coli and S. aureus cells, 
suggesting both extracellular and intracellular damage (Fischer et al., 2013). It 
was predicted that concentrations lower than MIC are tolerated and 
metabolised by the bacteria, but concentrations above the MIC are not (Fischer 
et al., 2013). 
Although the detailed antimicrobial mechanisms of sphingosine on bacteria at 
the molecular level are not fully established, several similar possibilities are 
proposed: sphingosine may act on S. aureus by penetrating and disrupting the 
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cell wall or altering changes in cytoplasmic membrane; or it may penetrate the 
cell walls and the cytoplasmic membranes of bacteria, then enter and disrupt 
the cytoplasm, similar to a mechanism described by Bergsson et al. (2001). 
 
1.5 Thesis aims 
The contribution of sphingosine to the composition of the human skin 
microbiome and colonisation of microbiota is poorly understood. The basis for 
differential survival and persistence across the staphylococcal species that 
colonise human skin is not clear and in particular their skin lipid resistance 
mechanisms and transcriptional responses remain to be resolved. This study 
investigates the effect of the host epidermal antimicrobial lipid D-sphingosine 
on S. aureus and S. epidermidis, with a focus on discovering components that 
contribute to resistance in the former. 
The initial aims of this study were to characterise and compare the 
transcriptional response of S. aureus and S. epidermidis to D-sphingosine. RNA-
Seq and qPCR would be used to dissect the transcriptional responses of S. 
aureus Newman and S. epidermidis Tü3298 after challenge with D-sphingosine.  
A parallel approach was designed to dissect the individual contributions of 
genes and SNPs that increase S. aureus survival to sphingosine, by combining 
data and approaches from previous work that used experimental evolution and 
selection for survival with increasing concentrations of D-sphingosine (Moran, 
2015). These two genetic approaches would then be used to identify candidate 
genes for further study, thereby constructing gene mutants and SNP variants as 
a combined approach to enable study of the physiology of cellular resistance.  
Overall, these approaches were designed to increase understanding of lipid 
responses and survival in staphylococci that colonise human skin. 
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Chapter 2: Methods and Materials 
 
2.1 Bacterial strains and culture 
The strains used in this study are displayed in Table 2.1. S. aureus strain Newman and S. epidermidis strain Tü3298 were used for RNA-
Seq analysis. S. aureus strains Newman, SH1000, RN4220 and E. coli Top10 were used in DNA cloning work and strain construction. 
Further strains were used in qPCR and survival tests as indicated. 
Todd Hewitt broth (THB) was used to culture bacteria for RNA purifcation and survival tests . Phosphate-deficient chemically defined 
media was used for measurement of cell growth with different phosphate concentrations. Remaining experiments were all conducted in 
BHI media. Solid medium was made by adding agar (12 g L-1) to broth. Plates were grown statically at 37 °C for 12-18 h unless otherwise 
stated. Overnight cultures were grown for 18 h at 37 °C with shaking. Optical density (600 nm) was measured during growth using a  1 
cm path length. D-sphingosine (Sigma-Aldrich) stock solution was prepared at concentration of 5 mg ml-1 in 100% (v/v) ethanol. 
Antibiotics used for S. aureus and their concentrations for selection were as follows: tetracycline 5 μg ml-1, erythromycin 5 μg ml-1, 
lincomycin 25 μg ml-1; For E. coli the selective concentration of ampicillin was 100 μg ml -1.  
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Table 2.1 Bacterial strains used in this study 
Species Strains Description References 
S. epidermidis Tü3298 Epidermin producer, used for RNA-seq,survival tests and cloning experiments (Allgaier et al., 1986) 
S. aureus 
Newman 
Osteomyelitis isolate,common lab strain, used for RNA-seq,survival tests, pigment assay and cloning 
experiments 
(Duthie and Lorenz, 1952) 
SH1000 
Lab strain (rsbU repaired 8325-4 derivative),dark golden color,used for survival tests, pigment assay 
and cloning experiments 
(Horsburgh et al., 2002) 
SF8300 CA-MRSA, used for qPCR as random selected S. aureus strain repeats (Diep et al., 2008) 
MRSA252 Fatal bacteraemia isolate, MRSA, used for qPCR as random selected S. aureus strain repeats (Holden et al., 2004) 
SH1000 farE::tet farE depletion mutant, selected for survival tests Horsburgh group, Liverpool 
SH1000 farR::tet farR depletion mutant, selected for survival tests Horsburgh group, Liverpool 
SH1000 vraR::tet vraR depletion mutant, selected for survival tests Horsburgh group, Liverpool 
SH1000 vraS::tet vraS depletion mutant, selected for survival tests Horsburgh group, Liverpool 
RN4220 cloning intermediate (Nair et al., 2011) 
E. coli  Top10 cloning intermediate Thermo Scientific 
 
Table 2.2 Plasmids used in this study. 
Plasmids Description Reference 
pMUTIN4 High copy number cloning vector, used for creation of SNP bearing variants and gene depletion mutants (Vagner et al., 1998) 
pSK5632 
low copy number S. aureus shuttle vector,  
high copy number in E. coli, used for creation of completed mutants 
(Grkovic et al., 2003) 
pDG1514 tetracycline cassette vector (Guérout-Fleury et al., 1995) 
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2.2 Survival tests 
2.2.1 Growth curves 
Overnight cultures were diluted with THB medium to OD600=0.5 and 2 ml of this 
dilution was added into 250 ml flasks containing 50 ml THB broth. The flasks 
were incubated at 37°C with shaking at 250 rpm. The optical density A600 was 
measured hourly from 0 to 8 h. Samples were ten-fold diluted with THB broth 
before recording the OD600. 
For the sphingosine challenge titration experiments, D-sphingosine was added 
at the appropriate concentration to the experimental groups when the OD600 
value reached 0.5. Ethanol (100 % v/v) was used as a solvent, since D-
sphingosine is insoluble in water, and therefore an ethanol control group was 
included in addition to a blank control group with no addition. 
 
2.2.2 Growth in phosphate deficient media 
Chemically-defined media (CDM) was prepared by adding Na2HPO4 (7 g), 
KH2PO4 (300 mg), adenine sulfate (20 mg), guanine-HCl (20 mg), L-glutamic 
acid (2.22 g), L-aspartic acid (2.22 g), L-proline (2.22 g), glycine (2.22 g), L-
threonine (2.22 g), L-serine (2.22 g), L-alanine (2.22 g), L-lysine-HCl (560 mg), 
L-isoleucine (560 mg), L-leucine (560 mg), L-histidine (440 mg), L-valine (440 
mg), L-arginine (330 mg), L-cysteine (220 mg), L-phenylalanine (190 mg), L-
tyrosine (170 mg), L-methionine (170 mg), L-tryptophan (60 mg), pyridoxal 
(0.8 mg), pyridoxamine-2HCl (0.8 mg), D-pantothenic acid (0.4 mg), riboflavin 
(0.4 mg), nicotinic acid (0.4 mg), thiamine-2HCl (0.4 mg), and biotin (0.02 mg) 
into one litre water. For use, sterile glucose and MgSO4 was added to obtain the 
final concentration of 10 g L-1 and 0.5 g L-1, respectively. Phosphate 
concentration was controlled by adding different amounts of molar Na2HPO4 
and KH2PO4 solutions. 
Cell growth in CDM without or with added phosphate was performed and 
measured using a 96-well plate using a Fluostar Omega (BMG Labtech) plate 
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reader. Overnight culture was diluted to OD600 0.02 then 200 µl was aliquoted 
into 96 well plates. Cells were challenged with D-sphingosine at various 
concentrations from 1.65-165 μM. Four concentrations of phosphate (0 mM, 12 
mM, 30 mM, 60 mM) were tested. Cell density was determined by measurement 
of OD600. 
 
2.2.3  Minimum inhibitory concentration (MIC) assay  
96 well plates were used for MIC determination. A range of different 
concentrations of D-sphingosine were prepared using ethanol as solvent and 
100 μl of prepared solution was added to each well. Tested strains were grown 
for 24 h and diluted to OD600=0.2 with BHI broth. Next, 100 μl of diluted culture 
was added to each well and incubated at 37°C for 24 h.  
 
2.2.4  Peroxide survival assay 
S. aureus Newman and S. epidermidis Tü3298 were grown in BHI with 5 μM 
sphingosine with 0.02% v/v ethanol, or with solvent alone for 24 h. The cultures 
were centrifuged and cell pellets were collected and washed twice with PBS.  
Cells were resuspended in the same buffer and diluted to OD600=0.1 (~1.5 x 108 
CFU ml-1). Hydrogen peroxide (Sigma) was added to the diluted cells with a final 
concentration of 7.5 mM for S. aureus and 3.2 mM for S. epidermidis. Cell 
suspensions were incubated at 37 ˚C statically. Samples were collected at  time 
points 0, 15, 30, 60, 90, 120 min into a 96-well plate, for the hydrogen peroxide 
treated cells, 10 mg ml-1 catalase was added immediately to the samples to 
neutralise the peroxide. Serial dilution and viable counts were performed to 
measure the survival rate.  
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2.2.5 Sphingosine survival assay 
Overnight cultures of S. aureus SH1000, SH1000 farE::tet, SH1000 farR::tet were 
diluted with THB medium to OD600=0.5 and 2 ml of this dilution was added to 
250 ml flasks containing 50 ml THB broth. The flasks were incubated at 37°C 
with linear shaking at 125 rpm. Next, 5 μM D-sphingosine (total volume of 15 μl) 
was added to the sphingosine-treated groups at mid-exponential phase 
(OD600=0.5), while 15 μl 100% (v/v) ethanol was added to the control groups as 
solvent control. The bacteria were incubated with the antibiotics at 37°C with 
shaking at 250 rpm for 24 h before harvesting. The cultures were centrifuged 
and cell pellets were collected and washed twice with PBS.  Cells were 
resuspended and diluted to OD600=0.1 (~1.5 x 108 CFU ml-1). A series of 
concentrations (5-20 μM) of D-sphingosine was added to the diluted cells. Cell 
suspensions were incubated at 37 ˚C statically. Samples were collected at time 
points 0, 15, 30, 60, 90 min into a 96-well plate. Serial dilution and viable counts 
were performed to measure the survival rate. 
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2.3 Construction of allelic replacement variants 
2.3.1 Extraction of plasmid DNA 
A plasmid extraction kit (Bioline) was used to purify plasmid DNA using 3-10 ml 
of a stationary-phase culture, according to the manufacturer’s instructions. 
Plasmid DNA concentration was determined using a NanoDrop-2000 
spectrophotometer (Thermo Scientific). 
 
2.3.2 PCR 
PCR primers were obtained from Eurofins. DNA amplifications using PCR were 
carried out with BioMix (Bioline) following the instructions provided. The PCR 
cycle template is shown below: For the reaction, initial denaturation was 
performed at 98 ˚C for 30s. Next, temperature cycles were: denaturation at 98 ˚C 
for 10s; annealing at 56 ˚C for 20s; and extension at 72 ˚C for 30 s-3 min. The 
cycle was repeated 30-35 times. Final extension was performed at 72 ˚C for 5 
min to complete DNA fully and then the sample was held at 4 ˚C until taken out.   
 
2.3.3 Restriction digests and ligation 
Digestions were performed in a waterbath following the instructions provided 
with the enzyme (New England BioLabs). For double digests, buffer 
compatibility was checked using NEB enzyme checker. Digestions were purified 
using the Bioline PCR clean-up kit, according to the manufacturer’s instructions. 
DNA ligations were carried out for 4 h at room temperature. One unit of T4 DNA 
ligase was used with the provided buffer as per the manufacturer’s instructions 
(Thermo Scientific). DNA was ligated at a ratio of 1:3 vector to insert, with the 
ligated DNA used directly in subsequent transformations. 
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2.3.4 Transformation of chemically competent E. coli 
Competent cells were defrosted on ice and DNA was added (approximately 100 
ng in a volume of 5 µl or less) or sterile water as a control. The cells were 
incubated on ice for 30 min to enable DNA uptake and then heat-shocked in a 
waterbath (42 ˚C for 90s) to increase uptake efficiency. Cells were transferred to 
ice for 2 min and 900 µl of LB was added. The transformation mixture of 
bacteria was incubated for one hour at 37 ˚C allowing recovery of cells and to 
give the bacteria time to switch on antibiotic resistance genes supplied by the 
plasmid. Bacteria were then plated (100 µl) onto antibiotic-containing plates. 
Plates were incubated for up to 24 h to select for transformants. 
Plasmids were extracted from the colonies and PCR was conducted on them to 
confirm the colonies contained the correct plasmid. 
 
2.3.5 Preparation of electrocompetent S. aureus  
A stationary phase culture of S. aureus RN4220 was diluted 1:100 into a flask 
and cells were grown to an OD600 of 0.5. Cells were pelleted by centrifugation 
(4000 g, 10 min, 4 ˚C). The cells were washed three times using sterile water, 
followed by a further three washes using 10 % (v/v) glycerol. These cells were 
aliquoted into 100 µl aliquots and frozen at -80 ˚C. 
 
2.3.6 Electroporation of S. aureus 
Plasmid DNA for electroporation was concentrated to a high concentration, 
above 800 ng µl-1. First, 10 µl plasmid was added to an aliquot of defrosted 
electrocompetent cells. Cells were transformed by electroporation in cuvettes 
with settings of: 100 , 2.5 kv, 25 µF producing a time constant ~2s. 
Immediately after electroporation, 900 µl of B2 medium with 0.5 M glucose was 
added to the cells before incubation for 1 h at 37 ˚C with 250 rpm shaking. Cells 
were plated onto selective antibiotic plates. Agar plates were incubated for up 
to 72 h. 
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2.3.7 Phage transduction 
The donor bacteria containing the locus for selection, marked with 
erythromycin resistance, were grown overnight in BHI with Erm (5 µg ml-1). 
Next, exponential phase (OD600=0.5) bacteria were mixed with 5 ml phage 
buffer and 100 µl of ϕ11 was then added into the mixture. The mixture was 
incubated stationary at 30 ˚C until complete lysis was observed. 
Recipient cells were grown overnight in 20 ml LK broth (1 % [w/v] tryptone, 
0.5 % [w/v], yeast extract, 0.7 % [w/v] potassium chloride). The culture was 
centrifuged (4000 g, 10 min), and the supernatant was removed; the bacterial 
pellet was resuspended in 1 ml LK broth. To 500 µl LK broth containing 10 mM 
CaCl2, 250 µl of cells was added, plus 250 µl of phage lysate. The mixture was 
incubated at 37 ˚C statically for 25 min and then incubated with shaking (250 
rpm) for 15 min. Next, 500 µl of ice-cold 0.02 M Na citrate was added and the 
samples were centrifuged (4000 g, 10 min). The pellets were resuspended in 
500 µl 0.02 M Na citrate and kept on ice for 2 h. Finally, 100 µl of the samples 
was plated onto LK plates containing 0.05% (v/v) citrate and covered with 5 ml 
of top agar containing erythromycin until dry. The plates were grown for 48 h 
until colonies appeared. The collected colonies were grown in BHI without any 
antibiotics for 72 h. The genome DNA was extracted after growth and PCR was 
conducted to verify that the plasmid had been deleted.  
 
2.3.8 Nebraska transposon library mutants 
An available resource, the Nebraska Transposon Mutant Library was used to 
obtain gene mutants.  The library was generated from the well-characterised 
community-associated methicillin-resistant S. aureus (MRSA) strain S. 
aureus USA300 LAC, isolated from a Los Angeles County jail inmate (Kennedy et 
al., 2008).  Gene insertions were generated for the library using bursa aurealis, a 
mariner-based transposon, in the USA300 LAC-derived strain JE2, following the 
procedures essentially as described by Bae et al. (2008). To examine interesting 
genes in Newman, the S. aureus USA300 JE2 variants with bursa aurealis Tn 
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insertions at described gene locations were selected from the library and 
transduced into S. aureus Newman; 5 μg ml-1 erythromycin (Erm) was used for 
selection. To verify the location of the transposon insertions and confirm 
successful transduction, primers were designed specific to the bursa aurealis 
transposon and were used together with primers of the target genes using PCR 
amplification as confirmation of correct gene insertion. Primers were designed 
according to Tn orientation within the gene: the ‘plus’ orientation used the 
‘Upstream’ primer of the transposon; the ‘minus’ orientation used the ‘Buster’ 
primer in combination with the gene-specific primer. The primers used in this 
thesis and expected/confirmed product size are indicated in table 2.3. 
 
Table 2.3 Primers for confirmation of transposon library mutants. 
Tn Primer Sequence (5'-3') Tn Orientation Distance 
 Upstream CTCGATTCTATTAACAAGGG Plus 464bp 
 Buster CTAAATGTTTTTTAAGTAAATCAAGTAC Minus 128bp 
Gene Primer Sequence (5'-3') Tn Orientation Product size 
  phoU GCAGCGACAAATGGATCGTTA Minus 166bp 
  phoR GATGAAGTTTCACCACCGCTT Minus 285bp 
  hrtB CAAGGGCTTGGTAGGGAGAA Minus 241bp 
  pstS TCTCTGGTGCTGCTACATATCC Minus 397bp 
 
 
2.4 Agarose gel electrophoresis 
1% (w/v) agarose gels were made with TAE buffer. Melted agarose was stored 
at 50 °C until required. Midori green (Nippon Genetics) was mixed into molten 
agarose gel at a ratio of 2 μl per 100 ml. A loading dye was added to samples 
when necessary and samples were run in 1x TAE buffer at 110 V for 45-60 min. 
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2.5 RNA sequencing 
Benches and pipettes were cleaned and wiped with RNase Zap. For all work 
done with RNA, RNase-free filter tips and plasticware were used.  
 
2.5.1 Bacteria growth and challenge condition 
For RNA extraction, cells grown in BHI were harvested 20 min after the absence 
or presence of challenge with D-sphingosine to a final concentration of 5 μM. A 
volume of 500 μl of each culture was sampled and then centrifuged at 4,000 RCF 
and 4°C for 5 min. Supernatants were removed and the pellets were 
resuspended in 500 μl RNAlater (RNA stabilization reagent) and incubated 
overnight at 4°C. 
 
2.5.2 Cell lysis 
The cells were pelleted at 4,000 RCF for 10 min at 4°C and resuspended with 1 
μl 100 X TE buffer, 21 μl lysostaphin (6 mg ml-1) and 33 μl mutanolysin (2 kU 
ml-1). Bacteria were incubated for 15 min at 37°C for cell lysis, mixing every 5 
min, before 25 μl proteinase K (1.25 μg ml-1) was added and incubation was 
continued for a further 30 min. 
 
2.5.3 RNA extraction 
RNA was extracted following the Qiagen RNeasy protocol with slight alterations. 
Briefly, 350 μl RLT buffer containing 1% v/v beta-mercaptoethanol was added 
to the lysed cells, followed by 250 μl of 100% (v/v) ethanol, and mixed well with 
pipetting. The mixture was centrifuged through an RNeasy column for 15 s at 
14,000 RCF. Then the column was washed twice with 700 μl RW1 buffer and 
three times with 500 μl RPE buffer. The column was centrifuged into a clean 
collection tube for 1 min and air dried for 5 min. RNA was eluted twice with 30 
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μl DEPC-treated water pre-warmed to 45°C. DNase treatment was performed in 
the column.  
 
2.5.4 DNase treatment 
DNase was removed using the Qiagen RNeasy MinElute clean up kit. RNA was 
eluted with 20 μl DEPC-treated water. The extracted RNA samples were tested 
with Qubit for quantification. Nanodrop and 2100 Bioanalyzer were used for 
Quality control. 3 μg of qualified RNA samples were submitted for RNA 
sequencing by the CGR facility at Liverpool and the remainder of the RNA was 
converted to cDNA for later qPCR assays. 
 
2.5.5 RNA quality control  
Quality control analysis was conducted using a Qubit (Invitrogen) for 
quantification, 2100 Bioanalyser (Agilent technologies) to assess degradation 
levels and Nanodrop (Thermo Scientific) to assess protein or solvent 
contamination. Tests were carried out according to manufacturer’s instructions 
for bacterial RNA. Samples were determined to be suitable for sequencing as 
follows: a paired control and test condition sample were determined to have 
Qubit read indicating  3 µg RNA, Bioanalyser RIN  ce 
indicating good integrity, Nanodrop 260/280 and 260/230  1.8.  
 
 2.5.6 RNA library preparation  
DNA sequencing libraries preparation was performed by the Centre for Genome 
Research, University of Liverpool. Total RNA samples were rRNA depleted using 
the Ribo-Zero magnetic kit for Gram-positive bacteria (Epicentre); this cleanup 
was repeated for samples with poor initial rRNA removal.  Libraries were then 
prepared using strand-specific ScriptSeq kits (epicentre).  Samples were 
sequenced using paired-end sequencing on the HiSeq platform (Illumina).  
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2.5.7 RNA sequencing differential expression analysis  
Bowtie (Langmead et al., 2009) and Edge R (Robinson et al., 2010; Robinson and  
Oshlack, 2010) were used to map reads and determine the differentially  
expressed (DE) genes, respectively. Genes with mapped transcripts that had a  
false discovery rate > 0.05, as determined by Benjamin and Hochberg analysis,  
and log2 fold change not ≥ ±1 were filtered out of the data set. The remaining  
gene set was considered differentially expressed between control and test  
conditions. This analysis was produced by the Centre for Genomic Research  
(CGR), Liverpool.  
Changes in gene expression in biosynthetic pathways were assessed using DE  
gene sets with KEGG mapper-search and colour (Kanehisa et al., 2012; Kanehisa  
and Goto, 2000). Gene ontology (GO) terms were attached to DE genes using  
Uniprot (UniProt, 2014).   
 
2.5.8 COG analysis  
The sequences of all genes within the genomes of S. aureus Newman and S. 
epidermidis Tü3298 were extracted into a fasta file using the Galaxy tool  
“Extract genomic DNA” (Goecks et al., 2010; Giardine et al., 2005). A bespoke  
perl script was then used to convert these gene sequences into protein 
sequences. These protein sequences were then submitted to WebMGA function 
annotation (COG) (Wu et al., 2011), which assigns a COG ID to each gene.  
Another bespoke Perl script was used to convert the names that had been  
assigned to the genes by the Galaxy extract genomic DNA tool back to their true  
gene names. The gene lists of DE genes were then labelled with their assigned 
COGs using a bespoke Perl script (Appendix II). The numbers of genes in each 
COG class and the percentage of the genome accounted for by each COG class 
was then calculated using a further bespoke Perl script.  
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2.6 qPCR 
2.6.1  First-strand cDNA synthesis 
Purified RNA was used to synthesise cDNA using the Tetro Reverse 
Transcriptase kit. For each sample, 1 ng total RNA was mixed with random 
hexamer primers. The priming premix were prepared on ice in RNase-free 
reaction tubes and mixed gently by pipetting. Samples were incubated at 25°C 
for 10 min, followed by 45°C for 30 min. The reaction was terminated by 
incubation at 85°C for 5 min. Samples were chilled on ice and stored at -20°C for 
further use. 
 
2.6.2  Primer design  
Primers for DNA amplification in PCR and qPCR were taken from the literature, 
where possible, or designed using primer-BLAST (Ye et al., 2012). Primers with 
a length between 15 and 25 bp, predicted to have only one product, a Tm of 60 
selected where possible (Table 2.3).   
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Table 2.4 Primers for qPCR 
       Gene Primer sequences (5’ to 3’) References 
NWMN_0542 
(Newman) 
F-TCAGTATCACTAAATGAATCGTCAC 
This study 
R-TCAGTATCACTAAATGAATCGTCAC 
phoU 
(Newman) 
F-CGATAGAGGCTTTGCACGAC 
This study 
R-GCAAATCACTCGCAATGGGC 
pstB 
(Newman) 
F-ATCATTACGTGGCGCTGC 
This study 
R-TGCTGATGTCGGTTCATCC 
saeR 
(Newman) 
F-TGGTCACGAAGTCCCTATGC 
This study 
R-TGGACATTCACGGTATTAGCATC 
norB 
(Newman) 
F-GCTACACCATCAACAGATACAGC 
This study 
R-CGCCAAATGCTCCACCTAATG 
pstA 
(Tü3298) 
F-CCAGGTAATGCTGCGGGTAA 
This study 
R-TTATTTGTTGGCGCAGCAGG 
copA 
(Tü3298) 
F-GAACAGCTCAAACCATCGCC 
This study 
R-GATGTGCCTTTTCTTCGGGC 
 
 
Primers were confirmed to amplify a product of the predicted length without 
any secondary products using standard PCR and genomic DNA as a template. 
The PCR mix was made using BioMix Red (Bioline) and ACCUZYME DNA 
polymerase (Bioline) according to the manufacturer’s instructions.  
Primer efficiency was confirmed to be within 90-100 % using a dilution curve 
with genome DNA, as described previously (Nolan et al., 2006). Efficiency 
testing was done using the same conditions as for qPCR reactions (described 
below). The reaction mix in a total volume of 20 µl was set up with 0.5 µM of 
each primer, 10 µl SensiFAST and a dilution range of gDNA between 1x100-
1x104, with a starting concentration of 10 million copies. Negative controls 
without template were also implemented. Efficiency values were generated by 
the qPCR machine software (ABI StepOnePlus), and an average of at least three 
resulting efficiency values was taken.   
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2.6.3  qPCR conditions  
All qPCR reactions were performed using the SensiFAST SYBR HiMROX kit 
(Bioline) with the ABI StepOnePlus (Life Technologies). The reaction mix 
contained 10 µl SensiFAST, 0.4 µM of each primer, 1 ng cDNA and DEPC-treated 
performed using the ABI StepOnePlus software. At least two technical replicates 
and three biological replicates were used to determine fold change in gene 
expression between samples.  
 
 
2.7 Staphyloxanthin expression and extraction 
Staphyloxanthin was extracted from S. aureus membrane using methanol and an 
absorbance spectrum was determined using a Fluostar Omega (BMG Labtech) 
plate reader. Bacteria were grown in the absence or presence of challenge 
growth conditions and harvested after 24 h incubation at 37˚C. The cultures 
were adjusted to OD600=5, and 10 ml of each sampe was harvested by 
centrifugation. Pelleted cells were resuspended in 1 ml methanol and incubated 
for 15 min at 37 C with shaking.  
Pigment was extracted by adding 1 ml of methanol to the cell pellet, with mixing 
and incubation for 15 min at 37 ˚C. Finally, the methanol extract was centrifuged 
again and 96-well polystyrene microtitre plates were loaded with 250 µl of 
extract in triplicate, prior to absorbance measurement. 
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Chapter 3: Comparative transcriptomics of the 
staphylococcal survival response to the epidermal lipid 
sphingosine 
 
3.1 Introduction 
3.1.1 Transcriptomics technologies 
Transcriptomics is the study of an organism’s sum of all the RNA transcripts 
found within a collection of cells (transcriptome). Sampling and measuring the 
expression of genes in different conditions can provide insight into how cells 
react to a given stimulus. Microarray and RNA-Seq are the dominant 
contemporary transcriptomics technologies, with the former developed in 1995 
(McGettigan, 2013) and the latter in 2008 (Mantione et al., 2014). Microarray is 
based on the use of a chip as a matrix, which is printed with an ordered grid that 
is structured with clusters of short fragments of DNA. Each cluster contains 
picomoles (10-12 moles) of a specific DNA sequence, which are alternately 
named as probes, reporters or oligos. Fluorescently labelled cDNA fragments 
from the test sample are hybridised with the corresponding probes on the 
microarray chips, and the fluorescence intensity detected from the 
hybridisation provides a relative abundance of each arrayed transcript in the 
sample.  
Microarray technology enables assay of 1000s of transcripts simultaneously at a 
relatively low cost (Heller, 2002) and is high throughput (Wang et al., 2009). It 
is able to detect splice variants and produces different results according to the 
probe used or due to cross-hybridisation. Sensitivity and dynamic range is 
limited as cross-hybridisation creates a lot of background noise, which leads to 
the loss of low-level transcripts (Wang et al., 2009). Approximately 1 μg mRNA 
is required for microarray input, and prior design and preparation of reference 
transcripts for probes is needed (Mantione et al., 2014). The quantitation 
accuracy can reach to 90% or higher, limited by the accuracy of fluorescence 
51 
 
detection. The dynamic range of bound fragments is 103-104, limited by the 
fluorescence saturation (Black et al., 2014). 
The more recent and emergent RNA-Seq technology takes advantage of 
advances in high-throughput sequencing combined with use of computational 
algorithms to detect and quantify transcripts in RNA samples (Wang et al., 
2009). cDNAs produced from a test RNA sample are sequenced and result in 
multiple reads for each transcript, which can be further aligned to a reference 
genome. This method has many advantages: firstly, it gives high throughput 
with a much lower amount of input RNA (~1 ng total RNA) (Hashimshony et al., 
2012) compared with microarray;  secondly, it does not prior require 
sequencing and annotation of the genome (Mantione et al., 2014), although a 
genome sequence is useful for data analysis;  thirdly, the background noise is 
very low (with 100bp background signals in non-repetitive regions) (Wang et al., 
2009), and has a large dynamic range (105) without limitation of fluorescence 
saturation (Black et al., 2014). 
 
3.1.2 Analysis tools 
The Clusters of Orthologous Groups (COGs) refers to a protein database 
generated by comparing predicted and known protein sequences in all 
completely sequenced microbial genomes.  Both prokaryotic clusters (COGs) 
and eukaryotic clusters (KOGs) databases have been built to date (Tatusov et al., 
1997).  
The COGs and KOGs are sorted into 25 classes, indicated as A (RNA processing 
and modification), B (Chromatin structure and dynamics), C (Energy production 
and conversion), D (Cell cycle control, cell division, chromosome partitioning), E 
(Amino acid transport and metabolism), F (Nucleotide transport and 
metabolism), G (Carbohydrate transport and metabolism), H (Coenzyme 
transport and metabolism), I (Lipid transport and metabolism), J (Translation, 
ribosomal structure and biogenesis), K (Transcription), L (Replication, 
recombination and repair), M (Cell wall/membrane/envelope biogenesis), N 
52 
 
(Cell motility), O (Posttranslational modification, protein turnover, chaperones), 
P (Inorganic ion transport and metabolism), Q (Secondary metabolites 
biosynthesis, transport and catabolism), R (General function prediction only), S 
(Function unknown), T (Signal transduction mechanisms), U (Intracellular 
trafficking, secretion, and vesicular transport), V (Defence mechanisms), W 
(Extracellular structures), Y (Nuclear structure), Z (Cytoskeleton). Ultimately, 
these COGs they can be further grouped into four classes: Cellular processes and 
signalling (D, M, N, O, T, U, V, W, Y, Z), Information storage and processing (A, B, 
J, K, L), Metabolism (C, E, F, G, H, I, P, Q) and poorly characterised (R, S). 
Each COG consists of either a group of proteins found to be orthologous or they 
are orthologous sets of paralogs across at least three lineages that likely 
correspond to an ancient conserved domain. This classification allows transfer 
of functional information from one member to an entire group, and enables 
predictions of protein function for poorly characterised genes (Tatusov et al., 
1997). 
KEGG (Kyoto Encyclopedia of Genes and Genomes) is a collection of databases, 
including genomes, orthologs, biological pathway, chemical compounds, 
diseases and drugs (Kanehisa and Goto, 2000). The KEGG pathway maps are 
composed of pathways across several categories, with a network of all pathways 
included, indicating molecular interactions and reactions. The pathways are 
designed to link to the genes involved, with information of gene names, 
sequences, functions, products and so on. The KEGG pathway-mapping tool 
enables comparison of datasets with the KEGG PATHWAY wiring diagram 
database, to search for those pathways associated with the provided gene list, 
which aids analysis of cellular and organismal functions (Kanehisa, 1997; 
Kanehisa et al., 2006; Kanehisa et al., 2014). 
SAMMD (Staphylococcus aureus Microarray Meta-Database) is an online 
database that includes transcriptional data from all the published work on the 
species, and curates all the genes found to be differentially expressed at a locus 
of a mutant strain or as a response to change environmental change e.g.  growth 
conditions. The database enables simple search by ORF (open reading frame) ID, 
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gene name or gene product name. The output displays differentially expressed 
gene data, along with the metadata, including experimental growth conditions 
that associate with the query (Nagarajan and Elasri, 2007).  
 
 
3.2 Chapter aims 
Sphingosines are epidermal skin lipids, derived from ceramide, that are able to 
kill S. aureus rapidly at micromolar concentrations (Parsons et al., 2012). The 
transcriptional responses of staphylococci and their resistance mechanisms to 
sphingosine have not been characterised. The main aim of this chapter is to 
identify differentially expressed genes of S. aureus and S. epidermidis in 
response to challenge with D-sphingosine (a representative, easily available 
sphingosine) and compare their transcriptional profiles . It was expected that 
this approach would find differences in responses and possible resistance 
determinants by bacteria, relative to the proposed mode of action for D-
sphingosine. These data might indicate the potential of sphingosine to influence 
the colonisation and persistence of staphylococci on human skin (Arikawa et al., 
2002).  
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3.3 Results 
3.3.1 D-Sphingosine challenge titration 
Sphingosine was proposed to have a role in suppressing S. aureus growth on 
skin (Arikawa et al., 2002). Whilst it is known that D-sphingosine has an 
antimicrobial effect on S. aureus, experiments determined that a narrow range 
of the amino alcohol decreased growth rate after challenge during exponential 
phase (Parsons et al., 2012). In this study, experiments tested a range of 
sphingosine concentrations to determine a defined micromolar range to enable 
further studies. 
To establish a suitable challenge concentration of the antimicrobial lipid D-
sphingosine for subsequent transcriptomics, S. aureus Newman and S. 
epidermidis Tü3298 were cultured in 50 ml of THB broth in 250 ml flasks to 
mid-exponential growth phase, prior to addition of sphingosine. A range of D-
sphingosine concentrations with 100% (v/v) ethanol as solvent within a 
consistent volume of 30 μl were prepared and added to separate growing 
cultures, making final D-sphingosine concentrations of 5 μM, 6 μM and 7 μM. A 
solvent control consisted of 30 μl 100 % (v/v) ethanol.  
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Figure 3.1  Growth curves of staphylococci challenged with a range of D-sphingosine 
concentrations. S. aureus Newman (a) and S. epidermidis Tü3298 (b) were cultured in THB to 
OD600=0.5, whereupon sphingosine was added at different concentrations: 5 μM D-sphingosine 
(green triangle); 6 μM D-sphingosine (purple closed circle); 7 μM D-sphingosine (light blue star); 
no solvent broth control (red cross); ethanol (0.3 mM) solvent control (dark blue square).  
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In separate experiments the growth rates of the broth and solvent control 
cultures of S. aureus and S. epidermidis were indistinguishable, indicating that 
the addition of 30 μl ethanol (0.06% v/v) had no significant effect on cell growth 
(Figure 3.1). Within one hour after challenge with D-sphingosine, the growth 
rates decreased for both species with increasing concentration of D-sphingosine. 
For D-sphingosine treated S. aureus, doubling times for 5 μM (49 min), 6 μM (55 
min), and 7 μM (75 min) increased relative to both the no solvent (40 min) and 
ethanol controls (41 min).  For D-sphingosine treated S. epidermidis, doubling 
times for 5 μM 49 min, 6 μM (56 min), and 7 μM (74 min) increased relative to 
both the no solvent (38 min) and ethanol solvent controls (37 min).  These data 
identify a concentration-dependent decrease of growth in the experimental 
groups caused by addition of D-sphingosine, and for both species treatment 
with 5 μM D-sphingosine was found to be a sub-lethal concentration that 
showed a consistent, observable difference from the controls. This 
concentration was chosen for subsequent RNA-Seq transcriptomic experiments. 
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3.3.2 RNA quality control 
The transcriptional response of S. aureus Newman and S. epidermidis Tü3298 to 
D-sphingosine was determined. THB cultures were challenged with 5 μM D-
sphingosine, using a 5 mg ml-1 stock prepared with ethanol, during the mid-
logarithmic phase of growth when OD600=0.5. Control samples were challenged 
with 0.03% v/v ethanol, an equivalent amount of solvent. RNA was purified 
from cells harvested after 20 min of incubation with D-sphingosine or ethanol 
control. RNA was stabilised by adding RNAlater (Qiagen) with incubation 
otal RNA was then purified from cells the next day using 
the method described in chapter 2 (section 2.5.3). 
Prior to submission for sequencing, purified RNA samples were examined to 
ensure that they were of sufficient standard using several quality tests (Table 
3.1). The ratio of absorbance at 260 nm and 280 nm was used to assess the 
purity of RNA. Nanodrop 260/280 and 260/230 ratios >1.8 indicated low 
protein, salt and solvent contamination. All samples of RNA were then 
determined to be of sufficient concentration (≥30 ng μl-1) and yield (≥3 μg) by 
Qubit assay reads. Finally, RNA integrity number (RIN) scores were determined 
using the Agilent bioanalyser that indicated levels of RNA degradation, and 
samples with RIN values ＞7.0 were qualified for RNA sequencing. 
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Table 3.1 Quality control of RNA-Seq samples.  Concentration was measured by Qubit, 
sample purity was assessed using Agilent NanoDrop, and sample integrity was determined 
using Agilent bioanalyser. Abbreviations: C=control condition, S= sphingosine challenged 
condition. 
Species Sample NanoDrop NanoDrop 
260/230 
Concentration Sample  RIN 
260/280 (ng μl-1) volume (μl) 
S. aureus 
C1 2.17 2.39 694 6 7.1 
C2 2.06 1.8 368 9 8.0 
C3 2.12 2.26 726 6 7.8 
S1 2.06 1.88 426 10 7.1 
S2 1.92 1.88 356 10 8.3 
S3 2.03 2.35 399 10 7.2 
S. epidermidis 
C1 2.16 2.32 1080 3 8.3 
C2 2.15 2.41 ≥1200 3 8.4 
C3 2.16 2.5 ≥1200 3 8.5 
S1 2.15 2.03 696 5 8.7 
S2 2.18 2.45 1040 3 8.6 
S3 2.16 1.8 820 4 7.3 
 
 
Agilent bioanalyser visual output (Figure 3.2) showed the expected RNA 
integrity and relative levels of particular sizes of RNA; using the Prokaryote 
Total RNA assay kit, the 16S and 23S  prokaryotic RNA fragments were detected. 
Thus, for the staphylococcal RNA purifications, two large peaks corresponding 
to 16S and 23S RNA were expected (from left to right).  The RNA LabChip kit has 
a marker solution, which contains a 25 nt DNA fragment that was used as a 
lower marker to align all samples. The marker is displayed on the left as the first 
small peak in the electropherogram, and as the green band in the gel-like image 
on the right. The presence of less pronounced peaks for 23S and 16S RNA or 
other small peaks indicate degradation and lower quality of the purified 
samples. 
 
59 
 
 
Figure 3.2 Bioanalyser QC of RNA-Seq samples. Samples are : S. aureus Newman control 1, 2 
and 3 (AC1, AC2 and AC3 respectively), S. aureus Newman sphingosine treated 1, 2 and 3 (AS1, 
AS2 and AS3 respectively), S. epidermidis Tü3298 control 1, 2 and 3 (EC1, EC2 and EC3 
respectively), and S. epidermidis Tü3298 sphingosine treated 1, 2 and 3 (ES1, ES2 and ES3 
respectively). The visual output for the determined RNA integrity using the Agilent bioanalyser 
showed the characteristic profiles for purified, intact RNA with expected levels of particular 
sizes of RNA. The pronounced two large peaks indicate the presence of 23S and 16S RNA and 
other small peaks suggest their degradation. The three bands in the gel image on the right show 
the presence of 23S RNA, 16S RNA and the assay marker. 
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3.3.3 Comparison of S. aureus Newman and S. epidermidis Tü3298 
transcriptional responses to D-sphingosine challenge 
Analysis of RNA sequence reads was performed by the Centre for Genome 
Research (CGR), Liverpool, which reported genes that were differentially 
expressed (DE) between the ethanol control and D-sphingosine-challenged 
samples for S. aureus Newman and S. epidermidis Tü3298. Following this, 
curated data for S. aureus Newman revealed 1331 DE genes (Appendix III) in 
response to D-sphingosine challenge, of which 665 were upregulated and 666 
genes were downregulated. In contrast, a smaller DE gene set was observed as 
the response of S. epidermidis Tü3298, which exhibited 340 DE genes, of which 
211 were upregulated and 129 were downregulated. 
Among the S. epidermidis Tü3298 DE genes, 260 genes had a homolog in S. 
aureus Newman. Of these, 142 DE genes were present in the S. aureus DE gene 
dataset, with 72 genes sharing upregulation and 42 genes sharing 
downregulation, while 28 genes were oppositely regulated. A heatmap was 
generated of up- and downregulated DE genes of D-sphingosine challenged S. 
aureus Newman to compare with those of S. epidermidis Tü3298 (Figure 3.3).  
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S. aureus Newman  S. epidermidis Tü3298 
Figure 3.3 Heatmap of differential homologous gene expression for S. aureus Newman 
and S. epidermidis Tü3298 after challenge with D-sphingosine. The genes are ordered from 
top to bottom based on S. aureus genome position: upregulated genes (red); downregulated 
genes (blue). White indicates genes that are not differentially expressed in the corresponding 
species. 
 
3.3.4 Comparison of DE gene COGs 
Classification of DE genes using Clusters of Orthologous Groups (GOG) analysis 
was used to assess the most affected cellular pathways in S. aureus and S. 
epidermidis following D-sphingosine challenge. DE genes found in the 
transcriptome data were sorted into 20 categories, which were further grouped 
into four higher functions: cellular processing and signalling, information 
storage and processing, metabolism and poorly characterised (indicated by “X”) 
genes with hypothesised or unknown function. On the basis that DE genes will 
be evenly distributed across the genome, the number of DE genes in each COG 
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class should be proportional to the number of genes encoded by the genome in 
that class. Thus, COGs analysis will reveal whether the numbers of DE genes in 
these orthologous classes are higher or lower than would be expected and so 
reflect the cell response at the pathway level.  
 
Table 3.2 COG classes and upper categories. 
Categories Classes Description 
Cellular 
processes and 
signalling 
D Cell cycle control, cell division, chromosome partitioning 
M Cell wall/membrane/envelope biogenesis 
N Cell motility 
O Posttranslational modification, protein turnover, chaperones 
T Signal transduction mechanisms 
U Intracellular trafficking, secretion, and vesicular transport 
V Defence mechanisms 
W Extracellular structures 
Y Nuclear structure 
Z Cytoskeleton 
Information 
storage and 
processing 
A RNA processing and modification 
B Chromatin structure and dynamics 
J Translation, ribosomal structure and biogenesis 
K Transcription 
L Replication, recombination and repair 
Metabolism 
C Energy production and conversion 
E Amino acid transport and metabolism 
F Nucleotide transport and metabolism 
G Carbohydrate transport and metabolism 
H Coenzyme transport and metabolism 
I Lipid transport and metabolism 
P Inorganic ion transport and metabolism 
Q 
Secondary metabolites biosynthesis, transport and 
catabolism 
and poorly 
characterised 
R General function prediction only 
S Function unknown 
 
D-sphingosine treatment of S. aureus Newman resulted in more up-regulated 
genes (Figure 3.4) than would be expected in the following COG classes: M, O, C , 
E, G, H, I, P, Q, R, S. A greater number of downregulated genes than expected 
were observed in the following COG classes: J, C, F and G. 
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Figure 3.4 Relative percentage of S. aureus Newman DE genes in each COG class.  
Data of the expected percentage (black bars) versus the observed percentage (grey bars) of 
genes in each COG class, assuming even expression across the genome, for up regulated DE 
genes (A) and downregulated DE genes (B). Genes were assigned to COG classes using WebMGA. 
Categories see table 3.2. 
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Figure 3.5 Relative percentage of S. epidermidis Tü3298 DE genes in each COG class. 
Data of the expected percentage (black bars) versus the observed percentage (grey bars) of 
genes in each COG class assuming even expression across the genome, for up regulated DE genes 
(A) and downregulated DE genes (B). Genes were assigned to COG classes using WebMGA. 
Categories are see table 3.2. 
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Analysis of S. epidermidis DE genes using COG classification (Figure 3.5) showed 
more up-regulated genes than would be expected in classes D, O, K, C, E, G, H, P, 
and Q.  
In comparison, both S. aureus and S. epidermidis show similar upregulation of 
genes involved in post translational modification, protein turnover and 
chaperones, which might reflect a requirement to repair and recycle the 
proteome. Both species exhibit greater than predicted downregulation in 
translation, ribosomal structure and biogenesis, as well as nucleotide transport 
and metabolism, indicative of a reduction in growth and de novo biosynthesis. 
Both species exhibit greater than predicted upregulation of most metabolism 
pathways (e.g. energy production and conversion, amino acid, carbohydrate and 
inorganic ion transport and metabolism).  The species differ in their regulation, 
however, with S. epidermidis showing a greater expression of energy related 
pathways than S. aureus, which could indicate that S. epidermidis has a faster 
and/or better adaptive response to D-sphingosine than S. aureus. 
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3.3.5 Comparison of DE metabolic pathways 
The metabolic pathways corresponding with the DE genes were displayed by 
using the KEGG mapper ‘search and colour pathway’ program (version 2.1) 
using the DE gene lists produced by the Centre for Genome Research (CGR), 
University of Liverpool. To achieve this, the S. epidermidis Tü3298 gene names 
were converted to S. epidermidis Rp62a homologous gene names using bespoke 
perl scripts prior to their use in KEGG mapper, because the S. epidermidis 
Tü3298 genome is not an available reference genome for the KEGG database. 
Fifty nine S. epidermidis Tü3298 DE genes had no homolog in strain S. 
epidermidis Rp62a, therefore these genes were removed from the analysis. The 
differentially expressed genes were highlighted in the KEGG pathway maps, 
using colours to show the range of up- or downregulated Log2FC (log2 fold 
change) values. These pathways enabled detection of metabolic processes 
corresponding with DE genes to propose an overview of the effects of D-
sphingosine on cell metabolism. 
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Table 3.3 DEenes involved in energy production pathways of D-sphingosine-treated S. 
aureus Newman and S. epidermidis Tü3298.   
Display of DE genes associated with energy production that were upregulated with Log2FC >0.5 
or downregulated Log2FC <-0.5 after D-sphingosine treatment in S. aureus Newman and S. 
epidermidis Tü3298. The fold level changes are indicated by different colour blocks in the colour 
key. Dark grey colour blocks indicate genes absent in one species, and a white colour block 
represents genes that were not differentially expressed in the RNA-Seq data. KEGG mapper 
output pathways relevant to this table are: glycolysis/gluconeogenesis; pentose phosphate 
pathway; phosphotransferase system (PTS); citrate cycle (TCA cycle); fructose and mannose 
metabolism; galactose metabolism; amino sugar and nucleotide sugar metabolism; pyruvate 
metabolism; propanoate metabolism; butanoate metabolism; and glutathione metabolism. 
 
  3.0 to 3.9 
  2.0 to 2.9 
  1.0 to 1.9 
  0.5 to 0.9 
  -0.9 to -0.5 
  -1.9 to -1.0 
  -2.9 to -2.0 
 
S. aureus S. epidermidis Enzyme EC 
number Log2FC Gene name Log2FC 
Sugar uptake 
-1.7 glcA   
2.7.1.199 
+1.0 NWMN_0177   
+1.7 NWMN_1333   
-1.5 ptsG   
-0.9 mtlF   
2.7.1.197 
-1.0 mtlA   
  NWMN_1619 SETU_01288 +1.3 2.7.1.193 
-0.7 NWMN_0136   
2.7.1.211 
-1.1 NWMN_2279   
+2.0 NWMN_0199   2.7.1.- 
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Table 3.3 continued 
S. aureus S. epidermidis Enzyme EC 
number Log2FC Gene name Log2FC 
Sugar uptake 
+0.7 NWMN_0182   2.7.1.200 
-0.9 mtlF   
2.7.1.197 
-1.1 mtlA   
-1.4 fruB fruK +2.6 2.7.1.56 
-1.2 fruA +2.6 
2.7.1.202 
  NWMN_2540 SETU_02093 +1.9 
+0.5 lacE +2.3 
2.7.1.207 
  lacF +2.2 
  NWMN_0621 SETU_02169 +1.2 2.7.1.195 
 
Glycolysis 
+0.5 glk   2.7.1.2 
+0.7 pgi   5.3.1.9 
+0.5 fbp   3.1.3.11 
+0.6 gapB   1.2.1.12 
-0.5 gpmA   5.4.2.11 
+0.5 pckA +1.8 4.1.1.49 
+0.9 NWMN_1858 SETU_01602   1.2.1.3 
+0.9 NWMN_0534   5.3.1.27 
-0.6 gntK +1.6 2.7.1.12 
+0.9 NWMN_0533   4.1.2.43 
+0.5 tkt   2.2.1.1 
+1.0 NWMN_1672   2.2.1.2 
+0.6 NWMN_0183   1.1.1.14 
-1.0 manA1   5.3.1.8 
-1.0 mtlD   1.1.1.17 
-0.6 gtaB   2.7.7.9 
-0.8 capE   
5.1.3.2 
-0.4 capN   
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Table 3.3 continued 
S. aureus S. epidermidis Enzyme EC 
number Log2FC Gene name Log2FC 
Glycolysis 
-0.9 capP   
5.1.3.14 
-0.6 capG   
  lacA +2.2 
5.3.1.26 
  lacB +2.4 
  lacC +2.6 2.7.1.144 
  lacD +2.7 4.1.2.40 
+0.6 lacG +2.0 3.2.1.85 
  malA +1.5 3.2.1.20 
+1.1 NWMN_0532   3.5.99.6 
+1.1 nagA   3.5.1.25 
-0.5 NWMN_2504   1.1.5.4 
-0.5 sdhC   
1.3.5.1 -0.7 sdhA   
-0.7 sdhB   
 
Pyruvate metabolism  
-1.0 ldh1   
1.1.1.27 
+0.4 ldh   
+0.6 NWMN_2422   
1.1.1.28 
+1.0 NWMN_2459   
-0.6 ackA   2.7.2.1 
+1.1 NWMN_1315 SETU_00980 +1.0 3.6.1.7 
+0.7 NWMN_2506   6.2.1.1 
-0.5 pdhA  
 1.2.4.1 
-0.4 pdhB 
 
-0.4 pdhC SETU_02150 +2.5 2.3.1.12 
-0.5 pdhD  
 1.8.1.4 
  lpdA SETU_02153 +3.3 
-2.2 pflB +3.7 2.3.1.54 
+1.0 NWMN_1263 
 
4.2.1.3 
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Table 3.3 continued 
S. aureus S. epidermidis Enzyme EC 
number Log2FC Gene name Log2FC 
Pyruvate metabolism  
+0.9 citZ gltA +1.0 2.3.3.1 
  sucA +1.6 1.2.4.2 
  sucB +1.6 2.3.1.61 
+1.0 ilvB +1.5 
2.2.1.6 
  SETU_01538 +2.1 
+1.7 alsD   
4.1.1.5 
  budA SETU_02007 +0.7 
  NWMN_0071 SETU_02090 +2.0 1.1.1.76 
+0.5 pckA +1.8 4.1.1.49 
NADH recycling 
-1.0 ldh1   
1.1.1.27 
+0.4 ldh   
+0.9 citC   1.1.1.42 
+1.0 zwf   1.1.1.49 
 
 
Following D-sphingosine challenge, genes associated with sugar uptake, 
glycolysis and pyruvate metabolism of S. epidermidis Tü3298 were notably 
upregulated, suggesting an overall increase in energy production (Table 3.3). In 
contrast, S. aureus Newman showed mainly upregulated pyruvate metabolism 
and NADH recycling, but downregulated sugar uptake pathways. Hence, there is 
no consistent identifiable trend in upregulation or downregulation of general 
energy production and substrate transport across S. aureus. 
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Table 3.4 DE genes involved in ammonia production pathways of D-sphingosine-treated S. 
aureus Newman and S. epidermidis Tü3298.   
DE genes associated with ammonia production that were upregulated with Log2FC >0.5 or 
downregulated Log2FC <-0.5 with D-sphingosine treatment in S. aureus Newman and S. 
epidermidis Tü3298 are displayed respectively. The levels of fold changes are indicated with 
different colour blocks in the colour key. A white colour block represents genes that were not 
differentially expressed in the RNA-Seq data. KEGG mapper output pathways relevant to this 
table were: purine metabolism; arginine and proline metabolism; nitrogen metabolism; and 
two-component systems. 
 
  1.0 to 1.9 
  0.5 to 0.9 
  -0.9 to -0.5 
  -1.9 to -1.0 
 
S. aureus S. epidermidis Enzyme EC 
number Log2FC Gene name Log2FC 
+1.2 ureA   
3.5.1.5 +1.3 ureB 
 
conti+1.1 ureC 
 
  arc arcA +1.1 2.7.2.2 
-0.5 NWMN_1852 SETU_01471 
 
1.14.14.47 
-0.6 narJ 
 
NarJ 
-0.8 narH 
 1.7.5.1 
-2.0 narG 
 
-1.0 nirD 
 1.7.1.15 
-1.4 nirB   
 
 
Similarly, no consistent trend across both species was observed in ammonia 
production after sphingosine challenge (Table 3.4). Upregulation of the ureABC 
operon was observed in S. aureus, where UreA, UreB and UreC are the urease 
subunits that catalyse the hydrolysis of urea to form ammonia and carbamate. 
Urease (urea amidohydrolase) is a nickel-binding enzyme, and each subunit 
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binds two nickel ions via four histidines, an aspartate and a carbamated-lysine 
(Jabri et al., 1995). Consistent with ammonia production, there was down 
regulation of nitric-oxide synthase oxygenase (NWMN_1852) that would 
preserve ammonia. However, downregulation of genes that encode for nitrate 
reductase (narG, narH, narJ) and nitrite reductase (nirB, nirD) would reduce 
ammonia generation from these alternative pathways. In S. epidermidis, the only 
pathway change was upregulated arcA that encodes arginine deiminase, which 
catalyses the conversion of arginine to produce ammonia.  
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Table 3.5 DE genes involved in amino acid production pathways of D-sphingosine-treated 
S. aureus Newman and S. epidermidis Tü3298.   
DE genes associated with amino acid production that were upregulated with Log2FC >0.5 or 
downregulated Log2FC <-0.5 after D-sphingosine treatment in S. aureus Newman and S. 
epidermidis Tü3298 are displayed respectively. The fold level changes are indicated by different 
colours in the colour key. A white colour block represents genes that were not differentially 
expressed in the RNA-Seq data. KEGG mapper output pathways relevant to this table are: 
Histidine metabolism; Glycine, serine and threonine metabolism; Cysteine and methionine 
metabolism; Lysine biosynthesis; Valine, leucine and isoleucine biosynthesis; and Alanine, 
aspartate and glutamate metabolism. 
 
  2.0 to 2.9 
  1.0 to 1.9 
  0.5 to 0.9 
  -0.9 to -0.5 
  -1.9 to -1.0 
  -2.9 to -2.0 
  -3.9 to -3.0 
  < -4.0 
 
S. aureus S. epidermidis Enzyme EC 
number Log2FC Gene name Log2FC 
+1.2 hisD SETU_02135 +0.9 1.1.1.23 
  hisG +2.0 2.4.2.17 
+1.1 NWMN_2577 
 
2.4.2.17 
+1.4 hisA 
 
5.3.1.16 
+1.2 hisF 
 
4.1.3.- 
+1.5 hisH 
 
2.4.2.- 
+1.4 hisB 
 
4.2.1.19 
+1.5 hisC 
 
2.6.1.9 
+0.9 NWMN_1858 
 
1.2.1.3 
-0.8 hutG 
 
3.5.3.8 
+1.7 NWMN_2331 garK +1.1 
2.7.1.165 
+0.5 NWMN_0711 
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Table 3.5 continued 
S. aureus S. epidermidis Enzyme EC 
number Log2FC Gene name Log2FC 
-4.9 NWMN_1348 
ilvA +1.6 4.3.1.19 
+1.1 NWMN_1967 
+0.9 NWMN_2509 betA +1.7 1.1.99.1 
+1.2 NWMN_2510 betB +1.6 1.2.1.8 
+2.4 thrC +1.9 4.2.3.1 
+2.6 thrB +1.6 2.7.1.39 
+2.5 metL hom +1.1 1.1.1.3 
+1.5 serA 
 
1.1.1.95 
+0.7 trpB 
 4.2.1.20 
+0.7 trpA 
 
+1.0 NWMN_1228 
 
4.1.2.48 
+1.3 asd 
 
1.2.1.11 
+2.6 thrA 
 2.7.2.4 
+1.3 lysC 
 
+0.7 NWMN_0350 
 
4.4.1.8 
+0.4 NWMN_0011 SETU_02277 +1.0 2.3.1.31 
+1.4 metH 
 
2.1.1.10 
+1.3 metE 
 
2.1.1.14 
+1.1 NWMN_1612 
 
1.8.4.14 
+1.6 dapA 
 
4.3.3.7 
+1.6 dapB 
 
1.17.1.8 
+1.7 dapD 
 
2.3.1.89 
+0.7 NWMN_0919 
 
2.6.1.- 
+1.0 NWMN_1644 
 
3.5.1.18 
+1.4 lysA 
 
4.1.1.20 
+0.5 murF 
 
6.3.2.10 
+1.2 leuC 
 4.2.1.33/4.2.1.35 
+1.1 leuD +2.1 
+1.1 leuB SETU_01541 +2.1 1.1.1.85 
+1.2 leuA SETU_01540 +2.2 2.3.3.13 
+0.9 ilvB SETU_01537 +1.5 
2.2.1.6 +1.8 alsS 
 
  SETU_01538 +2.1 
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Table 3.5 continued 
S. aureus S. epidermidis Enzyme EC 
number Log2FC Gene name Log2FC 
+1.1 ilvC SETU_01539 +2.3 1.1.1.86 
+0.7 ilvD SETU_01536 +1.1 4.2.1.9 
+0.9 ilvE 
 
2.6.1.42 
-1.9 pyrB -1.5 2.1.3.2 
+1.1 argG +1.6 6.3.4.5 
+1.8 argH SETU_00508 +1.6 4.3.2.1 
+0.5 ansA  
 
3.5.1.1 
-5.1 ald  
 
1.4.1.1 
  NWMN_2454 SETU_01983 +2.7 1.2.1.88 
  gltD +0.8 1.4.1.13/1.4.1.14 
-1.4 pyrAA SETU_00773 -0.7 
6.3.5.5 
-1.3 pyrAB   
 
 
Overall, gene expression concerned with amino acid production was 
upregulated for both S. aureus Newman and S. epidermidis Tü3298 (Table 3.5), 
which is consistent with upregulation of protein turnover and recycling and 
changes in nitrogen pathways. However, consistent with the greater number of 
DE genes observed in the S. aureus response there was a similar relative 
increase in these pathways compared with S. epidermidis. Consistent with this, 
the upregulation of pyruvate metabolism detailed in table 3.3 will increase 
metabolites for amino acid production. 
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Table 3.6 DE genes involved in peptidoglycan biosynthesis pathways of D-sphingosine-
treated S. aureus Newman and S. epidermidis Tü3298.   
Display of DE genes associated with energy production that were upregulated with Log2FC >0.5 
or downregulated Log2FC <-0.5 after D-sphingosine treatment in S. aureus Newman and S. 
epidermidis Tü3298. The fold level changes are indicated as different colours in the colour key 
shown. A white colour block represents genes that were not differentially expressed in the RNA-
Seq data. KEGG mapper output pathway relevant to this table is: Peptidoglycan biosynthesis. 
 
  1.0 to 1.9 
  0.5 to 0.9 
  -0.9 to -0.5 
 
S. aureus S. epidermidis Enzyme EC 
number Log2FC Gene name Log2FC 
-0.6 murA   
2.5.1.7 
+1.1 murZ   
+0.5 murF   6.3.2.10 
+0.5 mraY   2.7.8.13 
+0.8 uppP (bacA)   3.6.1.27 
+1.8 NWMN_1766 SETU_01431   2.4.1.129 
+0.8 pbpB   3.4.16.4 
 
 
Gene expression pertaining to peptidoglycan biosynthesis was mostly 
upregulated in S. aureus Newman, but was unaffected in S. epidermidis Tü3298 
(Table 3.6). This overall trend of increased peptidoglycan biosynthesis indicates 
a difference in the effect that D-sphingosine is having on the cell wall of S. aureus.  
One interpretation is that S. aureus repair and recycling pathways are activated 
that would help with turnover and/or growth of the cell wall as a protective 
mechanism. A thicker cell wall can act as a defence from certain antimicrobials 
due to the peptidoglycan interactions limiting disruption of the cell membrane, 
an effect well-described for vancomycin (Pechous et al., 2004; Utaida et al., 
2003). Alternatively, D-sphingosine activates the cell wall stress stimulon. 
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Genes murA and murZ encode the bacterial enzyme UDP-N-acetylglucosamine 
(UDP-GlcNAc) enolpyruvyltransferase (MurA). This enzyme adds enolpyruvyl to 
UDP-N-acetylglucosamine to form UDP-N-acetylmuramic acid (UDPMurNAc), 
which is the first step of bacterial cell wall biosynthesis (Eschenburg et al., 
2003). MurF catalyses the synthesis of UDP-N-acetylmuramoyl-pentapeptide, 
the cytoplasmic precursor (the precursor of murein) of the bacterial cell wall 
peptidoglycan (Longenecker et al., 2005). MraY is an integral membrane protein 
responsible for the formation of the first lipid intermediate of the cell wall 
peptidoglycan synthesis (Bouhss et al., 1999).  
UppP is a small, highly hydrophobic protein that involved with bacitracin 
resistance in Escherichia coli (Cain et al., 1993). The protein was originally 
proposed to be an undecaprenol kinase (BacA) (El Ghachi et al., 2004), but was 
renamed UppP when it was found to be an undecaprenyl pyrophosphate 
phosphatase (Bernard et al., 2005; El Ghachi et al., 2005). 
VraSR regulates transcription of penicillin-binding protein 2 (PBP2) in S. aureus 
(Kuroda et al., 2003). PBP2 functions in staphylococcal cell wall biosynthesis 
and susceptibility to antimicrobial agents (Kishida et al., 2006). It is an essential 
protein in methicillin and vancomycin resistance in S. aureus (Boyle-Vavra et al., 
2003; Severom et al., 2004), and was reported to be inducible by both 
vancomycin and oxacillin (Yin et al., 2006). Induction of pbpB and by β-lactam 
and related compounds was found to be dependent on vraS (Yin et al., 2006).  
Gene pbpB that encode PBP2 in S. aureus was found upregulated by 1.74 fold 
change in D-sphingosine treated S. aureus Newman RNA-Seq data. Moreover, 
cell wall biosynthesis gene murZ of vraSR regulon was also upregulated. 
Altogether, these changes in gene expression support that expression of the 
vraSR operon is inducible by D-sphingosine treatment. 
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Table 3.7 DE genes involved in membrane lipid biosynthesis pathways of D-sphingosine -
treated S. aureus Newman and S. epidermidis Tü3298.   
Display of DE genes associated with membrane lipid biosynthesis that were upregulated with 
Log2FC >0.5 or downregulated Log2FC <-0.5 after D-sphingosine treatment of S. aureus Newman 
and S. epidermidis Tü3298. The fold level changes are indicated as different colour blocks in the 
colour key shown. A grey colour block represents a gene absent in one species, and a white 
colour block represents a gene that was not differentially expressed in the RNA-Seq data. KEGG 
mapper output pathways relevant to this table are: Glycerolipid metabolism; 
Glycerophospholipid metabolism; Fatty acid degradation; Fatty acid biosynthesis; and 
Carotenoid biosynthesis. 
 
  1.0 to 1.9 
  0.5 to 0.9 
  -0.9 to -0.5 
  -1.9 to -1.0 
  -2.9 to -2.0 
 
S. aureus S. epidermidis Enzyme EC 
number LogFC Gene name LogFC 
Glycerolipid biosynthesis     
-0.6 plsK 
 2.3.1.15 
-0.6 plsX 
 
+0.9 glpK 
 
2.7.1.30 
-2.6 geh SETU_02128 +1.9 
3.1.1.3 
-1.8 lip 
 
 
Glycerol, glycerolipid, glycerophospholipid metabolism 
+0.9 NWMN_1858 SETU_01602 
 
1.2.1.3 
-0.6 plsK 
 2.3.1.15 
-0.6 plsX 
 
+1.3 glpQ 
 
3.1.4.46 +0.8 NWMN_0984 
 
+1.0 NWMN_1614 
 
 
 
79 
 
Table 3.7 continued 
S. aureus S. epidermidis Enzyme EC 
number Log2FC Gene name Log2FC 
Glycerol, glycerolipid, glycerophospholipid metabolism 
+1.7 NWMN_2331 SETU_01869 +1.0 
2.7.1.165 
+0.5 NWMN_0711 
 
+0.7 NWMN_0619 SETU_02171 +1.0 
2.7.1.- 
+0.6 NWMN_0620 SETU_02170 +1.3 
+1.6 glpD 
 
1.1.5.3 
+0.5 NWMN_1230 
 
2.7.8.- 
-0.6 NWMN_1926 
 
3.1.4.3 
 
Fatty acid degradation    
+0.9 NWMN_1858 SETU_01602 
 
1.2.1.3 
+1.0 fadE 
 
6.2.1.3 
+0.8 NWMN_0346 SETU_00013 
 
2.3.1.9 
-0.7 adhE 
 
1.1.1.1 -2.3 adh1 SETU_00229 +1.6 
+0.9 NWMN_2091 SETU_01662 -0.8 
+0.6 fadA 
 
2.3.1.16 
+0.6 fadB 
 
1.1.1.35 
+0.9 accC 
 6.4.1.2 
+0.8 accB 
 
-0.5 fadD 
 
2.3.1.39 
-1.0 NWMN_0853 
 
2.3.1.180 
-0.8 NWMN_0854 
 
2.3.1.179 
-0.5 fabG 
 
1.1.1.100 
Carotenoid biosynthesis 
  -1.3 crtM 
 
2.5.1.96 
-1.2 crtN 
 
1.3.8.2 
-1.7 crtI 
 
1.14.99.44 
-1.6 NWMN_2463 
 
2.4.1.- 
-1.5 NWMN_2465 
 
2.3.1.- 
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There was a stark difference in membrane lipid biosynthesis gene expression 
between both species of staphylococci. Fatty acid biosynthesis and degradation 
pathways were mainly upregulated in S. aureus, while glycerophospholipid 
biosynthesis was downregulated (Table 3.7). This may indicate that D-
sphingosine treated S. aureus utilise fatty acids as a source of membrane lipid 
rather than undergoing glycerophospholipid biosynthesis. In contrast, D-
sphingosine causes little change to lipid pathway gene expression in S. 
epidermidis, indicative of an absence of changes to gene expression being 
required due to the presence of sphingosine. These data support that 
sphingosines are metabolised differently in S. aureus and S. epidermidis, and 
more toxic in S. aureus than S. epidermidis. 
The operon crtMNOPQ encodes enzymes for catalysis of staphyloxanthin 
biosynthesis and these genes were downregulated in S. aureus. Staphyloxanthin 
is a yellowish-orange carotenoid pigment that gives this species its descriptive 
golden colour, and was described as an important antioxidant virulence factor 
(Liu and Nizet, 2009). Staphyloxanthin contributes to integrity of the S. aureus 
cell membrane (Mishra et al., 2011) and facilitates bacterial survival under 
oxidative stress and during infections (Giachino et al., 2001; Kahlon et al., 2010; 
Clauditz et al., 2006). Downregulation of staphyloxanthin production will 
decrease ROS resistance and alter membrane composition although these 
changes as a response to the antimicrobial activity of sphingosine are unclear. 
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Table 3.8 DE virulence factor genes of D-sphingosine treated S. aureus Newman and S. 
epidermidis Tü3298.   
Display of DE virulence factor genes that were upregulated with Log2FC >0.5 or downregulated 
Log2FC <-0.5 after D-sphingosine treatment of S. aureus Newman and S. epidermidis Tü3298. The 
levels of fold changes are indicated as different colour blocks and the colour key is shown. A 
grey coloured block represents absent genes, and a white colour block represents genes that 
were not differentially expressed in the RNA-Seq data. The KEGG mapper output pathway 
relevant to this table was: Staphylococcus aureus infection. 
 
  1.0 to 1.9 
  0.5 to 0.9 
  -0.9 to -0.5 
  -1.9 to -1.0 
  -2.9 to -2.0 
  -3.9 to -3.0 
  < -4.0 
 
S. aureus S. epidermidis Enzyme EC 
number Log2FC Gene name Log2FC 
-0.5 clfA   ClfA 
-1.6 clfB   ClfB 
-0.5 sdrE   SdrC/D 
-4.1 NWMN_1069   Efb/Ecb 
-1.9 NWMN_0165   
SCIN -4.2 NWMN_1070   
-4.3 scn   
-0.9 spa   Spa 
-3.8 sbi   Sbi 
-4.2 NWMN_1067   FLIPr 
-5.4 chp   CHIPS 
-3.0 map   Map 
-1.1 ssl5nm   SSL5 
-4.8 ssl7nm   SSL7 
-4.6 ssl11nm   SSL11 
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Table 3.8 continued 
   
S. aureus S. epidermidis Enzyme 
Name Log2FC Gene name Log2FC 
-0.5 dltA   
Dlt 
-0.4 dltB   
-0.6 dltC   
-0.5 dltD   
-0.5 lukE   
Luc -3.0 lukF   
-3.2 lukS   
-2.2 hlgA   
Hlg -1.8 hlgC   
-1.6 hlgB   
+1.1 NWMN_1503   
Enterotoxin 
-0.5 sea   
-0.9 eta   Eta 
 
 
There was a pronounced downregulation of virulence factor genes in S. aureus 
(Table 3.8) most of which are restricted to this species. This includes genes 
related to tissue adhesion: clfA (Clumping factor A), clfB (Clumping factor B), 
sdrE (Serine-aspartate repeat-containing protein E), NWMN_1069 (Fibrinogen-
binding protein); innate immune evasion genes: scn (Staphylococcal 
complement inhibitor), spa (Immunoglobulin G binding protein A), sbi 
(Immunoglobulin-binding protein sbi) , NWMN_1067 (Formyl peptide receptor-
like 1 inhibitory protein), chp (Chemotaxis inhibitory protein of S. aureus), SSLs 
(ssl5nm, ssl7nm and ssl11nm),  map (MHC class II analog protein Map); and 
secreted toxins: leukocidin (lukE, lukF, lukS), gamma-hemolysin (hlgA, hlgB, 
hlgC), exterotoxins (NWMN_1503 and sea) and exfoliative toxin (eta). 
The dltABCD operon encodes enzymes that esterify lipoteichoic acid (LTA) with 
D-alanine, which plays an important role in controlling the net anionic charge of 
LTA.  Increased expression of the dlt operon in the presence of cationic 
antimicrobial peptides (CAMPs) limits binding of cationic antimicrobial 
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peptides since addition of d-alanine to the cell wall results in a net positive 
charge on the bacterial cell surface, and as a consequence, reduces interaction 
with CAMPs (Peschel et al., 1999). Expression of the dlt operon is also cation-
induced in S. aureus; dlt mRNA was demonstrated to be induced within 15 min 
by high concentrations of Na+ and moderate concentrations of Mg2+ and Ca2+ 
(Koprivnjak et al., 2006). Downregulation of the dlt operon by D-sphingosine 
may indicate that interaction with sphingosines is not perceived as being similar 
to interaction with CAMPs, despite some overlap with the temporin and 
ovispitin transcriptional responses (Figure 3.8) according to comparison with 
the SAMMD datasets. 
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3.3.6 Comparison of sphingosine transcriptome to other S. aureus 
transcriptome data sets 
The online bioinformatics web server SAMMD (S. aureus Microarray Meta-
Database) was used to search for overlaps in gene regulation between the D-
sphingosine challenge datasets and published S. aureus transcriptomics datasets. 
Both sphingosine-challenged S. aureus Newman and S. epidermidis Tü3298 
transcriptomes were compared with all datasets in SAMMD (Appendix I).  
The gene names were converted to their homologs in strain S. aureus N315 to 
enable the data to be used to search in SAMMD. Genes with a Blast hit to the S. 
aureus N315 genome with an E-value lower than 0.0001 were considered 
homologous. This resulted in 1239 of 1331 S. aureus Newman DE genes and 261 
of 340 S. epidermidis Tü3298 DE genes being converted to their best match in S. 
aureus N315. Overlaps between S. epidermidis Tü3298 and the compared 
datasets were limited compared with S. aureus Newman due to the numbers 
and matches for DE genes in the S. epidermidis data. 
Where multiple datasets for the same antimicrobial were available, the dataset 
using the most similar experimental conditions to that used in the D-
sphingosine study was selected. The growth conditions and references of the 
selected datasets are listed in Appendix.   
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Figure 3.6 SAMMD comparison of D-sphingosine transcriptomes with S. aureus 
vancomycin, teicoplanin, telavancin and enduracidin challenge transcriptomes. Genes in 
D-sphingosine transcriptome datasets are represented by blue circles and the comparison 
transcriptome datasets are represented by orange circles, where green circles indicate inversely 
regulated genes between the datasets. Comparisons between (A) S. aureus Newman (B) S. 
epidermidis Tü3298. References and selected experiment conditions of comparison datasets see 
appendix I.  
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Although it cannot be argued that the chosen antimicrobials for comparison 
have similar modes of action, they were nevertheless used to provide insight of 
potential overlap of cell responses to determine the effects of sphingosine on 
transcription.  In this regard, when considering the high numbers of 
differentially expressed genes in the S. aureus sphingosine dataset there was 
greatest overlap of regulation (proportion of similarly upregulated or 
downregulated in the antibiotic challenge comparison dataset) with the 
vancomycin (64%), teicoplanin (45%), telavancin (61%) and enduracidin (61%) 
datasets (as a proportion of the comparator datasets)(Figure 3.6). 
Of these antimicrobials, vancomycin is a widely-used cell-wall targetting 
antibiotic in bacterial infection, including methicillin-resistant S. aureus (MRSA). 
Teicoplanin is a semisynthetic glycopeptide with a similar spectrum of activity 
to vancomycin in the treatment of infections caused by Gram-positive bacteria. 
Telavancin is a semisynthetic antimicrobial lipoglycopeptide derivative of 
vancomycin, for use against MRSA and other Gram-positive bacteria that 
inhibits peptidoglycan biosynthesis (Higgins et al., 2005), and disrupts 
membrane barrier function by increased cell permeability and depolarisation 
(Leadbetter et al., 2004). Enduracidin (also named enramycin) is an 
antimicrobial peptide that induces a similar transcriptome response of S. aureus 
to telavancin (Song et al., 2012). 
The overlap between the D-sphingosine challenge response and these 
transcriptomics datasets of cell-wall targeted and cell membrane targeted 
antimicrobials supports both cell wall and membrane stress caused by 
sphingosine. The overlapped gene regulation in these datasets includes cell 
envelope-related genes lytM, murF, murZ, pbpB (named pbp2 in strain N315), 
bacA and vraRS, encoding the cell wall stress TCS.  
In addition to the shared cell wall stimulon response, various protease and 
chaperone protein genes groES, groEL, dnaJ, dnaK, clpP and prsA shared 
upregulation in the overlapped datasets, likely indicating accumulation of 
protein damage. The clpC repressor gene ctsR, which is part of the protein 
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quality control system in Gram-positive bacteria, was downregulated in both 
datasets.  
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Figure 3.7  SAMMD comparison of D-sphingosine transcriptomes with S. aureus cell wall 
biosynthesis inhibitor transcriptomes.  
Genes in D-sphingosine datasets are represented by blue circles, the comparison datasets are 
represented by orange circles, and green circles indicate inversely regulated genes between the 
datasets. (A) S. aureus Newman. (B) S. epidermidis Tü3298. References and selected experiment 
conditions of comparison datasets see appendix I. 
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Given the output from the comparative analysis above, where an overlap with 
the sphingosine and cell wall antibiotic responses was observed, further cell 
wall active antimicrobials, including AMPs were included in additional 
comparisons (Figure 3.7): bacitracin is a mixture of cyclic peptides; oxacillin is a 
beta-lactam similar to methicillin; fosfomycin is a phosphoenolpyruvate 
analogue; and human beta defensin3 is a cationic antimicrobial peptide (CAMP). 
Fosfomycin was an inhibitor of murA and murZ and show similar transcriptomic 
responses as that in murB or murE depletion mutants (O’Neill et al., 2009). Each 
of these listed compounds are reported as cell wall active antibiotics (O’Neill et 
al., 2009; Utaida et al., 2003; Sass et al., 2008) despite their different molecular 
structures.  
Overlapping regulation (proportion of similarly upregulated or downregulated 
in the listed antimicrobial comparison dataset) was observed between the S. 
aureus D-sphingosine transcriptome and those of the bacitracin (66%), oxacillin 
(66%), fosfomycin/murE/B mutant (79%) and human beta defensin3 (55%) 
transcriptomes (as a proportion of the comparator datasets); low overlap 
numbers were seen for oppositely regulated genes.  While a high proportion of 
these transcriptomes’ differentially-regulated genes was determined to 
resemble the sphingosine transcriptome, a lesser extent of overlapped data was 
seen with the daptomycin transcriptome (23% similar regulation and 22% 
opposite regulation; Venn diagram not shown).   
The transcriptomic overlaps between the responses to D-sphingosine and these 
cell wall biosynthesis inhibitors supports an interpretation that part of the 
response to D-sphingosine is inhibition of cell wall biosynthesis. This could be 
through direct inhibition of biosynthesis pathways, or via downregulation of 
genes involved in cell wall biosynthesis both of which could be hierarchically 
coordinated by VraSR and other described regulators of transcription. Because 
KEGG pathway analysis (Table 3.6) indicates an overall upregulation in 
peptidoglycan synthesis, it is equally likely that D-sphingosine simultaneously 
affects cell wall biosynthesis by direct interactions. 
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Figure 3.8 SAMMD comparison of D-sphingosine transcriptomes with S. aureus 
membrane disrupting antimicrobials transcriptomes. Genes in D-sphingosine datasets are 
represented by blue circles and comparison datasets are represented by orange circles, with 
green circles indicating inversely regulated genes between the datasets. (A) S. aureus Newman 
(B) S. epidermidis Tü3298. References and selected experiment conditions of comparison 
datasets see appendix I. 
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The transcriptomes of the S. aureus responses to AMPs that are reported to 
cause membrane disruption were also compared with the sphingosine 
transcriptome (Figure 3.8). The responses of S. aureus to D-sphingosine 
exhibited partial overlap with that of the AMPs  ovispirin (76%) and temporin 
(75%) responses (as a proportion of the temporin and ovispirin datasets). 
Whilst a lesser overlap was revealed with dermaseptin (38%) and nisin (19% 
similar and 21% opposite). 
Comparative analysis revealed that the transcriptomes of S. aureus responses to 
ovispirin, temporin and dermaseptin all bear a signature downregulation in 
nitrate respiration (nar operon) and virulence factor genes (sbi, hlgA, ssl11, clfA, 
clfB and spa), which were coincident with the D-sphingosine challenge 
transcriptome.  Since the virulence factor genes are all members of the SaeRS 
regulon this potentially identifies a common response to membrane 
perturbation via these antimicrobials is a reduction in secreted virulence factors, 
most of which are concerned with innate immune evasion from complement, 
antibodies and phagocytes. 
Few overlaps were identified between the S. epidermidis transcriptomic data 
and the various cell wall or AMP-related datasets, except upregulation of 
general stress response genes including the ctsR-clpC operon, groELS and dnaJK, 
as well as vraSR, encoding the two-component system that controls the cell well 
biosynthesis regulon. 
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Figure 3.9 SAMMD comparison of D-sphingosine transcriptomes with S. aureus acid shock, 
linoleic acid and heat shock transcriptomes.  
Genes in D-sphingosine datasets are represented by blue circles and comparison datasets are 
represented by orange circles, with green circles indicating inversely regulated genes between 
the datasets. (A) S. aureus Newman (B) S. epidermidis Tü3298. References and selected 
experiment conditions of comparison datasets see appendix I. 
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As a further comparative exercise, the S. aureus D-sphingosine transcriptome 
was aligned with transcriptomes of acid and heat shock and linoleic acid, 
another antimicrobial lipid (Figure 3.9). The S. aureus data comparison showed 
a relatively high overlap with the heat shock dataset (51% similar and 9% 
opposite) (as a proportion of the comparator datasets) including a large number 
of amino acid metabolism and some general stress response genes. The linoleic 
acid data was compared because previous work suggested similar transport 
pathways (farER described in chapter 5) for exporting linoleic acid and D-
sphingosine, but these datasets were poorly matched (19% similar and 25% 
opposite)(as a proportion of the comparator datasets). 
In contrast, the S. aureus D-sphingosine transcriptome overlaps the acid shock 
dataset to a greater extent, with a high similar proportion (53%) and low 
opposite proportion (7%) of DE genes (Figure 3.9). Again, this overlap included: 
upregulation of the urease genes (ureA, ureB, ureC, ureF) that encode production 
of neutralising ammonia as a direct defence to acid shock; genes related to 
NADH recycling (zwf, tkt, pgi, gnd) that assist in reducing energy generation; 
copper-transporting ATPase copA (SA2344, NWMN_2457) that pump excess Cu2+ 
to lower metal ion toxicity and oxidative damage caused by excess metal ions; 
and DNA repair system (dinP, polA, rexA, rexB). Additionally, pyrimidine 
ribonucleotide biosynthesis, ribosomal protein genes and ribosome recycling 
factor Frr were downregulated in both datasets.  
The overlap between the S. epidermidis Tü3298 D-sphingosine transcriptome 
and that of the S. aureus acid shock dataset was evident, however, most 
overlapping regulated genes encode ribosomal proteins. Only two genes were 
upregulated in both datasets, specifically ammonia production (arcC) and copA 
(SETU_01986) metal transport. 
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3.3.7 Comparative transcriptomic responses shared between S. aureus and 
S. epidermidis 
To build a broader view of the effects that D-sphingosine challenge has on cells 
of both S. aureus and S. epidermidis, a catalogue of common DE gene expression 
was created. Table 3.9 exhibits all common DE homologous genes in response to 
D-sphingosine challenge of S. aureus Newman and S. epidermidis Tü3298. These 
genes can be considered a D-sphingosine stimulon. The changes in gene 
expression appear to be coordinated by a suite of transcriptional regulators: 
both species upregulated global regulator vraSR, whilst downregulating saeRS 
and together they control most changes in gene expression encoding secreted 
proteins.  In addition, there appears a role for LytR in regulation of autolytic 
activities. Further hierarchical regulators include: CtsR, HrcA and PhoU.  The 
pstS and pstCABphoU operon was of specific interest since all members of this 
operon were strongly upregulated, with Log2FC value greater than 3 (i.e. >8 fold 
increase). This operon encodes and regulates expression of the Pst (phosphate-
specific transport) system, which is a high-affinity, low-velocity, free-Pi 
transport system that is structurally similar to an ABC transporter (Ames, 1986). 
Further investigation of this operon is described in chapter 4. 
Upregulated genes associated with transport and metabolism of carbohydrates, 
amino acids, coenzymes and inorganic ions, identifies an increased need for 
energy production and conversion. Both species decreased gene expression of 
nucleotide metabolism and ribosomal biosynthesis, while both species 
increased expression of genes associated with transcription, post-translational 
modification, protein turnover and chaperones production. Altogether, this 
indicates protein damage due to sphingosine challenge and this pattern of gene 
expression is a general stress response common to various environmental 
stimuli, including heat and acid stress, and various antimicrobials targeting the 
cell wall and membrane.   
Differences in the responses of both species of Staphylococcus include decreased 
expression of genes for protection against oxidative stress in S. aureus 
contrasting with increased expression in S. epidermidis (Table 3.10). The 
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reduction in expression of staphyloxanthin biosynthesis genes (crtM,N, P, Q, O) 
(Table 3.7) is known to increase susceptibility to oxidative stress in S. aureus 
(Clauditz et al., 2006)  
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Table 3.9 The D-sphingosine stimulon of S. aureus and S. epidermidis.  Common DE 
homologous genes with the same trend of regulation in response to D-sphingosine challenge of S. 
aureus Newman and S. epidermidis Tü3298.  DE genes with greater than two-fold change are 
listed. 
S. aureus Newman 
Description 
S. epidermidis Tü3298  
Gene Log2FC Log2FC Gene 
 
Posttranslational modification, protein turnover, chaperones  
clpC 2.3  Clp protease subunit ClpC 2.5  clpC 
NWMN_0845 2.1  Clp protease subunit ClpB 3.1  SETU_00522 
dnaJ 1.3  chaperone protein DnaJ 1.1  SETU_01152 
dnaK 1.5  chaperone protein DnaK 1.5  dnaK 
grpE 1.4  heat shock protein GrpE 1.7  SETU_01154 
NWMN_1615 1.5  osmotic stress-related protein 1.1  SETU_01284 
NWMN_1621 2.4  heat-shock protein htrA 3.0  SETU_01290 
prsA 2.2  peptidyl-prolyl cis/trans-isomerase 1.9  SETU_01367 
clpP 2.1  Clp protease proteolytic subunit 1.6  clpP 
NWMN_0653 1.0  ABC transporter, MsbA family protein 1.4  SETU_00305 
NWMN_0654 1.1  ABC transporter, MsbA family protein 1.4  SETU_00306 
 
Signal transduction mechanisms  
saeS -3.0  sensor histidine kinase SaeS -2.3  SETU_00325 
saeR -3.0  DNA-binding response regulator SaeR -2.4  SETU_00326 
vraS 2.3  sensor histidine kinase VraS 2.7  SETU_01442 
vraR 2.3  DNA-binding response regulator VraR 2.7  vraR 
 
Translation, ribosomal structure and biogenesis  
NWMN_1481 1.1  ribosomal protein L11 methylase 1.0  prmA 
rplT -1.2  50S ribosomal protein L20 -1.0  rplT 
rpmI -1.2  50S ribosomal protein L35 -1.1  rpmI 
infC -1.0  translation initiation factor IF-3 -1.2  infC 
rpsD -1.0  30S ribosomal protein S4 -1.1  rpsD 
rpsI -1.1  30S ribosomal protein S9 -0.9  rpsI 
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Table 3.9 continued 
S. aureus Newman 
Description 
S. epidermidis Tü3298  
Gene Log2FC Log2FC Gene 
Transcription  
ctsR 2.1  transcriptional regulator CtsR 2.6  SETU_00140 
hrcA 1.5  heat-inducible transcription repressor 1.8  SETU_01155 
NWMN_2211 1.2  lyt expression attenuator LytR 1.0  SETU_01766 
NWMN_2213 1.0  DeoR family transcriptional regulator 1.3  SETU_01768 
Replication, recombination and repair   
  
dinP 0.9  DNA polymerase IV 0.9  SETU_01453 
NWMN_1985 -1.0  RNA helicase  -1.0  SETU_01562 
Energy production and conversion  
NWMN_1315 1.1  acylphosphatase 1.0  SETU_00980 
citZ 0.9  citrate synthase 1.0  SETU_01259 
NWMN_2510 1.2  dehydrogenase gbsA 1.6  SETU_02028 
NWMN_0653 1.0  ABC transporter, MsbA family protein 1.4  SETU_00305 
NWMN_0654 1.1  ABC transporter, MsbA family protein 1.4  SETU_00306 
ndhF 1.1  NADH dehydrogenase subunit 5 2.2  SETU_00056 
Amino acid transport and metabolism  
leuB 1.1  3-isopropylmalate dehydrogenase 2.1  SETU_01541 
NWMN_0486 2.3  Arginine kinase 2.6  SETU_00142 
NWMN_0547 -1.5  cationic amino acid transporter -1.1  SETU_00208 
argH 1.8  argininosuccinate lyase 1.6  SETU_00508 
argG 1.1  argininosuccinate synthase 1.6  argG 
metL 2.5  homoserine dehydrogenase 1.0  SETU_00905 
thrC 2.4  threonine synthase 1.9  SETU_00906 
thrB 2.6  homoserine kinase 1.6  SETU_00907 
NWMN_1602 1.5  proline dipeptidase 0.9  SETU_01271 
leuA 1.2  2-isopropylmalate synthase 2.2  SETU_01540 
leuD 1.1  isopropylmalate isomerase subunit 2.1  leuD 
ilvA 1.1  threonine dehydratase 1.6  SETU_01544 
NWMN_2509 0.9  choline dehydrogenase 1.7  SETU_02027 
hisD 1.2  histidinol dehydrogenase HisD 0.9  SETU_02135 
hisG 1.1  ATP phosphoribosyltransferase 2.0  hisG 
ilvB 0.9  acetolactate synthase large subunit 1.5  SETU_01537 
ilvC 1.1  ketol-acid reductoisomerase 2.3  SETU_01539 
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Table 3.9 continued 
S. aureus Newman 
Description 
S. epidermidis Tü3298  
Gene Log2FC Log2FC Gene 
 
Nucleotide transport and metabolism  
pyrP -1.1  uracil permease -2.5  SETU_00770 
pyrB -1.8  aspartate carbamoyltransferase -1.5  pyrB 
 
Carbohydrate transport and metabolism  
NWMN_2331 1.7  glycerate kinase 1.0  SETU_01869 
NWMN_2048 -1.0  oxidoreductase ylbE -0.9  SETU_01623 
 
Coenzyme transport and metabolism  
ilvB 0.9  acetolactate synthase large subunit 1.5  SETU_01537 
ilvC 1.1  ketol-acid reductoisomerase 2.3  SETU_01539 
serA 1.5  D-3-phosphoglycerate dehydrogenase 0.9  SETU_01286 
 
Inorganic ion transport and metabolism  
phoU 2.7  Pst regulatory protein PhoU 1.2  SETU_00960 
pstB 3.1  phosphate ABC transporter 1.7  SETU_00961 
NWMN_1298 3.5  phosphate ABC transporter 1.6  SETU_00962 
NWMN_1299 3.8  phosphate ABC transporter 1.5  SETU_00963 
pstS 4.1  phosphate ABC transporter, PstS 1.5  SETU_00964 
NWMN_1317 0.9  tellurite resistance protein 1.3  SETU_00982 
NWMN_2457 1.3  copper-transporting ATPase copA 3.7  SETU_01986 
 
Predicted or unknown function 
oppF 1.0  oligopeptide ABC transporter 1.2  SETU_00530 
NWMN_1316 0.9  phosphate hydrolysis protein XpaC 1.2  SETU_00981 
oatA -1.1  secretory antigen precursor SsaA  -1.9  SETU_01990 
NWMN_0157 -3.3  S-isoprenylcysteine methyltransferase -2.1  SETU_02228 
NWMN_0366 -1.6  Transglycosylase associated protein -1.1  SETU_00029 
NWMN_0419 1.1  transmembrane protein 2.2  SETU_00057 
NWMN_0485 2.2  UvrB/UvrC domain-containing protein 2.6  SETU_00141 
NWMN_1824 2.1  transporter associated with VraSR 2.7  SETU_01443 
NWMN_2490 -1.0  hypothetical protein -1.1  SETU_02000 
NWMN_0542 6.1  hypothetical protein 5.6  SETU_00201 
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Table 3.9 continued 
S. aureus Newman 
Description 
S. epidermidis Tü3298  
Gene Log2FC Log2FC Gene 
 
Predicted or unknown function 
NWMN_0605 2.5  hypothetical protein 1.3  SETU_00260 
NWMN_0676 -3.6  DoxX family protein -2.6  SETU_00327 
NWMN_0677 -3.2  lipoprotein -2.7  SETU_00328 
NWMN_1294 1.2  hypothetical protein 1.4  SETU_00958 
NWMN_1552 2.6  hypothetical protein 1.1  SETU_01217 
NWMN_1553 2.9  hypothetical protein 3.8  SETU_01218 
NWMN_1825 1.7  hypothetical protein 2.4  SETU_01444 
NWMN_2223 1.8  hypothetical protein 1.4  SETU_01779 
NWMN_2332 2.0  hypothetical protein 1.4  SETU_01870 
 
Table 3.10 Opposite DE  homologous genes with the same trend of regulation in response 
to D-sphingosine challenge of S. aureus Newman and S. epidermidis Tü3298.  DE genes 
with more than two fold changes were listed. 
S. aureus Newman 
Description 
S. epidermidis Tü3298  
Gene Log2FC Log2FC Gene 
Sugar uptake and energy production     
NWMN_0008 -1.0  homoserine-o-acetyltransferase 1.0  SETU_02277 
pflB -2.2  formate acetyltransferase 3.7  pfl 
NWMN_0163 -2.1  pyruvate formatelyase  4.6  pflA 
NWMN_0667 -1.2  fructose operon  repressor  2.3  SETU_00318 
fruB -1.4  fructose 1-phosphate kinase 2.6  SETU_00319 
fruA -1.2  PTS fructose-specific transporter 2.6  SETU_00320 
Protection against oxidative stress  
  
ahpF -0.9  alkyl hydrogen peroxide reductase 1.2  SETU_00034 
ahpC -1.0  alkyl hydrogen peroxide reductase 1.2  SETU_00035 
Predicted or unknown function  
  
NWMN_0511 0.9  amino acid amidohydrolase -0.9  SETU_00167 
adh1 -2.3  alcohol dehydrogenase 1.6  SETU_00229 
NWMN_2585 -1.0  hypothetical protein 1.2  SETU_02143 
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3.3.8 Quantitative PCR validation 
Validation of the RNA-Seq data was performed by quantification of selected DE 
genes in the sphingosine challenge RNA-Seq dataset using qPCR. Method and 
primers were described in chapter 2 (section 2.6). The fold changes between 
ethanol control and sphingosine-treated samples were determined for each 
examined gene. RNA integrity was assessed prior to conversion to cDNA using 
Bioanalyser, and samples with RIN≥6.5 were considered qualified for 
subsequent experiments. At least three biological and three technical qPCR 
replicates were used for each gene. 
 
 
 
Figure 3.10 Differential expression of NWMN_0542, phoU, pstB, saeR and norB in S. aureus 
after challenge with D-sphingosine. Black bars indicate the fold change from RNA-Seq data, 
grey bars indicate fold change from qPCR validation. Error bars refer to standard deviation of 
fold changes of all replicates. 
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The log2 fold changes determined by qPCR were consistently lower than the 
fold changes from RNA-Seq data (Figure 3.10), but all tested genes showed 
regulation in the same direction and were mostly proportional to the RNA-Seq 
fold change values. This discrepancy between quantification may be due to 
underestimation of gene expression by qPCR, or overestimation of gene 
expression by RNA-Seq or a combination of both. Overall, the qPCR results 
indicate that regulation direction and general fold changes of RNA-Seq data 
were consistent. 
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3.4 Discussion 
The transcriptomic dataset of S. epidermidis Tü3298 D-sphingosine challenge 
has much fewer DE genes (340 genes) than the dataset of S. aureus Newman 
(1331 genes). Within those homologous genes shared across the species, 142 
genes were differentially expressed in both datasets, which accounts for 42% of 
all DE genes in S. epidermidis Tü3298. Moreover, 80.3% of these DE genes 
covered in both datasets were regulated in the same direction (50.7% both 
upregulated and 29.6% both downregulated). Only 19.7% were inversely 
regulated, indicating a high overlap rate between the transcriptomics response 
of the two species to D-sphingosine.   
Unsurprisinlgy, COG and KEGG pathway analysis also exhibited a strong overlap 
in transcriptional data of both species, given the gene overlaps. The reasons for 
the enlarged transcriptional response to sphingosine in S. aureus is unclear.  
This difference could arise for several reasons including: there are more 
responsive transcriptional regulation regulators; more surface associated 
damage is caused relative to S. epidermidis; sphingosines are not as readily 
metabolised in S. aureus causing widespread changes to occur. The latter 
explanation might be expected to lead to a reduced MIC for sphingosine. The 
different primary niches of each species could also have selected for distinct 
responses to stimuli encountered in their life-cycle and the discrete responses 
might be indicative of separate evolutionary trajectories.  
 
3.4.1 Virulence factors 
Both species of staphylococci showed marked downregulation in the expression 
of the global regulator saeRS operon (8-fold decrease of saeR and saeS in S. 
aureus; 5.3 and 5 fold decrease of saeR and saeS in S. epidermidis respectively).  
SaeRS is a two-component regulatory system that controls a regulon of 
staphylococcal virulence factors, mostly immune evasion proteins such as 
coagulase (Liu et al., 2016) that directs localised clotting and to protect bacteria 
from phagocytic and immune defences (Guo et al., 2017). 
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The majority of the S. aureus downregulated virulence factors (Table 3.10) are 
members of the SaeRS, regulon, including Hla, Hlb, HlgABC, LukED, FnbA, Efb, 
Ecb, SCIN, Sbi, FLIPr, CHIPS, Map, SSL5, SSL7 and SSL11 (Giraudo et al., 1999, 
Liang et al., 2006; Rogasch et al., 2006; Nygaard et al., 2010; Steinhuber et al., 
2003). These virulence factors promote infection by increasing bacterial 
survival from the host and the transcriptional changes indicates a specific 
adjustment of the bacteria to sphingosine, that is also described for other 
stimuli. Disruption in the SaeRS signalling pathway (loss of function) resulted in 
cytotoxicity to epithelial and endothelial cells and an increased ability of S. 
aureus to adhere to and invade (Liang et al., 2006; Steinhuber et al., 2003).    
In contrast to the findings for S. aureus, in which the large majority of the genes 
regulated by SaeR code for extracellular toxins and cellular adherence factors 
(Liang et al., 2006; Rogasch et al., 2006), genes affected by the loss of SaeR in S. 
epidermidis have multiple functions, including pyruvate metabolism genes pflA, 
pflB, ackA and butA that are positively regulated by SaeR; amino acid synthesis 
and metabolism genes hisG, hisD, hisH, argC, argJ and argG that are negatively 
regulated by SaeR; and redox regulation genes trxA and trxB that are negatively 
regulated by SaeR in S. epidermidis strain 1457 (Handke et al., 2007). Consistent 
with downregulation of SaeRS by D-sphingosine in S. epidermidis Tü3298, hisG, 
hisD and argG were upregulated by 4, 1.9 and 3.1 fold, respectively. However, 
expression of pflA and pflB were also increased by 24 and 13 fold although they 
were predicted to be decreased by downregulation of SaeRS. Differential 
expression of pflA and pflB might be altered by other regulators changed by D-
sphingosine treatment. 
A key response to D-sphingosine observed with S. aureus is a reduction in 
virulence gene expression, while no determined virulence factors of S. 
epidermidis (such as cap operon) were differentially expressed. This suggests 
that sphingosines on the skin may act against colonisation of S. aureus via 
altering adhesion and virulence of the bacteria. 
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3.4.2 Cell wall stress 
KEGG pathway analysis indicated upregulation of peptidoglycan biosynthesis in 
D-sphingosine challenged S. aureus. In addition, the SAMMD analysis revealed 
D-sphingosine transcriptome overlap with transcriptome datasets of several 
cell-wall-targetting antibiotics, such as vancomycin, bacitracin, fosfomycin and 
oxacillin.  This shared aspect of the responses supports a role for D-sphingosine 
where it exerts activity towards the cell wall either from direct damage or 
inhibition of its biosynthesis. 
Both species showed marked upregulation in expression of the genes encoding 
the cell wall biosynthesis controlling TCS VraSR (~5 fold increase for both vraS 
and vraR in S. aureus and ~6.5 fold increase for both in S. epidermidis). 
Inhibition of cell wall biosynthesis induces expression of the cell wall stress 
stimulon (Campbell et al., 2012; Muthaiyan et al., 2008; Sass et al., 2008; Utaida, 
2003), which enhances resistance to cell wall biosynthesis inhibitors and is 
primarily regulated by the two-component regulator VraSR (Gardete et al., 2006; 
Boyle-Vavra et al., 2006). Cell wall targetting agents such as the glycopeptide 
vancomycin and β-lactam oxacillin are potent inducers (Pechous et al., 2004; 
Utaida et al., 2003).  
Upregulation of the cell wall biosynthesis genes murZ (~2 fold change) and 
pbpB (~1.74 fold change) that belong to vraSR regulon and expression of other 
genes commonly found upregulated by cell wall inhibitor treatment were also 
increased in the D-sphingosine challenge transcriptome of S. aureus, including 
genes involved in intermediary metabolism such as thrB (~6 fold change), thrC 
(~5.2 fold change), dapA (~3 fold change) and serA (~2.8 fold change); and 
genes encoding chaperones, heat shock proteins, and osmoprotectant 
transporters such as prsA (~4.7 fold change), opuD (~1.5 fold change) and 
NWMN_1621 (5.2 fold change) (Kuroda et al., 2003; McAleese et al., 2006; 
Utaida et al., 2003). In addition, and comparatively, thrB (~3 fold change), thrC 
(~3.7 fold change), prsA homolog gene SETU_01367 (~3.8 fold change), 
NWMN_1621 homolog gene SETU_01290 (~8 fold change) showed strong 
upregulation by D-sphingosine treatment in S. epidermidis RNA-Seq data. 
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In addition to expression of the cell wall stress stimulon, there was altered 
regulation after D-sphingosine challenge of the autolysis regulatory genes fmt 
and lytR, matching observations in a previous study of responses to cell wall 
stress (Utaida et al., 2003). This supports a hypothesis that the cells 
coordinately regulate autolysis in response to cell wall active antimicrobials 
that interfere with wall biosynthesis. Although fmt transcription was expected 
to be upregulated consistent with upregulation of VraSR (Utaida et al., 2003), 
fmt was downregulated in the D-sphingosine challenge transcriptome data. The 
two-component regulator LytSR, which suppresses autolysis in S. aureus and S. 
epidermidis by positively regulating murein hydrolase activity and which is 
upregulated in response to cell wall stress (Zhu et al., 2010; Groicher et al., 
2000), was downregulated ~2 fold in D-sphingosine challenged S. aureus. In 
contrast, neither the fmt or lytSR genes were DE  in D-sphingosine treated S. 
epidermidis transcriptional data.  
 
3.4.3 Membrane disruption 
The induction of a cell wall stress-like response by D-sphingosine suggests that 
it may lead to cell wall biosynthesis inhibition or membrane destabilisation, or 
both. Membrane destabilisation is supported in part from the observation that  
there was pronounced overlap between the transcriptomes of the membrane-
targetting antimicrobials temporin (75.3%) and ovispirin (75.6%) and the D-
sphingosine dataset (as a proportion of the temporin and ovispirin datasets). 
The S. aureus transcriptional response to D-sphingosine had most DE genes 
overlapping with both of these CAMPs that  disrupt the cell membrane electrical 
potential through membrane perturbation (Yang et al., 2013).  In contrast, there 
was limited similarity between S. aureus D-sphingosine transcriptomic data and 
the dermaseptin or nisin transcriptomes, which are also membrane-targetting 
antimicrobials. Both dermaseptin and ovispirin permeate and disintegrate the 
membrane by disrupting the bilayer curvature (Pietiäinen et al., 2009). 
Temporin and nisin are pore forming, while nisin is reported to be active on 
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both formation of membrane pores and inhibition of cell wall biosynthesis 
(Wiedemann et al., 2001; Breukink et al., 1997). 
CAMPs can disrupt the cell membrane electrical potential through membrane 
perturbation and induce upregulated expression of the LytSR regulon (Yang et 
al., 2013). LytSR is reported to sense alterations of the membrane potential due 
to perturbations (Sharma-Kuinkel et al., 2009; Yang et al., 2013) in addition to 
regulating genes that control cell apoptosis, autolysis, and biofilm formation 
(Groicher et al., 2000; Rice et al., 2003). However, while lytSR is upregulated in 
response to membrane potential disruption (Patton et al., 2006), it was 
downregulated in D-sphingosine treated S. aureus. 
Consistent with this LytSR-dependent downregulation, the lrgAB operon was 
downregulated (5 fold, 3.7 fold, respectively) and gene cidA of the cidABC 
operon suppressed by lrgAB operon was upregulated (4 fold). IrgAB inhibits 
murein hydrolysis activity and cell lysis (Groicher et al., 2000; Rice et al., 2005), 
while the cidABC gene products enhance murein hydrolysis activity and 
antibiotic tolerance (Rice et al., 2003). IrgAB and CidABC were proposed to 
control the programmed cell death and lysis during biofilm formation (Rice et 
al., 2007; Bayles, 2007; Rice and Bayles, 2008).  
The expression of lytSR, lrgAB and cidABC operons were unchanged in the S. 
epidermidis D-sphingosine challenge transcriptome. This might indicate that the 
concentration of D-sphingosine used for challenge experiments was insufficient 
to cause a similar disruption effect on S. epidermidis cell membrane or that a 
discrete response is used to counteract the effects of sphingosine. 
Whilst few DE genes related to membrane lipid biosynthesis were determined 
in S. epidermidis, KEGG pathway analysis showed an overall increase in fatty 
acid degradation and decrease in glycerolipid biosynthesis, which may indicate 
that D-sphingosine challenged S. aureus preferentially use fatty acid as a source 
of membrane lipid rather than undergoing glycerophospholipid biosynthesis. 
Although sphingosines are not fatty acids, they share similar carbon backbone 
structures, and was suggested to act similarly with antimicrobial fatty acids on 
staphylococci (Parsons et al., 2012). Sphingosine at relatively low 
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concentrations (below MIC) was predicted as a potential resource for uptake 
and metabolism by S. aureus (Fischer et al., 2013). Interaction of D-sphingosine 
may alter the metabolism pathways to use fatty acids in priority in S. aureus. 
 
3.4.4 Capsule biosynthesis 
Capsule protects bacteria from antimicrobials by limiting access to and 
penetration of the membrane. The cap operon that encodes the S. aureus 
Newman type 5 capsule biosynthesis proteins (Herbert et al., 2001; O'Riordan 
and Lee, 2004) was downregulated after D-sphingosine challenge. According to 
Meier et al (2007), capsule biosynthesis is dependent on yabJ-spoVG and the 
latter gene was also downregulated (2.4 fold decrease) showing coordination of 
expression.  
S. epidermidis does not possess a similar cap operon for polysaccharide capsule 
production. Instead, S. epidermidis produces poly-γ-glutamic acid (PGA) 
(McKenney et al., 1998; Kocianova et al., 2005). The genes involved in PGA 
biosynthesis (pgsABCD) were not DE in D-sphingosine challenged S. epidermidis 
data indicating that capsule expression is not affected by D-sphingosine. 
 
3.4.5 Oxidative stress 
The carotenoid pigment provides integrity of the pathogen’s cell membrane 
(Mishra et al., 2011). Staphyloxanthin is found to assist in bacterial survival 
under stress and during infections (Giachino et al., 2001; Kahlon et al., 2010). 
The pigment has an antioxidant action that enhances bacterial resistance to 
reactive oxygen species (ROS) generated by host immune system (Clauditz et al., 
2006). Thus, decrease in staphyloxanthin production would result in increased 
bacterial susceptibility to oxidative stress as well as membrane disruption. 
Although the biosynthesis pathway for the carotenoid staphyloxanthin was 
downregulated in response to D-sphingosine challenge in S. aureus, further 
investigation of the crt operon (Chapter 4) indicated that its expression was 
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upregulated after prolonged incubation (24h) with D-sphingosine, suggesting  
that in contrast adaptation and continued growth includes increased 
staphyloxanthin expression.  
Exprssion of msrA encoding methionine sulfoxide reductase was increased after 
D-sphingosine challenge of S. aureus but not S. epidermidis, which shows 
differences in protein repair due to damage, which is an upregulated function 
category in the COGs analysis. MsrA increases resistance to oxidative stress by 
reducing methionine sulfoxide residues in proteins to methionine and therefore 
restore protein function (Brot and Weissbach, 2000; Moskovitz et al., 1995). A 
study by Singh and Wilkinson (2001) indicated that a msrA mutant is more 
susceptible to hydrogen peroxide. MsrA is strongly induced by cell wall active 
antimicrobials, and it was proposed by the authors that exposure to cell wall 
active antimicrobials causes oxidative damage to proteins that must be repaired 
(Singh and Wilkinson, 2001; Singh et al., 2001; Utaida et al., 2003).  
S. epidermidis does not produce staphyloxanthin, so resistance against 
membrane fluidity changes and destabilisation/disorder must be achieved 
through other methods. A major mechanism to alter membrane fluidity is via 
adjusting branched chain fatty acid and saturated fatty acid content in the 
membrane, where branched chain fatty acids increase membrane fluidity while 
saturated fatty acids increase rigidity of the membrane (Singh et al., 2008; 
Schujman and de Mendoza, 2005). The lpd gene, which controls synthesis of 
branched chain fatty acids in staphylococci, (Singh et al., 2008) was not 
differentially expressed in either S. epidermidis or S. aureus meaning the control 
mechanisms differentiating these species remain unresolved. 
 
3.4.6 General stress response of both S. aureus and S. epidermidis 
The CtsR regulon is upregulated in protein damaging conditions, such as heat 
shock (Derre et al., 1999; Elsholz et al., 2010). The D-sphingosine challenge 
induces a general stress response that includes upregulation of ctsR (4.3 fold in 
S. aureus, 6.1 fold in S. epidermidis), and its regulon genes, dnaJ (increased 2.5 
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fold in S. aureus and 2.1 fold in S. epidermidis), dnaK (increased 2.8 fold in S. 
aureus and S. epidermidis). Further, protease and chaperone protein genes 
concerned with repair and recycling were upregulated in both species 
supporting the requirement for repair and recycling of proteins.  
The mode of action of sphingosine is similar to that of sapienic acid and results 
in loss of low molecular weight solutes, amino acids and proteins (Alnaseri et al., 
2015). In light of this, the notable upregulation of amino acid biosynthesis in 
both species could represents a general response to osmotic stress due to 
leakage caused by membrane disruption. The downregulation of pyrimidine 
metabolism together with the upregulation of amino acid biosynthesis and 
stress response genes is similar to the stringent response to nutrient starvation, 
where cellular energy is directed away from growth toward nutrient stocking 
(Durfee et al., 2008).  
Energy production in S. epidermidis was strongly upregulated while no 
significant regulation trend was observed in S. aureus. This may indicate that S. 
epidermidis has more efficient mechanisms for D-sphingosine resistance than S. 
aureus. Of note, energetically expensive resistance mechanisms of S. aureus such 
as capsule and staphyloxanthin biosynthesis were downregulated when 
challenged with D-sphingosine, possibly signifying a need for greater energy 
conservation and restoration.  
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Chapter 4: Characterisation of DE genes in the 
Transcriptome of S. aureus Challenged with D-
Sphingosine 
 
4.1 Introduction 
4.1.1 Staphyloxanthin biosynthesis 
Staphyloxanthin is a yellowish-orange carotenoid pigment that gives S. aureus 
its golden colour and is described to have a role in the oxidative resistance and 
membrane integrity of S. aureus (Liu & Nizet, 2009).   
A series of crt enzymes are involved in staphyloxanthin biosynthesis (Figure 
4.1): dehydrosqualene synthase (CrtM) enzyme catalyses formation of 
dehydrosqualene (4,4’-diapophytoene); CrtN dehydrogenates dehydrosqualene 
to form the intermediate 4,4’-diaponeurosporene (Raisig and Sandmann, 1999), 
which is a yellow pigment;  CrtP oxidizes the terminal methyl group to generate 
4,4’-diaponeurosporenic Acid; finally CrtQ and CrtO esterifies glucose to yield 
the final compound staphyloxanthin (Pelz et al., 2005). 
The carotenoid pigment contributes to the integrity of the pathogen’s cell 
membrane (Mishra et al., 2011). It was reported that more than 90% of S. 
aureus isolates from infected humans are pigmented (Lennette et al., 1985) and 
staphyloxanthin assists survival under stress and during infections (Giachino et 
al., 2001; Kahlon et al., 2010). The pigment has an antioxidant action that 
enhances resistance of the bacteria to reactive oxygen species (ROS) generated 
by host immune system (Clauditz et al., 2006). 
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Figure 4.1 Staphyloxanthin biosynthesis pathway. (Leejae et al., 2013; Pelz et., al., 2015) 
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4.1.2 Phosphate-specific transport (Pst) system 
The Pst (phosphate-specific transport) system is a high-affinity, low-velocity, 
free-Pi transporter that is structurally similar to ABC transporters (Ames, 1986) 
and is expressed by many species, including E. coli, Bacillus subtilis, and S. 
aureus. The proteins encoded by the pst operon comprise a binding protein PstS, 
two integral inner membrane proteins PstC and PstA, and an ATP binding 
protein PstB (Webb et al., 1994). In S. aureus, the organisation of the genes is 
such that pstS is monocistronic followed downstream by the pstCABphoU 
polycistronic operon. 
The first four genes pstS, pstC, pstA and pstB in the pst operon of E. coli are 
required for phosphate transport when the concentration of Pi  is low (Cox et al., 
1981). Mutation of any of these genes will abolish Pi uptake (Sprague et al., 
1975). Two phosphate transport systems are involved in Pi intake during 
phosphate-replete growth in E. coli: Pit is a low-affinity Pi transporter (Harris et 
al., 2001) that is independent of Pi concentration; and PhoPR (Carter et al., 
2004). In contrast, the pst operon encodes a PhoP-dependent high-affinity Pi 
transporter that is induced specifically in response to Pi starvation (Qi et al., 
1997).  The pst operon is transcribed from a housekeeping sigma A-type 
promoter, which is located upstream of pstS (Qi et al., 1997) and can be induced 
during alkali stress (Atalla and Schumann, 2003); it becomes the main 
transporter of phosphate when Pi concentration is lower than 0.1 mM.  A 
reduction in Pi uptake (approximately 7 fold) was observed in pst mutants 
(Prágai et al., 2001). 
Both E. coli and S. aureus have a regulatory gene phoU, while B. subtilis does not. 
The ATP binding protein of B. subtilis consists of PstBA and PstBB subunits 
(similar to PstB for E. coli and S. aureus), and the pstB2 gene is in the position of 
phoU in E. coli and S. aureus at the 3’ end of the operon. PhoU is considered to be 
a switch in E. coli multidrug tolerance and impacts on widespread processes 
beyond inorganic phosphate (Pi) transport (Li and Zhang, 2007).  
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4.1.3 PhoRP alkaline phosphatase synthesis regulatory system 
S. aureus, S. epidermidis and S. xylosus are phophatase producers (Varaldo and 
Satta, 1978). Phosphatase was found in approximately 90%, 70%, and 89% of 
the S. aureus, S. epidermidis and S. xylosus strains respectively (Soro et al., 1990). 
PhoRP is a TCS for alkaline phosphatase biosynthesis and is well studied in B. 
subtilis and E. coli (Liu and Hulett, 1997; Seki et al., 1988; Seki et al., 1987). PhoP 
is a substrate for both the kinase and phosphatase activities of its cognate 
sensor kinase PhoR (Liu and Hulett, 1997). B. subtilis genes encode three 
secreted alkaline phosphatases (APases): phoA (APaseA); phoB (APaseB); and 
phoD (APaseD) (Hulett, 1993; Hulett, 1995; Hulett, 1996) and activation of phoB 
is controlled by PhoP (Liu and Hulett, 1997). The APases are expressed during 
phosphate starvation, generating inorganic phosphate that can be mobilised by 
the phosphate-specific transport system (Pst system) for translocation into the 
cell (Rao and Torriani, 1990; Willsky et al., 1973) 
 
4.1.4 Haem-sensor system (HssRS) and haem regulated transporter 
(HrtAB) 
Haem-iron acquisition is vital to staphylococcal pathogenesis (Skaar et al., 2004; 
Torres et al., 2006). Iron is an essential cofactor for many biochemical processes 
and is required by all pathogenic bacteria for infection; its limitation is a 
significant barrier encountered when colonising verebrates (Bullen, 1999). 
Most vertebrate iron is in the form of the metalloporphyrin haem, which is the 
functional cofactor of haemoglobin for blood and myoglobin for muscle oxygen 
transport and storage (Deiss, 1983). S. aureus acquires haem as a nutrient 
source through expression of high efficiency uptake systems to transport host-
derived haem into the staphylococcal cytoplasm (Mazmanian et al., 2003; Skaar 
et al., 2004; Torres et al., 2006; Vermeiren et al., 2006). This process is 
facilitated by hemolysin-mediated rupture of erythrocytes upon entry into the 
blood stream (Bernheimer et al., 1968; Skaar and Schneewind, 2004). 
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Whilst being an important nutrient source for invading pathogens, the 
intracellular accumulation of haem is toxic due to its reactivity (Torres  et al., 
2007). An increasing inhibitory effect of hemin on growth of S. aureus was 
revealed with concentrations ranging from 5 - 10 μM in iron-replete medium 
(Torres et al., 2007). Therefore, the value of haem as an iron source is balanced 
against its toxicity at high concentrations using adaptable mechanisms to 
prevent surplus haem accumulation and make use of exogenous haem to satisfy 
iron needs (Everse and Hsia et al., 1997).  
Torres et al (2007) reported that S. aureus senses haem and subsequently alters 
protein expression, using a haem-sensor system (HssRS) responding to haem to 
upregulate HrtAB haem transporter. HrtAB consists of an ATP-binding protein 
(HrtA) and a permease (HrtB), making up a canonical ABC-type transporter 
system. The HrtAB efflux pump plays an essential role in intracellular haem 
homeostasis of S. aureus (Torres et al., 2007) with major upregulation (45 fold) 
observed in S. aureus challenged with exogenous hemin (the oxidised form of 
haem) (Friedman et al., 2006).  
 Inactivation of either hssRS or hrtAB resulted in increased expression and 
secretion of staphylococcal virulence factors (Torres et al., 2007). The HssRS 
and HrtAB proteins are conserved across Gram-positive pathogens, including S. 
epidermidis and Bacillus anthracis that also show adaptation to hemin toxicity, 
and it was proposed that these important human pathogens sense their 
vertebrate hosts to modulate virulence and orthologous Hss and Hrt systems 
may act across genera to coordinate a response to excess hemin exposure 
(Torres et al., 2007). 
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4.2 Chapter aims 
In the previous chapter, an RNA-Seq directed approach was undertaken to 
document the transcriptomic response of S. aureus Newman and S. epidermidis 
Tü3298 to D-sphingosine challenge. The analysis defined a sphingosine 
stimulon across both species with which it is possible to test individual genetic 
contributions of loci to the survival of each species from sphingosine. 
Given the relative ease of genetic manipulation of S. aureus, this chapter 
describes experiments of selected genes in the RNA-Seq data analysis to 
characterise D-sphingosine resistance of S. aureus. Primary focus was on two 
hierarchical regulators, the two component systems VraSR (vraSR) and SaeRS 
(saeRS), the Pst phosphate transport system (pstS and pstCABphoU) and a 
hypothetical gene NWMN_0542.  These were selected because they were highly 
up or down regulated (>2 or <-2 Log2 FC) in both S. aureus and S. epidermidis.  
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4.3 Results 
Target loci were selected from the transcriptomic study in the previous chapter 
based on common regulation by both S. aureus and S. epidermidis in their 
response to D-sphingosine.  The chosen subset of genes was also proposed for 
further study based on their known roles or the extent of up/down regulation in 
the transcriptional responses (Table 4.1).  To investigate the contribution of 
each of the selected genes in turn, primary studies were pursued with a 
determination of MICs of gene mutants. 
 
Both species showed marked upregulation of VraSR (~5 fold increase for both 
vraS and vraR in S. aureus and ~6.5 fold increase for both in S. epidermidis) after 
challenge with D-sphingosine. VraSR is a TCS involved in the control of cell wall 
peptidoglycan biosynthesis (Cui et al., 2009). Increased expression of vraSR 
together with its cognate cell wall stress stimulon (including pbpB, murZ, and 
msrA1 described in chapter 3) supports that D-sphingosine causes cell wall 
damage or inhibits cell wall biosynthesis. To explore this potential, the role of 
vraRS in sphingosine resistance in S. aureus was investigated further. MIC assay 
of vraR and vraS allelic replacement mutant strains (SH1000 vraR::tet and 
SH1000 vraS::tet) was undertaken using the described methods. Both SH1000 
vraR::tet and SH1000 vraS::tet showed a lower MIC (6.6 μM) than the wild type 
SH1000 strain (16.3 μM), which supports that VraSR TCS contributes to D-
sphingosine resistance in S. aureus.  
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Table 4.1 Comparison of selected genes of the D-sphingosine responses from RNA-Seq 
analysis of S. epidermidis Tü3298 and S. aureus Newman. Differential expression of genes 
after D-sphingosine challenge is indicated with colour blocks shown in the colour key.  Values 
indicate Log2 fold change values. A white colour block represents no differential expression; A 
grey colour block and a cross ‘X’ indicates that the gene is absent in the species. 
  > 4.0 
  3.0 to3.9 
  2.0 to 2.9 
  1.0 to 1.9 
  0.5 to 0.9 
  -0.9 to -0.5 
  -1.9 to -1.0 
  -2.9 to -2.0 
  -3.9 to -3.0 
 
S. epidermidis Tü3298 S. aureus Newman Alternative 
gene names Gene name Log2 Fold Change Gene name 
Global regulators 
vraR 2.7 2.3 vraR   
SETU_01443 2.7 2.3 vraS   
SETU_00326 -2.4 -3.0 saeR   
SETU_00325 -2.3 -3.0 saeS   
Phosphate uptake 
X   2.7 phoU   
SETU_00964 1.5 4.1 pstS   
SETU_00963 1.5 3.8 NWMN_1299 pstC 
SETU_00962 1.6 3.5 NWMN_1298 pstA 
SETU_00961 1.7 3.1 pstB   
SETU_01249   0.9 phoR   
SETU_01250   0.9 phoP   
SETU_02057   2.0 phoB 
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Table 4.1 continued 
S. epidermidis Tü3298 S. aureus Newman Alternative 
gene names Gene name Log2 Fold Change Gene name 
Iron uptake 
SETU_01817   1.6 NWMN_2261 hrtA 
SETU_01818   1.6 NWMN_2262 hrtB 
SETU_01819   0.9 NWMN_2263 hssR 
SETU_01820   0.7 NWMN_2264 hssS 
Staphyloxanthin biosynthesis 
X   -1.3 crtM   
X   -1.2 crtN   
X   -1.6 NWMN_2463 crtQ 
X   -1.7 crtP   
X   -1.5 NWMN_2465 crtO 
Predicted protein 
SETU_00201 5.6 6.1 NWMN_0542 vraX 
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4.3.1 Phosphate specific transport (pst) system 
The pstS and pstCABphoU operons of S. aureus were investigated further based 
upon each gene being highly upregulated over 8-fold, which could indicate a 
contributory role of Pst transport of phosphate in survival from D-sphingosine.   
The importance of phosphate for protection from or adaptation to D-
sphingosine challenge was first examined by supplementation of culture 
medium with phosphate in an MIC assay (Figure 4.2). 
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Figure 4.2 D-sphingosine MIC assay of S. aureus Newman survival in the absence and 
presence of 0.1 M phosphate. Cells were assayed in BHI broth with a range of concentrations 
of D-sphingosine from 16.5 to 165 uM across wells 1-10 as indicated. Three technical repeats 
were set for each group and blank controls were prepared without any antibiotics. The two 
blank controls at the top corners were mixed with diluted culture and BHI broth only, and the 
bottom blank controls were mixed with diluted culture, BHI broth and additional Pi. 
 
 
Minimum inhibitory concentration (MIC) was determined using 96 well plates 
to culture bacteria. Tested strains were grown for 24 h, diluted to OD600=0.2 
with BHI broth and 100 μl of diluted culture was then added to each well 
containing different concentrations of D-sphingosine; cells were incubated at 
37°C for 24 h. MIC was performed in the absence and presence of 0.1 M 
phosphate buffer.  
121 
 
Addition of Pi dramatically increased resistance of wild type S. aureus Newman 
to D-sphingosine such that growth inhibition was not observed at even the 
highest concentrations (Figure 4.2). The same experiment was repeated on S. 
aureus strains SH1000 and Newman with various growth media (BHI, THB and 
chemical defined media incorporating different phosphate concentrations), and 
similar results were observed to confirm that this phenomenon was not strain 
and media dependent. Different phosphate concentrations were tested to detect  
the lowest additional Pi concentration that would produce a difference in D-
sphingosine resistance. Fifty μM of added Pi was found to result in a consistent 
increased D-sphingosine resistance in both WT Newman and SH1000, which 
doubled the MIC value to 33 μM compared with 16.3 μM when cultured in BHI 
only. 
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4.3.2 Construction of a pst operon mutant 
The Pst transporter of E. coli functions as a high affinity Pi transport system 
activated by phosphate limitation (Qi et al., 1997; Ames, 1986). To investigate 
the role of the S. aureus Pst system in sphingosine survival, a pstSCAB allelic 
replacement mutant was constructed using an antibiotic resistance cassette in 
place of the four genes.  Flanking DNA consisting of upstream DNA plus pstS’ 
(first part of pstS), and downstream flanking DNA plus pstB’ (latter part of pstB) 
was ligated together with a tetracycline resistance cassette into the suicide 
plasmid vector pMUTIN4 (Vagner et al., 1998) (Figure 4.3). This vector was 
designed to remove most of the pstS and pstCAB operons and replace with the 
resistance cassette. 
 
 
 
Figure 4.3 Cloning of pstS-pstCAB vector for allelic replacement.  Plasmid pMutin4 was 
digested with BamHI and HindIII and co-ligated with the DNA fragments: pstS’ DNA fragment 
digested with BamHI and KpnI; tetracycline cassette digested with KpnI; pstB’ DNA fragment 
digested with KpnI and HindIII. DNA fragments were ligated using T4 DNA ligase. 
 
123 
 
 
Figure 4.4 Restriction digest of plasmid from candidate clones. Plasmid was extracted from 
selected clones and was digested BamHI and HindIII. The expected sizes of DNA were observed 
indicating successful cloning: pMUTIN4 (~8.6kb); pstS’tetB’ insert (~3kb).  
 
Correct vector cloning was confirmed by restriction digest of purified plasmid 
from successfully transformed E. coli colonies (Figure 4.4).  The purified plasmid 
was used for subsequent electro-transformation of S. aureus RN4220 and a 
lysate of this strain made with phage phi11 for transduction of strain Newman 
with selection for tetracycline resistance. Transductants were selected and 
confimed to have the designed pstS and pstCAB operons deleted in Newman.  
This allelic replacement mutant was used in a series of experiments to 
investigate if there was a role for the Pst transporter system in D-sphingosine 
resistance of S. aureus. 
A chemically defined medium (CDM) was prepared according to the method 
described by Hussain et al. (1991) to control phosphate concentrations during 
cell culture (Chapter 2, section 2.2.2). Sufficient trace metals were added to 
assist bacterial growth and a range of phosphate concentrations were added to 
the culture to test the effect of differing amounts. The bacteria grew very slowly 
when phosphate concentrations were reduced, and the lowest concentration 
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that was found to be able to support S. aureus growth (overnight culture reach 
OD600=1) was about 12 mM. A lower MIC of D-sphingosine is predicted for the 
pst operon mutant if D-sphingosine causes phosphate deficiency or a 
requirement to metabolise the lipid, on the basis that this phosphate 
transporter contributes to D-sphingosine resistance in S. aureus. 
Results of MIC tests showed no difference between the constructed pst mutant 
and wild type Newman strain (tested with THB, BHI and CDM media containing 
12-60 mM Pi). A possible explanation for the lack of a phenotype could be that 
depletion of this transporter triggers expression of other phosphate related 
transport systems, such as PhoRP, to maintain Pi uptake. Therefore, to examine 
this the transcription of a set of PhoRP related genes (include phoP, phoR, phoB) 
was assessed with the mutant strain using qPCR under the same culture and 
challenge conditions as RNA extraction for RNA-Seq. However, no altered 
regulation was detected for any of the tested genes. 
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4.3.3 Characterising transposon library mutants for survival phenotypes 
A targeted approach was used to determine the involvement of genes that were 
DE in the RNA-Seq data and pathways that were of interest for D-sphingosine 
survival.  The Nebraska Transposon Library of S. aureus JE2 (for information see 
section 2.3.8) is a research community resource that contains bursa aurealis 
transposon inactivation of over 1,900 genes.  To further investigate the role of 
Pst phosphate transporters, pstS and phoU single gene mutant strains were 
obtained and the transposon insertions were selected in S. aureus Newman by 
phage transduction.  
Consistent with pronounced upregulation of the pst operon, upregulated 
expression of phoR (1.9 fold change increase) also suggested an increased need 
for inorganic phosphate uptake by upregulation of alkaline phosphatase. PhoPR 
was investigated as it regulates synthesis of alkaline phosphatase, which is 
expressed during phosphate starvation and yields inorganic phosphate that can 
be ultimately targeted by the phosphate-specific transport system (Pst system), 
for translocation into the cell (Rao and Torriani, 1990; Willsky et al., 1973).  
Previous work in the Horsburgh group in Liverpool identified an efflux pump 
(encoded by Sar2632) that exports the AFA linoleic acid in S. aureus MRSA252. 
This efflux transporter was hypothesised to be induced by sphingosine since its 
mode of action was proposed to be similar to AFA lipids with membrane 
damage and leakage of solutes (Bibel et al., 1993; Fischer et al., 2013; Bergsson 
et al., 2001). However, the homologous gene NWMN_2442 in strain Newman 
was not differentially expressed by D-sphingosine challenge. It is likely that 
there is an alternative or more efficient way to export sphingosines. Therefore, 
other upregulated transporters were investigated. A hrtB mutant was created to 
investigate this upregulated transporter regulatory system (hrtAB-hssRS) in D-
sphingosine resistance. 
To verify the location of the transposon insertions and confirm successful 
transduction, primers were designed that were specific to the bursa aurealis 
transposon and these were used together with primers of the target genes to 
use PCR amplification for confirmation of correct gene insertion (indicated in 
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chapter 2, table 2.3). PCR amplification confirmed that each transposon/gene 
was amplified with correct size (Figure 4.5).  
 
 
 
Figure 4.5 PCR amplification of transductants from JE2 to Newman. PCR primers and 
expected product sizes are listed in chapter 2, table 2.3. Corresponding gene names are shown 
in the figure, and the numbers represent for different replicates of the same gene (e.g. phoU1 
and phoU2 indicate two successful phoU allelic replaced transductants confirmed by PCR). 
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Figure 4.6 D-sphingosine MIC of S. aureus Newman bursa aurealis transposon mutants.  
Assays were performed in BHI broth. Error bars indicate standard deviation of three repeat 
experiments. 
 
 
All of the mutant strains show lower MICs compared with wild type Newman 
strain as expected (Figure 4.6). phoU, pstS and phoR mutants (loss of function) 
show lower MICs than the wild type control, suggesting that the phosphate-
specific transport Pst and the alkaline phosphatase synthesis regulatory system 
PhoPR play a role in D-sphingosine resistance in S. aureus, which furthermore 
indicated the role of phosphate in S. aureus survival from sphingosine. MIC 
results for the hrtB mutant suggest that haem transport and regulation plays a 
role in D-sphingosine resistance. 
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4.3.4 DE comparison of various S. aureus strains by qPCR 
Transcriptomics analysis of the response to D-sphingosine was assessed using S. 
aureus strain Newman and S. epidermidis strain Tü3298. qPCR validation was 
done to support RNA-Seq data. In addition to qPCR validation with S. aureus 
Newman, other S. aureus stains, including wild type SH1000, MRSA252 and 
SF8300 (references see chapter2, table2.1) were included in qPCR quantitation 
to further compare host genetic background influences. (Table 4.2)  
 
 
Table 4.2   Differential expression of selected genes in response to D-sphingosine 
challenge determined by qPCR. Coloured boxes represent the range of fold change. A grey box 
indicates no expression of the gene. 
  > 6.0 
  3.0 to 5.9 
  2.0 to 2.9 
  1.0 to 1.9 
  -0.9 to 0.9 
  < -2.9 
 
strains  pstB saeR NWMN_0542 vraA 
Newman        
SH1000   
 
   
MRSA252   
 
   
SF8300   
 
   
Tü3298        
 
 
Upregulation of pstB was seen in all tested strains, indicating a consistent 
change in expression of the Pst transporter in S. aureus by D-sphingosine 
challenge. Both species showed downregulation in expression of global 
regulator saeRS (8 and 8 fold decrease of saeR and saeS respectively in S. aureus; 
5.3 and 4.9 fold decrease of saeR and saeS respectively in S. epidermidis). 
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Although saeRS was found to be down regulated 8-fold in Newman, all the other 
tested S. aureus strains (SH1000, MRSA252, SF8300) did not show differential 
expression by qPCR (Table 4.2). The strain Newman SaeS contains a L18P 
substitution (SaeSP) in the first transmembrane helix due to SNP polymorphism 
of the gene, while strain SH1000, MRSA252 and SF8300 do not (Steinhuber et al., 
2003). This SNP results in the increased kinase activity of SaeS in Newman, 
which may be responsible for the difference in saeR differential expression 
found in these qPCR examined S. aureus strains. 
 
 
 
Figure 4.7 Gene clusters of NWMN_0537, NWMN_0542, and vraABC operon. VraA is a long 
chain fatty acid CoA ligase; VraB is an acetyl-CoA C-acetyltransferase; VraC is a conserved 
hypothetical protein with 2 predicted transmembrane domains; NWMN_0537, NWMN_0541 and 
NWMN_0542 are conserved hypothetical proteins.  
 
The most upregulated genes in the transcriptome analysis data of S. aureus 
Newman were NWMN_0537 (4.9 log2FC, 30 fold increase) and NWMN_0542 (6.1 
log2FC, 70 fold increase), both of which are hypothetical proteins with unknown 
function. NWMN_0542 was named vraX and was suggested without 
experimentation to play a role in glycopeptides resistance of S. aureus (Scherl et 
al., 2006). More recently, it was reported to have a role in innate immune 
evasion by binding C1q to inhibit the formation of C1-complex of the classical 
complement pathway (Yan et al., 2017). 
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Both RNA-Seq and qPCR results show that expression of other genes of the 
vraABC operon were not coregulated with NWMN_0542 or NWMN_0537, thus 
suggesting NWMN_0542 and NWMN_0537 are part of the sphingosine stimulon 
independently regulated compared with the glycopeptide stimulon that sees 
coregulation of the vraABC operon and NWMN_0542 , NWMN_0537 (Scherl et al., 
2006).  
 
131 
 
4.3.5 Sphingosine-induced changes in pigment gene expression and H2O2 
survival 
Expression of each gene in the operon encoding enzymes for staphyloxanthin 
biosynthesis was downregulated by D-sphingosine challenge: crtM, crtN, crtQ, 
crtP, crtO; 2.5, 2.3, 3.2, 3.0, 2.8-fold, respectively in the RNA-Seq data (Chapter 3, 
Table 3.7). Therefore, a lower level of pigmentation was predicted in bacteria 
treated with D-sphingosine. To test this hypothesis, S. aureus culture was 
incubated with 5 μM D-sphingosine, with a 0.03% ethanol solvent control for 24 
h, followed by pigment extraction. A photometric absorbance spectrum assay 
was performed on the methanol extract. 
The lab strains S. aureus Newman and SH1000 were tested in the absorbance 
assay using three biological and three technical replicates to calculate mean 
values. The results indicated that sphingosine treatment caused increased 
staphyloxanthin production compared with the ethanol control (Figure 4.8), 
which was opposite to RNA-Seq data. However, it is not possible to measure 
pigment very easily during early exponential growth phase, so the cells for 
assay were harvested after 24 h incubation with sphingosine. The 
transcriptome study saw RNA harvested 20 min after challenge with D-
sphingosine. Thus, the crt genes expression immediately after challenge reveals 
their downregulation, while long-term exposure generates a different response 
that might reflect adaptation during subsequent growth phases and D-
sphingosine might induce either an oxidative or general stress response upon 
prolonged exposure. 
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Figure 4.8 Absorbance spectrum assay of methanol-extracted staphyloxanthin.  Cells of S. 
aureus Newman(a) and SH1000 (b) were tested by methanol extraction after exposure to 5 μM 
D-sphingosine (red) or ethanol control (yellow). The x-axis corresponds to the light wavelength 
and the y-axis is the absorbance value for the corresponding wavelength.  
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To explore the detected increase in pigmentation after long-term exposure to D-
sphingosine, survival from peroxide was tested.  Cells of both S. aureus and S. 
epidermidis strains were challenged with 7.5 mM hydrogen peroxide after 
culture in the absence and presence of D-sphingosine, as described in section 
2.2.4. Pre-treatment of cells was achieved by 24 h incubation with 5 μM D-
sphingosine with 0.03% (v/v) ethanol serving as a solvent control.  Cells were 
harvested by centrifugation, and washed with PBS. To generate a similar killing 
dynamic, 3.2 mM H2O2 was used with S. epidermidis Tü3298 because its 
susceptibility to H2O2 was much higher than that of S. aureus.  
Both S. aureus Newman and SH1000 cultures with sphingosine showed greater 
survival in the presence of the peroxide over the first 60 min of the assay 
compared with the control, untreated cells (Figure 4.9b, 4.9c). This outcome is 
consistent with the increased pigmentation described above for cells treated 
with D-sphingosine and consistent with the reported effect of staphyloxanthin 
in the protection of the bacteria from peroxide.  For S. epidermidis Tü3298 D-
sphingosine treated cells, there was no obvious difference (Figure 4.9a) in 
survival from H2O2 and this is consistent with the absence of pigment in this 
species.  Higher peroxide concentrations only increased the rate of bacterial 
killing, with no observable difference for D-sphingosine pre-treated groups and 
the control cells. 
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Figure 4.9 Survival of peroxide challenged S. aureus and S. epidermidis with or without 5 
μM D-sphingosine pre-treatment. Cells of S. epidermidis Tü3298 (a), S. aureus Newman (b) or  
S. aureus SH1000 (c) were challenged with hydrogen peroxide (7.5 mM H2O2 S. aureus; 3.2 mM 
H2O2 S. epidermidis). Blue triangle represents D-sphingosine treated cells and red star 
represents ethanol control cells. Experiments were repeated three times. 
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4.4 Discussion 
The experiments in this chapter confirmed that the increased expression of the 
VraSR global regulator of cell wall synthesis has a role in D-sphingosine 
resistance of S. aureus. As proposed in chapter 3, sphingosine might be a cell 
wall targetting antimicrobial that inhibits cell wall biosynthesis or lead to cell 
wall damage. Upregulation of VraSR could be a response for damage repair, or 
may alter regulation of cell wall biosynthesis to produce a thicker or more rigid 
cell wall layers to prevent penetration of D-sphingosine. 
HrtAB is a haem regulated transporter that is controlled by the haem-sensor 
system HssRS. Both HrtAB and HssRS were upregulated in response to D-
sphingosine challenge (3 fold for hrtA, 3 fold for hrtB, 1.9 fold for hssR, 1.6 fold 
for hssS). To compare, the Haem-sensor system (HssRS) and haem regulated 
transporter (HrtAB) were not differentially expressed in S. epidermidis after 
challenge with D-sphingosine. Although the MIC results for the hrtB mutant 
suggest that haem transport and regulation could play a role in D-sphingosine 
resistance, only an increase in expression of hrt and hss must be sufficient to 
indicate haem/iron-starvation since none of the many genes (such as isd operon, 
sir, sfa, and sbn) involved in iron acquisition were differentially expressed. Other 
than iron acquisition, HrtAB system may be activated by sphingosine, or it might 
export D-sphingosine or a derivative made by metabolism.  
The downregulation of the crt operon for staphyloxanthin biosynthesis evident 
in the transcriptomic data makes it tempting to suggest a lower pigmentation 
level with alteration in membrane lipid synthesis could result from D-
sphingosine interaction. The downregulation of pigment production does 
results in decreased resistance to oxidative stress. However, further 
experiments in this chapter revealed that the pigmentation level of S. aureus 
was increased after sphingosine addition for 24 h, suggesting bacteria respond 
differently during growth in its continuous presence. The hydrogen peroxide 
killing test supports this increased staphyloxanthin production due to D-
sphingosine since the sphingosine challenged cells had higher resistance to 
hydrogen peroxide compared with ethanol controls. 
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4.4.1 Inorganic phosphate (Pi) and S. aureus survival to D-sphingosine 
Inorganic phosphate (Pi) is an essential nutrient to living organisms. Cellular 
metabolism depends on the maintenance of appropriate concentrations of 
intracellular Pi (Watanabe et al., 2008; Wongwisansri and Laybourn, 2005; 
Konberg et al., 1999; Ghillebert et al., 2010). Pi is not only required for 
biosynthesis of cellular components such as ATP, nucleic acids, phospholipids 
and proteins, it is also central to many metabolic pathways including protein 
activation, energy production, and carbon and amino acid metabolic processes 
(Wu et al., 2003). Pi starvation-responsive genes are linked with multiple 
metabolic pathways, implying a complex Pi regulation system in 
microorganisms and plants (Yang and Finnegan, 2010; Luan,2003; Hunter, 
1995).  
In this study, upregulation of the high affinity inorganic phosphate transporter 
Pst, and the alkaline phosphatase PhoB plus its synthesis regulatory system 
PhoRP, suggests a requirement for Pi acquisition in S. aureus challenged with D-
sphingosine. No difference was observed between the D-sphingosine survival of 
a pstS-pstCAB depletion mutant strain compared with the wild type Newman 
strain (described in section 4.3.2). Similar regulation of these genes was 
observed in a study of methicillin-resistant S. aureus where strong upregulation 
of the pstS and pstCABphoU operons was induced by antimicrobial peptide 
ranalexin (Overton et al., 2011). Similarly, in their further investigation, genetic 
disruption of the pstC transmembrane component of the Pi transporter did not 
have any effect on ranalexin sensitivity. It was suggested that MRSA adopts a 
PhoU-mediated persister phenotype to acquire antimicrobial tolerance, but 
upregulation of the Pi transporter is not a major component of this response 
(Overton et al., 2011). These genes could be part of a cell wall or cell membrane 
stress response that is not directly involved or essential in protection from 
these antimicrobial stimuli. 
In contrast, the pstS::Tn mutant in this study showed different results from the 
above data. This pstS mutant cells were more sensitive to D-sphingosine 
compared with wild-type cells, which supports the hypothesis that the pst 
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transporter increases sphingosine survival in S. aureus. Altogether, these results 
might indicate that Pst plays a role in D-sphingosine resistance in S. aureus, and 
deletion of the phosphate-binding protein PstS was essential for disruption of 
the phosphate ABC transporter Pst. Given that a single allelic replacement 
variant pstS has a different phenotype from the combined operon depletion 
mutant pstS-pstCAB, PstS might also have a role separate from Pst transporter. 
Deletion of the pstS and pstCAB genes may alter expression of other genes, such 
as its repressor regulator phoU that increases bacterial resistance to D-
sphingosine. Additionally, phoU was proposed to suppress the pst S and pstCAB 
operons (Overton et al., 2011), but both phoU and pstSCAB were found 
upregulated, suggesting a secondary regulatory mechanism for either or both of 
these genes. 
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Figure 4.10 Double digestion of pst complement after E. coli transformation. Plasmids 
extracted from the transformed E. coli colonies were double digested with restriction enzymes 
BamHI and HindIII. Two clear bands in the same column of the gel image was expected for 
successfully transformation (one 5.6 kb sized for plasmid psk5632, one 4.2 kb sized for pst 
complete DNA insert). However, no successful transformants were detected. 
 
 
Complementation of the gene mutants can be achieved by introducing a shuttle 
vector, such as pSK5632, into S. aureus with the relevant operon cloned using 
sufficient upstream and downstream DNA to include leader and any terminator 
sequences. A higher expression level of the target gene can be achieved when 
using high copy number plasmids and the plasmid pSK5632 is low copy in S. 
aureus (Grkovic et al., 2003). Whether the pst operon plays a role in 
staphylococcal resistance to sphingosine could also be determined if higher 
expression of the pst operon increases bacterial resistance. Yet, the creation of 
complementation strains was unsuccessful, as the plasmid extracted from the 
transformants were modified in E. coli (figure 4.10). The gel image for digested 
plasmid indicated a range of plasmid sizes but there was no identification of 
correctly-sized plasmid and insert, supporting rearrangements in E. coli.  This 
phenomenon is well known for S. aureus membrane proteins and has been 
described (Horsburgh et al., 2004; Kenny et al., 2013).  It is likely that there is 
toxicity associated with the insertion and mistargeting of the newly synthesised 
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protein, which can lead to destabilisation of the membrane upon aggregation of 
expressed proteins. This membrane disruption may trigger proton leak and loss 
of energy homeostasis (Wanger et al., 2007; Hattab et al., 2014). The presence of 
near consensus transcription and translation sequences for E. coli that are 
present in S. aureus operons compounds the problem, and the toxicity of 
overexpression of membrane proteins in E. coli may explain the problem of no 
successful transformants detected.  
To bypass the toxicity in E. coli, previous solutions include direct transformation 
of ligation reactions into S. aureus RN4220 and this was also conducted for the 
pst plasmid construct in several attempts at electroporation, but no successful 
transformation occurred.  
 
 
 
Figure 4.11 Different media based MIC tests of Newman pstSCAB::tet strain. Wild type S. 
aureus Newman was tested using BHI and CDM media, with or without additional Pi. Final 
phosphate concentrations (mM) in the media are indicated in the brackets. The highest D-
sphingosine concentration used in this test was 165 μM, the exact MIC that the bacteria can 
tolerate in the media with additional phosphate could be higher. Error bars indicate standard 
deviation of three biological repeats. 
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Having established that addition of Pi dramatically increased MIC of S. aureus to 
D-sphingosine (Figure 4.2), it was investigated if this effect was broth-
dependent, since it is possible that the components of growth media may 
interact with additional inorganic phosphate and D-sphingosine to collectively 
produce this phenomenon. Therefore, the growth experiment was performed 
using standard and low phosphate CDM, and BHI with or without additional Pi 
(Figure 4.11). The results exhibited a similar pattern as that in the original THB 
experiment, suggesting the nature of the growth medium is not relevant to the 
effect.  
Sphingosine can be phosphorylated in vivo via sphingosine kinase to form 
sphingosine-1-phosphate (S1P), which is a bioactive sphingolipid metabolite 
involved in mammalian cell growth regulation (Zhang et al., 1991; Spiegel and 
Milstien, 2000). S1P was found to be a second messenger in cellular 
proliferation and survival (Olivera and Spiegel, 1993; Cuvillier et al., 1996).  It 
was also suggested that S1P protects cells from ceramide-mediated apoptosis 
(Cuvillier et al., 1996). Fischer et al (2013) predicted sphingosine uptake by S. 
aureus. However, whether sphingosine can be phosphorylated via bacterial 
enzyme activity, or phosphorylated sphingosine has similar signalling activity in 
bacteria is not known.  From these transcriptome data there is no obvious 
candidate for an extracellular kinase activity, though the cell could import S1P 
and might dephosphorylate S1P using its alkaline phosphatases.  Specific 
experiments were not performed to investigate this further. 
To summarise, while Pi is required as a component of energy metabolism and 
kinase/phosphatase signalling processes, whether treatment of D-sphingosine 
leads to phosphate starvation in staphylococci thereby inducing the pst 
transporter genes, or whether Pst possesses other functions facilitating 
staphylococcal sphingosine resistance remains to be resolved.  
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Chapter 5: The individual contributions of farE/R genes 
and SNPs that increase S. aureus survival to D-
sphingosine 
 
5.1 Introduction 
5.1.1 Mechanism of action of sphingosines and AFAs 
Human skin possesses two discrete sets of lipids associated with its superficial 
layers of keratinocytes: the uppermost outward facing surface is coated with 
sebaceous lipids; and beneath these topmost layers the stratum corneum lipids 
form a structured supportive network. These two lipid fractions differ markedly 
in their composition, with the sebaceous lipids being dominated by squalene, 
wax esters and triacyclglycerols, whereas the epidermal lipids comprise a 
stoichiometric 1:1:1 ratio of ceramide, fatty acids and cholesterol. Both of these 
sets contain antimicrobial lipids. The epidermal lipids contain antimicrobial 
sphingosines, generated from the hydrolysis of ceramide. Antimicrobial lipids of 
the skin include sphingoid bases (sphingosines) and fatty acids.  
Sphingosines are widely active against bacteria and fungi (Drake et al., 2008; 
Desbois and Smith, 2010). Approximately 270 μM of sphingosine can be 
observed on healthy skin, whilst only 140-160 μM is present on atopic 
dermatitis skin that becomes typically heavily colonised by S. aureus (Arikawa 
et al., 2002), suggesting an association between sphingosine and S. aureus 
colonisation on skin. D-sphingosine was described to have a similar mode of 
action as AFAs through membrane leakage and loss of low molecular weight 
components of S. aureus (Parsons et al., 2012). However, the carboxyl group was 
believed to be essential for toxicity of AFAs (Zheng et al., 2005), while 
sphingosines do not have carboxyl groups. Moreover, sphingosines cause 
profound morphological changes, including rugged membrane surface, decrease 
in cell size and loss of cell wall (Fischer et al., 2013), while AFA treated S. aureus 
cells have no significant change in morphology (Parsons et al., 2012). 
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Sphingosines are evidently more efficient than AFAs at causing membrane 
disruption as they lead to visible effects and cell lysis (Fischer et al., 2013).  
While sphingosines and AFAs do not have an identical action mode, similar 
mechanisms are found with each targeting the cell membrane. Previous studies 
have focused on responses to AFAs only, with the effects of sphingosine on cell 
transcriptional and translational outcomes remaining unstudied. By 
investigating the effects of sphingosine on survival and transcriptional 
responses of staphylococci it will be possible to determine the extent to which 
there are overlapping resistance mechanisms that protect S. aureus against 
different skin lipids, including sphingosines. 
 
5.1.2 FarRE fatty acid resistance regulator and effector system  
Previous research in the Horsburgh group identified an MmpL efflux pump 
(encoded by sar2632) in S. aureus MRSA252 that contributed to survival from 
the AFA, linoleic acid (Kenny et al., 2009). Transcripts of the sar2632 gene were 
2-fold upregulated after linoleic acid challenge and an allelic replacement 
mutant had three-fold reduced survival on linoleic acid containing agar plates. 
Subsequent studies by others characterised the sar2632 gene homolog in S. 
aureus USA300 encoding the MmpL efflux pump and ascribed the ‘fatty acid 
resistance’ gene as farE. The farR and farE genes are a divergon that encode a 
TetR-like regulator and a membrane transporter effector in S. aureus and FarR 
regulation was shown to be induced by arachidonic acid, in addition to the 
previously assigned linoleic acid (Alnaseri et al., 2015; Kenny et al., 2009). 
Expression of the FarE efflux pump of S. aureus is controlled by the regulator 
FarR and contributes to resistance to linoleic and arachidonic acids (Alnaseri et 
al., 2015), and was found to support resistance to sapienic acid of S. aureus 
(Moran, 2015).  
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5.2 Chapter Aims 
Previous research conducted in the Horsburgh group at Liverpool, sought to 
investigate the determinants that contribute to survival of S. aureus and S. 
epidermidis from the amino alcohol sphingosine, using D-sphingosine as a 
readily available representative of these skin lipids. An experimental evolution 
approach was used in the previous study, where in vitro selection of both 
species was performed for clones with increased MIC to sphingosine (Moran, 
2015). Genome re-sequencing and mapping of genetic variance revealed 
multiple single nucleotide polymorphisms (SNPs), and several SNPs mapped to 
the previously identified mmpL lipid efflux locus (Moran, 2015), and those genes 
subsequently named farRE (Alnaseri et al., 2015).  
Taking into consideration the potentially contributing roles of those identified 
SNPs, together with the described roles of FarR and FarE in S. aureus lipid 
resistance, the aim of this chapter is to dissect the SNPs and identify the 
individual contributions of the farR and farE genes and the mapped SNPs to 
resistance of S. aureus to sphingosine.  This investigation will be achieved using 
allelic replacement mutants and generation of allelic variants with defined SNPs, 
to determinate the contribution of this genetic locus in resistance of S. aureus to 
D-sphingosine. 
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5.3 Results  
5.3.1 Construction of allelic variants of farE and farR genes 
Previous work in the Horsburgh lab group revealed that in vitro selection of S. 
aureus for increased growth yield at high concentrations of sphingosine resulted 
in multiple genetic changes, which included SNPs in the divergon farE-farR 
(Moran, 2015). Three evolved strains: 9A, 9B, 15C, were identified and 
characterised by Moran (2015) (Table 5.1) and these strains had various 
combinations of three non-synonymous SNPs in the farR gene (FarR A40S, D94Y 
and E151K). The study determined that the selected clones bearing these SNPs 
(amongst other SNPs) had increased sphingosine MIC. To provide confirmatory 
evidence for the role of the individual SNPs in the farR genes contributing to 
increased MIC, attempts were made to generate mutants bearing the annotated 
nucleotide changes (see chapter 2, section 2.3).  
 
Table 5.1  Genetic polymorphisms identified in the farR locus in a previous study. (Data 
from Moran, 2015) 
Gene 
Evolved 
isolate 
Position of change 
Gene SNP 
position 
Base change 
Amino acid 
substitution 
farR 9A 2641724 451/549 bp G/A E151K 
farR 9B 
2641391 118/549 bp G/T A40S 
2641553 280/549 bp G/T D94Y 
farR 15C 
2641553 280/549 bp G/T D94Y 
2641724 451/549 bp G/A E151K 
 
Table 5.2 PCR primers for farR gene cloning. Primers were designed with addition of 
restriction enzyme recognition sequences (underlined) AAGCT and GGATCC for HindIII and 
BamHI, respectively. 
Primer name Sequence 5'-3' product size 
FarR_Forward ACTAAGCTACGATGAAAGAGACTGA 
572bp 
FarR_Reverse ACTGGATCCACGCTATTTAATCTTAAT 
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Figure 5.1Cloning of farR alleles into pMUTIN4.  (a) Digested farR DNA fragments. The farR 
alleles were PCR amplified from DNA of strains 9A, 9B and 9C, respectively, followed by 
digestion with restriction enzymes BamHI and HindIII. (b) Uncut and digested plasmid 
pMUTIN4. Plasmid pMUTIN4 was extracted and digested with BamHI and HindIII;  plasmid 
pMUTIN4 before (right lane) and after (left lane) double digestion. 
 
 
Primers for PCR amplification of farR were designed with the addition of 
restriction enzyme recognition sequences AAGCT and GGATCC for HindIII and 
BamHI, respectively (Table 5.2). Insert DNA fragments for cloning into the 
vector pMUTIN4 in E. coli were amplified from evolved strains 9A, 9B and 9C, 
with different combinations of the target SNPs A40S, D94Y and E151K (Table 
5.1). The PCR products were purified and digested with BamHI and HindIII 
(Figure 5.1a) with different restriction enzymes used to limit self-ligation 
between the DNA fragments. 
Plasmid pMUTIN4 used in this experiment is a high copy number vector 
(Vagner et al., 1998) when it replicates in E. coli and acts as a suicide vector in S. 
aureus. The plasmid was digested with the same combination of restriction 
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enzymes BamHI and HindIII as the insert DNA fragments, again to minimise self-
ligation. The single band of linear plasmid DNA of correct size confirmed 
digestion (Figure 5.1b). The double digested plasmid and insert DNA fragments 
were ligated using T4 ligase and E. coli Top10 was transformed followed by 
selection and screening for correct clones. 
 
 
 
 Figure 5.2. Double digestion of farR plasmids purified from E. coli. Plasmids were extracted 
form the E. coli transformants and double digested with restriction enzymes BamHI and HindIII 
to release the cloned DNA with the sizes of fragments shown. DNA markers from an adjacent 
section of gel are shown alongside.  
 
 
E. coli transformant clones were screened for those that contained plasmids 
with a farR insert. Purified plasmids were double digested with BamHI and 
HindIII to identify the desired plasmids, i.e. correctly sized farR insert DNA band 
and plasmid pMUTIN4 band (Figure 5.2). Correctly cloned plasmids were then 
purified and used to transform S. aureus RN4220 via electroporation, using the 
method described by Schenk and Ladagga (1992). S. aureus RN4220 can accept 
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foreign DNA since it a restriction gene mutation means incoming DNA is 
modified with addition of methyl groups but degraded at a reduced rate. The 
plasmid pMUTIN4 cannot replicate in S. aureus but recombination with the 
genome can be selected if cloned homologous regions are present. A 
combination of 5 μg ml-1 erythromycin and 25 μg ml-1 lincomycin was used to 
select for recombination of the suicide vector and to minimise selection of 
spontaneous erythromycin resistance.   A chosen clone was then lysed with 
phage φ11 to propagate generalised transducing phage bearing the allele for 
transduction of the integrated plasmid to S. aureus SH1000. 
 
 
 
Figure 5.3 Schematic of integration and resolution of SNP alleles using pMUTIN4.  SNP 
containing farR DNA fragment shares near identical sequnce with the gene of the recipient 
RN4220 stain. The insert-vector plasmid construct was integrated into the RN4220 genome via 
single Campbell integration event. Plasmid lost occurs after recombination of farR and farR’ 
(SNP containing farR gene) during growth in the absence of antibiotic selection. 
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S. aureus SH1000 was used as recipient strain to generate the farR SNPs found 
in clones 9A, 9B and 15C in the same strain used for evolution with D-
sphingosine. After selection, transductants were grown in BHI without 
antibiotic for 48 h to permit recombination that will generate a single locus and 
potentially replace wild-type farR by the constructed farR SNP allele.  During 
this recombination, the plasmid is deleted (Figure 5.3), with loss of 
erythromycin resistance encoded by pMUTIN4, and this change of phenotype 
was used to identify clones where recombination had occurred.  
 
 
Table 5.3 PCR primers for SNP screening. Forward primers for farR SNPs A40S, D94Y and 
E151K. PCR reactions were prepared with these SNP screening forward primers and the 
FarR_Reverse primer (Table 5.2) respectively for detection of each SNP. 
Primer name Sequence 5'-3' product size 
SNP screening_A40S TTTGCGACAACT (12) 454 bp 
SNP screening_D94Y GCGATTTCTCTCAAATA (17) 298 bp 
SNP screening_E151K CGACTCGTTGATTA (14) 124 bp 
 
 
Figure 5.4 PCR optimisation of SNP screening primer D94Y.  DNA of S. aureus SH1000 was 
used as template for negative controls (-), DNA of 15C evolved clone was used as template for 
positive controls (+).  Both positive and negative templates were amplified with 50-54°C 
annealing temperature; only positive controls were amplified with 58-62°C annealing 
temperature; neither positive nor negative templates were amplified at 66°C annealing 
temperature. 
149 
 
To identify those clones having undergone recombination that have maintained 
the SNP containing allele, primers for screening to identify the presence of the 
SNP were designed with the desired nucleotide mismatch at the 3' end (Table 
5.3). The location of the mismatch at this position prevents amplification of the 
wild-type DNA amplicon at high annealing temperatures; short lengths (12-17 
nt) and high annealing temperature increase primer specificity to SNP 
containing template rather than wild type. The optimum annealing temperature 
of each SNP screening primer was determined with PCR reactions at various 
annealing temperatures, using DNA of strain SH1000 as negative template and 
strains 9A, 9B or 15C as positive (SNP) template. For SNP D94Y, the screening 
primer only amplified the positive template with 58-62°C annealing 
temperature, with greater amplification yield at 58°C than 62°C (Figure 5.4); 
58°C was considered to be the optimum annealing temperature for SNP 
screening primer D94Y. Utilising the same method, the determined optimum 
annealing temperature for SNP screening primers A40S and E151K were 58°C 
and 50°C, respectively. 
 
    
Figure 5.5.  PCR screening of SNPs in a selected farR clone after recombination. Single 
colonies were tested with SNP screening primers (Table 5.3) to detect potential correct SNP-
bearing clones. A variant with both SNPs D94Y and E151K was found. 
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Using this PCR screen method, colonies that were positive for the target SNPs 
were selected. The farR gene fragments were then PCR amplified and sent for 
sequencing using the Sanger method for confirmation (GATC, UK). The DNA 
sequences were compared with wild type using NCBI nucleotide BLAST (Basic 
Local Alignment Search Tool) algorithm (NCBI). Although a range of desired 
farR allelic variants were sought (table 5.1), only one farR SNP variant strain 
was constructed and confirmed by Sanger sequencing: FarR.D94Y.E151K, 
contains two SNPs: Saouhsc-02867-(E151K;  G2641724A) and Saouhsc-02867-
(D94Y; G2641553T). 
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5.3.2 D-sphingosine survival test of farE and farR allelic replacement 
mutants and farR SNP variant 
To assess the role of the S. aureus farE and farR genes in sphingosine survival, 
the minimum inhibitory concentration (MIC) of D-sphingosine was determined 
for the farE and farR allelic replacement mutants (unpublished lab strain 
SH1000 farE::tet and SH1000 farR::tet from Horsburgh Lab) and the farR SNP 
variant (SH1000 FarR.D94Y.E151K). MIC values were compared with wild type 
SH1000. Bacteria were cultured in BHI broth, then 96 well plates were used for 
MIC tests. A range of concentrations of D-sphingosine were prepared with BHI 
broth and 100 μl was added to each well of the 96 well plate. Test strains were 
grown for 24 h, diluted to OD600=0.2 with BHI broth, then 100 μl was added to 
each well and incubated at 37°C for 24 h. Each experiment comprised at least 3 
technical repeats and 5 biological repeats. 
The SNP variant SH1000 FarR.D94Y.E151K was capable of growth at high 
concentrations of D-sphingosine (165 μM), although the MIC was not as high as 
the original evolved isolate 15C (485 μM) (Figure 5.6b) that contained further 
SNPs not studied here. Other non-synonymous SNPs present in coding regions 
of 15C include genes encoding: ATP synthase (saouhsc_02341); hypothetical 
CAAX protease (saouhsc_02587); extracellular matrix binding protein homolog 
(ebh); methicillin resistance determinant (fmhA); sorbitol dehydrogenase 
(saouhsc_00217); and upstream substitution of sigmaB regulator (rsbU); 
transglycosylase (Saouhsc_01840), hypothetical proteins (saouhsc_00235, 
saouhsc_01130, saouhsc_01584, saouhsc_01918, saouhsc_02189) (Moran, 2015).  
In support of the genes contributing to sphingosine resistance, both farE and 
farR allelic replacement mutants had reduced MIC for sphingosine (9.9 and 
11.75 μM respectively), compared with 16.3 μM in the wild type (Figure 5.6a). 
Altogether, the MIC tests support the hypothesis that the FarRE regulator-
transport system contributes to resistance of S. aureus to the antimicrobial lipid 
D-sphingosine (Figure 5.6). 
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Figure 5.6  D-sphingosine MIC assay of farE and farR mutant strains. D-sphingosine MIC 
results of (a) farE and farR allelic replacement mutants and (b) SH1000 FarR.D94Y.E151K 
compared with wild-type SH1000. The strains SH1000 farE::tet, SH1000 farR::tet, original 
evolved isolate 15C and the farR SNP variant SH1000 FarR.D94Y.E151K were assayed in BHI 
medium and compared with wild type SH1000. Error bars indicate standard deviation of three 
repeated experiments. 
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As a further assay of D-sphingosine survival, wild type S. aureus SH1000 and 
isogenic mutant strains farE::tet, farR::tet were cultured with a sub-lethal 
concentration of D-sphingosine (5 μM). Control groups were cultured with 
solvent only (0.03% v/v ethanol). Bacteria were grown for 24 h prior to survival 
assay with sphingosine. It was hypothesised that bacteria pre-treated with a 
sub-lethal concentration of D-sphingosine would have greater resistance to D-
sphingosine. Harvested cells were challenged with 5 μM, 10 μM, 15 μM, or 20 
μM D-sphingosine. This range of D-sphingosine concentrations was used to find 
an appropriate lethal concentration to differentiate killing over time due to D-
sphingosine and for comparing pre-treated groups and controls.  
Both farE and farR allelic replacement mutants were 100% killed by 15 μM D-
sphingosine rapidly within 15 min (Figure 5.7bc), while wild type SH1000 was 
60% killed in 30 min (Figure 5.7a). Ten μM D-sphingosine was not lethal to wild 
type SH1000 (Figure 5.7d), but killed 95% SH1000 farE::tet in 30 min (Figure 
5.7e) and killed 80% SH1000 farR::tet in 90 min (Figure 5.7f). These data 
support the conclusion of the MIC tests that farE and farR depletion results in 
decreased tolerance of S. aureus to D-sphingosine. Moreover, the results also 
indicated that pre-treatment of a sub-lethal concentration of D-sphingosine 
increased the resistance to a previously lethal concentration in all three strains 
(death rate of the pre-treated bacteria was slower, and less bacteria were killed 
than control), and was more pronounced in farE and farR allelic replacement 
mutants. These data support inducible resistance mechanisms of S. aureus to D-
sphingosine. 
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Figure 5.7 D-sphingosine survival of S. aureus strains cultured in the absence and 
presence of D-sphingosine. Cells were cultured in the absence (ethanol solvent control;  
triangle) or presence of 5 uM D-sphingosine (open square). WT SH1000 challenged with 15 μM 
(a) or 10 μM (d) D-sphingosine. SH1000 farE::tet strain challenged with 15 μM (b) or 10 μM (e)  
D-sphingosine. SH1000 farR::tet strain challenged with 15 μM (c) or 10 μM (f). Data is 
representative of 2 experiments showing similar results. 
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5.4  Discussion 
Whilst one aim of this part of the research study was to generate a range of SNP 
variants of the farR gene encoding a lipid efflux transporter, this had only 
limited success.  Of the three SNPs previously identified in farR and targetted for 
construction as single isogenic variants in S. aureus, just SH1000 variant 
encoding protein FarR.D94Y.E151K variant was created successfully.  No 
mutants with either single or double SNPs could be found from those colonies 
screened. However, the single variant generated SH1000 FarR.D94Y.E151K had 
increased resistance to D-sphingosine, compared with its isogenic parent.  This 
strongly supports a potential role for the FarR-FarE gene locus in resistance to 
the lipid D-sphingosine.   
In addition to this experiment, analysis of farE and farR allelic replacement 
mutants was performed with D-sphingosine MIC assays and challenge survival 
assays.  These studies revealed that SH1000 farE::tet and SH1000 farR::tet both 
had markedly reduced resistance to D-sphingosine.  The contrast with the farR-
SNP variant is important since the reduced resistance supports that the farR 
SNPs might be more regulatory rather than mutations affecting specificity for D-
sphingosine.  However, such declarations require further study with more 
elegant experiments looking at transport and gel retardation of the farE 
promoter/leader DNA.  Nonetheless the data supports that the FarR-FarE 
proteins play a role in facilitating D-sphingosine resistance in S. aureus. Given 
these findings it might be expected that upregulation of farR-farE would be seen 
in the RNA-seq data (Chapter 3). Yet, no differential expression of either farE or 
farR was observed in the D-sphingosine challenge S. aureus transcriptome.  
Therefore, it is credible that the ability of FarR to sense sphingosine is absent, 
while FarE is capable of sphingosine export.  A combination of biochemical and 
structural studies would resolve this knowledge gap. 
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Figure 5.8 Protein model of S. aureus FarR protein showing sites of amino acid 
replacements. The FarR protein encoded by strain SH1000 (left) and the variant SH1000 
FarR.D94Y.E151K (right) are highlighted with the relevant amino acid positions of the SNP. 
Protein models were constructed using modeller (version 9.17), then visualised with Pymol. The 
mesh like pattern shows surface charge of the protein, where red shows positive charge, blue 
shows negative charge, and green is neutral.  
 
 
The FarR protein belongs to the TetR family with known structures forming 
homodimers, with the N-terminal domain containing a DNA binding helix-turn-
helix motif, and the C-terminal domain acting as the substrate binding domain 
(Ramos et al., 2005). TetR proteins have a pocket structure in the substrate-
binding domain. The protein is in relaxed state when not binding with the 
substrates, and this relaxed state is capable of DNA binding. TetR protein shifts 
to a tensed state when binding its substrates, so that binding of DNA is inhibited. 
This enables transcription from TetR-regulated promoters (Ramos et al., 2005). 
Previous work in the laboratory proposed that FarR could be a transcriptional 
regulator of the FarE efflux transporter (Moran, 2015), which transports fatty 
acids and this was later confirmed to be the case for linoleic acid and 
arachidonic acids (Alnaseri et al., 2015). It was hypothesised that FarR functions 
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as repressor of farE in the absence of inducer, but may act to promote 
expression of a positive-acting transcription factor that is needed to activate 
farE in presence of exogenous fatty acids (Alnaseri et al., 2015). 
In this study, protein models were constructed using modeller (version 9.17), 
then visualised with Pymol (Figure 5.8). In the variant protein SH1000 
FarR.D94Y.E151K, the amino acid changes cause tyrosine substitution for 
aspartic acid and lysine substitution for glutamic acid. The substitution of 
negatively-charged aspartic acid with the neutral amino acid tyrosine which has 
a bulky hydrophobic side chain, and the substitution of negatively-charged 
glutamic acid with the positively-charged lysine appear to alter surface charge 
of the protein (Figure 5.8, blue indicates negative charged, red means positive 
charged, and green stays neutral). It is possible that these amino acid changes 
affect how this repressor interacts with its substrate, or alternatively changes 
the protein to a tensed state, independent of substrate binding (always tensed 
causing constitutive expression of FarE). 
While the FarR SNP mutant strain exhibited higher resistance to D-sphingosine 
compared with the wild type strain, the lack of differential expression of either 
farE or farR in the transcriptomics response of S. aureus to D-sphingosine may 
suggests that D-sphingosine is not a natural substrate for FarR, and does not 
induce expression of either FarE (or FarR). The experimental evolution that 
resulted in the protein variants after D-sphingosine selection reveals potential 
plasticity in this transporter system. The changes in structure and surface 
charge may contribute to recognition of D-sphingosine as a substrate, and thus 
activate transcription factor for expression of FarE. Future studies could use 
qPCR to test the hypothesis that expression of FarE in the variant SH1000 
FarR.D94Y.E151K is independent of the presence of of D-sphingosine.  
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Chapter 6: General Discussion 
This study investigated the effects of skin antimicrobial lipid D-sphingosine 
upon S. aureus, with a focus upon discovering determinants that affect 
antimicrobial lipid resistance of S. aureus. These responses and determinants 
were expected to inform on the mechanism of action of D-sphingosine and 
evolved mechanisms of S. aureus. To complete these aims, RNA-Seq and qPCR 
were used to dissect the transcriptional responses of S. aureus Newman and S. 
epidermidis Tü3298 after challenge with D-sphingosine. Combined with 
experimental evolution data, individual contributions of genes and SNPs that 
increase S. aureus survival to sphingosine from transcriptomics data and from 
previous work of the Horsburgh group were further investigated. 
Antimicrobial lipid sphingosine is less well studied than AFAs, where their 
mode of action was proposed to be similar with membrane damage and leakage 
of solutes (Bibel et al., 1993; Fischer et al., 2013; Bergsson et al., 2001). 
Although the detailed antimicrobial mechanisms of sphingosine on bacteria is 
not well established, several possibilities exist: sphingosine may act on S. aureus 
by penetrating and disrupting the cell wall or altering changes in cytoplasmic 
membrane; it may penetrate the cell walls and the cytoplasmic membranes of 
bacteria, then enter and disrupt the cytoplasm similar to the mechanism 
described by Bergsson et al. (2001) for S. aureus. The RNA-Seq data analysis 
(Chapter 3) showed: increased expression of the cell wall stress stimulon 
(including VraSR, Pbp2, MurZ and MsrA1); overlap with the transcriptomic 
response to antibiotics that target cell wall (vancomycin, bacitracin, fosfomycin 
and oxacillin) and membrane (such as ovispirin and temporin); increased 
expression of genes for peptidoglycan and membrane lipid biosynthesis. 
Collectively, these S. aureus transcriptomic responses support D-sphingosine as 
having both cell wall stress and membrane disrupting actions. 
Whilst colonising skin, there is a further way, distinct from cell wall or 
membrane disruption, whereby sphingosine could affect S. aureus. Epidermal 
sphingosine can be phosphorylated by host sphingosine kinase to form 
sphingosine-1-phosphate (S1P) that is sensed for regulation of cellular 
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proliferation and survival of mammalian cells (Zhang et al., 1991; Spiegel and 
Milstien, 2000). S1P is a major regulator of the vascular system, where it 
regulates angiogenesis, vascular stability, and permeability. S1P is also 
recognized as a regulator of T- and B- cells in the immune system (Sharma et al., 
2013). In addition, Fischer et al (2013) predicted sphingosine uptake by S. 
aureus. Moreover, transcriptomic data analysis (Chapter 4) has revealed 
phosphate acquisition in response to D-sphingosine. However, whether 
sphingosine can be phosphorylated via bacterial enzyme activity, or if 
phosphorylated sphingosine has similar signalling activity in bacteria is not 
known.  S. aureus alkaline phosphatase activity may also permit manipulation of 
environmental S1P to influence the skin regulatory pathways and should be 
investigated in future studies. 
The transcriptomic analysis of D-sphingosine challenged S. aureus that was 
undertaken in this study identified upregulation of the high affinity phosphate 
specific transporter (Pst) and the PhoRP alkaline phosphatase synthesis 
regulatory system, both of which control import of inorganic phosphate (Pi) 
into the cell cytoplasm. The reason for this induction was not determined in the 
study and several possibilities exist as to why the lipid drives this expression 
change. It is likely that sphingosine induce lipid synthesis due to damage, or 
sphingosines might be directed into lipid biosynthesis pathways that require 
phosphate. Alternatively, D-sphingosine might cause effects such as phosphate 
starvation through an undefined action or induction of phospholipid synthesis 
that requires increased phosphate. Inductively coupled plasma mass 
spectrometry (ICP-MS) could be utilised in future work to quantitatively 
determine variation of phosphate concentration in cells of untreated and D-
sphingosine-treated S. aureus.  ICP-MS combines a high temperature ICP 
(Inductively Coupled Plasma) source with a mass spectrometer. The ICP source 
atomises and ionises the sample. These ions are then brought into the mass 
spectrometer and are separated and detected by the mass spectrometer via 
their specific mass-to-charge (M/Z) ratio. The most commonly used type of 
mass spectrometer is the quadrupole mass filter (Ruth, 2005). ICP-MS is able to 
analyse phosphorus levels via quadrupole detection of the natural isotope of 
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phosphorus, 31P at m/z=31 and the PO+ moiety at m/z=47 (Zhang et al., 2010; 
Profrock and Prange, 2012).  
Further investigation of the phosphate transporter (Chapter 4) indicated that 
increased environmental Pi concentration assisted D-sphingosine resistance of 
S. aureus strains, and both pstS and phoR mutants are more susceptible to D-
sphingosine than wild type control. These experiments provide the possibility of 
phosphorylation of sphingosine within S. aureus cells that reduces toxicity by 
directing the lipid towards metabolism. Alternatively, phosphorylated 
sphingosine may serve as a messenger that induce bacterial growth and survival 
to antimicrobial lipids. Ericson et al., (2017) reported that fatty acids (FAs) 
negatively regulate SaeRS signalling, and FA kinase activates production of 
SaeRS-dependent virulence factor in S. aureus by lowering inhibitory FA levels. 
SaeRS-mediated transcription was found to be restored in FA kinase-negative 
strains when the intracellular FA pool is reduced (Ericson et al., 2017). Given 
the similar action mode between sphingosine and AFAs, together with the 
downregulation of SaeRS in both S. aureus and S. epidermidis by D-sphingosine 
treatment, sphingosine might also affect the FA pool and FA kinase activity to 
induce similar effects on cellular lipid homeostasis regulation. 
Isotope labelling techniques can help with investigation of sphingosine and 
phosphate metabolism in the bacteria. Biological studies based on isotope 
labelling have been widely established. This technique is particularly powerful 
in biochemical pathway analysis allowing scientists to trace the conversion of 
one chemical to another following incorporation of heavy atoms from precursor 
substrates into different metabolic products (Chokkathukalam et al., 2014; Fan 
et al., 2012). Usage of radioactive isotopes is a common method in isotope 
labelling research due to its high sensitivity. The amount of radioactive isotope 
used in the study must be strictly controlled within the limits of what an 
experimental organism can support, since excess radiation will induce 
mutations and alter outcomes, and instead stable isotopes remove mutagenic 
effects for ease of study. Stable isotopes have the same number of protons as the 
common elements, and consequently share the same physicochemical 
properties, but differ in mass due to a difference in the number of neutrons, 
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which enables mass spectrum based analytical tools to easily separate 
isotopically labelled compounds based on mass differences (Chokkathukalam et 
al., 2014).  
By treatment of staphylococci with a customised isotope-labelled D-sphingosine 
and then tracking its flux in bacterial metabolic pathways, it could be 
determined whether sphingosine enters the cell membrane; whether bacteria 
consume sphingosine as a carbon source, and if so, which metabolic pathways 
sphingosine passes through. To facilitate our understanding of the potential 
reaction between inorganic phosphate and D-sphingosine, S. aureus cells pre-
cultured in chemical defined medium (CDM) with 31Pi and then transferred into 
a new CDM medium with radioactively labelled 32Pi, could be followed by 
challenge with 14C labelled D-sphingosine. 14C and 32P emit β rays (i.e. electrons), 
which cause flashes of light and can then be detected in a photomultiplier tube 
(Rennie, 1999). The energy spectra of 14C and 32P are different, with 32P having a 
higher average energy. Thus, the detector can separate isotope counts by 
frequency distribution of kinetic energy consumption and emitted β particle 
number, which enables dual-labelling techniques (Rennie, 1999). Through the 
radioactively labelled isotope method, it could be predicted whether D-
sphingosine reacts with inorganic phosphate by comparing the tracing signals of 
14C and 32P. Furthermore, isotope tracing may also indicate the location for 
phosphorylation of D-sphingosine (for example, in the medium, on the cell 
surface, or the cytoplasm) if D-sphingosine can be phosphorylated by S. aureus. 
 
To further identify determinants that may affect antimicrobial lipid resistance of 
S. aureus, the transcriptional response of S. epidermidis after D-sphingosine 
treatment was investigated and compared (Chapter 3). These data revealed 
there were more described resistance responses in S. aureus than S. epidermidis. 
Some of these determinants are not common to both species, and no obvious 
functionally analogous alternatives to these resistance mechanisms were 
reported in S. epidermidis. 
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Both S. aureus and S. epidermidis downregulated expression of global regulator 
SaeRS. Since the strain Newman contains a L18P substitution mutation (SaeSP) 
in the first transmembrane helix, other S. aureus strains (SH1000, MRSA252 and 
SF8300) were examined by qPCR to inspect whether the differential expression 
of saeRS by D-sphingosine challenge is strain-dependent (Chapter 4). It was 
found that although saeRS was strongly down regulated 8-fold in Newman, 
while all the other tested S. aureus strains did not show differential expression. 
In contrast, S. epidermidis Tü3298 also downregulated saeRS despite the 
conclusion that differential expression of saeRS was strain dependent in S. 
aureus. As discussed in chapter 3, SaeRS mainly regulates expression of 
extracellular toxins and cellular adherence factors genes in S. aureus (Liang et al., 
2006; Rogasch et al., 2006); it regulates expression of biosynthesis genes, 
including pyruvate metabolism and amino acid synthesis and metabolism genes 
in S. epidermidis (Handke et al., 2007). Whether SaeRS is a functional 
determinant for D-sphingosine resistance is unclear. For future studies, the saeS 
restored Newman HG strain (Mainiero et al., 2010) can be assessed, including D-
sphingosine survival tests and its transcriptional response. 
In response to D-sphingosine, both S. aureus and S. epidermidis upregulated 
expression of the VraSR two component regulatory system. MIC assay using 
vraR and vraS allelic replacement mutant strains (SH1000 vraR::tet and SH1000 
vraS::tet) supported the hypothesis that VraSR TCS contributes to D-
sphingosine resistance in S. aureus (Chapter 4). To determine whether the 
contribution of VraSR is a common feature of staphylococcal responses, vraR 
and vraS mutants in S. epidermidis could be generated for further investigation. 
Gene mutation is less straightforward for S. epidermidis, but the equivalent 
transposon mutant library generated with bursa aurealis has been made similar 
to the Nebraska library for S. aureus and this would enable a facile approach to 
study gene contributions (Yajjala et al., 2016). VraSR controls cell wall 
peptidoglycan biosynthesis, and its upregulation might indicate that the 
bacteria produce a thicker cell wall to protect from the antimicrobial lipid 
sphingosine, or the lipid might cause loss of cell wall material that must be 
replaced. Electron microscopy can be used to visualise and measure cell wall 
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thickness of wild type and allelic replacement strains with or without D-
sphingosine treatment. 
Aside from staphyloxanthin gene expression, no major transcriptional changes 
were observed with genes regulating membrane fluidity in the transcriptomic 
response to D-sphingosine challenge. There could still be changes in membrane 
fluidity, since several studies of Gram-positive bacteria have shown that 
alterations in membrane fluidity are not controlled at the transcriptional or 
translational level (Pesakhov et al., 2007; Fozo and Quivey, 2004; Schujman and 
de Mendoza, 2005). Membrane fluidity is commonly assessed using various 
fluorogenic membrane probes and fluorescence polarization (FP) 
measurements (Kaneko et al., 2007; Fox and Delohery, 1987). Alterations in 
lipid phase transitions change the mobility of a membrane bound fluorophore, 
which can be excited by polarised light and measured (Kushnareva and Dell, 
2009; Finegold, 1976). Samples can be taken at different growth phases (mid-
exponential phase, late-exponential phase, early stationary phase and mid-
stationary phase) for comparison. Decreases in membrane integrity and 
increases in membrane fluidity are expected in the sample taken at the early 
stage after exposure to D-sphingosine due to the ability of D-sphingosine to 
permeabilise the cell membrane. The membrane may become rigid to prevent 
penetration of D-sphingosine during later growth.   
These analyses could be supported by lipidomic analyses. The lipidome is 
defined as the complete lipid profile within a cell, tissue, organism, or ecosystem. 
Study of the lipidome can provide insight investigation of pathways and 
networks of cellulr lipids in biological systems (Wenk, 2005; Watson, 2006). 
Lipidomics can help to examine the structures, functions, interactions, and 
dynamics of cellular lipids and the changes that occur during perturbation of the 
system (Han and Gross, 2003). Lipidomics research can identify and quantify 
the thousands of cellular lipid species and their interactions with other 
metabolites. This advance is based on recent advances in technologies such as 
mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, 
fluorescence spectroscopy, dual polarisation interferometry and computational 
methods. The momentum is due to recognition of the role of lipids in many 
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metabolic diseases such as obesity, atherosclerosis, stroke, hypertension and 
diabetes (Han, 2007).  
The staphyloxanthin biosynthesis genes in S. aureus were downregulated after 
20 min of D-sphingosine treatment (Chapter 3), while production of 
staphyloxanthin was upregulated following 24 h incubation with the lipid 
(Chapter 4). To broaden the RNA-Seq data, which reports the immediate 
transcriptomic response, further RNA-Seq studies of later growth stages could 
be investigated. Further, determining the differential transcription when there 
is constant exposure to D-sphingosine would produce data on adaptation.  
Additionally, these data could be supported with a quantitative proteomics 
application in future research. The focus of this method is study of the proteome, 
which is dynamic and defined as the set of proteins expressed in a specific cell 
under a particular condition (Aebersold and Mann, 2003). To prepare samples 
for proteomics, S. aureus and S. epidermidis can be grown and challenged with 
D-sphingosine with the same conditions as the RNA-Seq experiments, 
harvesting samples at equivalent growth stages. Study of the proteome of 
staphylococci after D-sphingosine exposure, together with the transcriptome 
analysis, would help to establish a more comprehensive understanding about 
the bacterial response to this antimicrobial lipid. 
Previous in vitro experimental evolution experiments with S. aureus with 
selection for growth with D-sphingosine above MIC conducted in the Horsburgh 
group detected multiple single nucleotide polymorphisms (SNPs) in an 
identified lipid efflux locus (Moran, 2015), later named farRE (Alnaseri et al., 
2015). Allelic variants with defined SNPs and inactivation mutations were 
generated to determine the contribution of this genetic locus. MIC and survival 
assays supported that the farRE contributes to D-sphingosine resistance in S. 
aureus (Chapter 5). Alnaseri et al. (2015) hypothesised that FarR functions as 
repressor of farE in the absence of inducer, but acts to promote expression of 
farE in the presence of exogenous fatty acids. Upregulation of farRE was not 
found in the RNA-seq data, indicating that D-sphingosine is not a natural 
substrate for FarR to activate expression of FarE. However, changes in structure 
and surface charge in SH1000 FarR.D94Y.E151K may contribute to recognition 
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of D-sphingosine as a substrate, thus activating the transcription factor for 
expression of FarE. The evolved FarR with D-sphingosine challenge reveals 
potential plasticity in the transporter system under selection.  Curiously, both 
the farR and farE mutants had increased sensitivity to sphingosine as judged by 
their reduced MIC values.  This could be explained if the lipid pools were 
examined to identify the transitional lipid that is formed during detoxification 
and presumed incorporation into lipid pools.  Should the converted lipid not 
enter metabolism, then the intermediary lipid would need to be exported from 
the cell and it could be this form that is recognized by the FarE exporter.  
Further experiments, including lipidomics to identify the cellular/membrane 
associated lipids would add value to the study to resolve the fate of sphingosine 
intracellularly in S. aureus, which has not yet been determined. 
During construction of the SNP allelic variant, the most time-consuming 
procedure was to screen and select for correct SNP-containing clones. Since the 
SH1000 FarR.D94Y.E151K variant has 10-fold increased  MIC, compared with 
wild type SH1000, a high concentration of D-sphingosine (for example, 2-3 fold 
of the MIC of wild type) could be applied as preliminary selection for potentially 
SNP-bearing variants. The anticipation would be that this would not select for 
secondary mutations, however clones could be tested after identification by 
whole genome sequencing for confirmation of the single SNP variant only.  
When creating the FarR.D94Y.E151K variant, genomic DNA was extracted from 
single colonies and PCR screened for SNPs, with only one desired variant in 200-
300 tested colonies. To save time, pools of genomes from 10-20 colonies could 
be made to serve as the PCR template for SNP screening. After a pool was 
identified as positive, single colonies in the pools can be further assessed using 
the screening method. If a more simple and faster method for SNP variants 
creation can be established, study of the contribution of single SNP to 
sphingosine resistance will become more effective. The position of the SNP in 
the cloned segment of DNA will also be important for outcross to ensure that the 
WT copy is lost together with the suicide plasmid by recombination. Further 
experiments to identify the most efficient positioning and length of insert would 
also facilitate this process.   
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Once the remaining farR SNP variants are regenerated, qPCR could be utilised to 
determine differential expression of farE in the SNP variant treated with D-
sphingosine. Increased expression is expected if the variant FarR can recognize 
sphingosine as its substrate and induce expression of farE.  
The collective contribution of lipids to antimicrobial activity is poorly 
understood.  Both the epidermal and sebaceous lipids are combinations of 
several antimicrobial activities together with lipids of various forms and 
concentrations, some of which have no demonstrated antimicrobial activity.  
The individual roles of lipids can be studied in research, such as the study 
presented here, however the actions of the lipids can be studied in future with 
analysis of sebum.  This is not entirely straightforward since sebum is likely to 
vary from one individual to another, as well the level of production on skin.  
However, future experimental evolution experiments could be conducted with 
sebum or with a combination of D-sphingosine and other skin antimicrobial 
lipid such as linoleic acid, oleic acid, and sapienic acid. MIC assays can be applied 
prior to evolution passaging. Combinatorial lipid studies will also help to show 
synergistic antimicrobial effects on bacteria, where lipid combinations may 
share similar modes of action; the combinations that increase bacteria 
resistance may indicate shared determinants for bacterial resistance to these 
antimicrobial lipids. 
 
Over the process of this investigation, one concern that could limit the validity 
and impact of these data is: how do results gained in vitro differ from the in vivo 
scenario. For example, approximately 270 μM of sphingosine can be observed 
on healthy skin, whilst only 140-160 μM is present on atopic dermatitis skin 
that becomes typically heavily colonised by S. aureus (Arikawa et al., 2002). 
However, 10-15 μM of D-sphingosine was found to kill S. aureus rapidly in in 
vitro experiments by Parsons et al. (2012). The D-sphingosine concentrations 
used in this study were 5 μM, even lower than their study and much below that 
reported on the human skin. The effects of other lipids may act to buffer some of 
the toxicity of individual lipids given the higher availabilities of cholesterol and 
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its esters, squalene and waxes.  Moreover, the skin is a much more complex 
environment, with the stress of water supply, pH gradient, antimicrobial effects 
from a series of peptides from the host and other bacteria, as well as 
competition for resources. 
To overcome the perceived and known divergence between in vitro and in vivo 
scenarios, animal models were established. A useful animal model system must 
be clinically relevant, experimentally robust, ethically acceptable, convenient to 
perform and provide both reliable and reproducible results (Kugelberg et al., 
2005). Rodent Epidermal skin models were used for studies of S. aureus 
(Onunkwo et al., 2010). However, the results from studies using rodent skin 
models have shown a lack of consistency over extended periods of time, which 
complicates interpretation of data with respect to bacterial localisation and 
replication in the skin (Kanzaki et al., 1996; Abe et al., 1993; Kugelberg et al., 
2005). Besides, human skin and rodent skin have considerable differences in 
both histology and immunology and the amount of sphingosine. Moreover, the 
majority of existing S. aureus animal skin models require severe mechanical 
disruption of the skin to compromise the initial barrier function which 
facilitates bacterial growth (Nippe et al., 2010; Cho et al., 2011; Inoshima et al., 
2011).  
Due to the need for a physiologically relevant model system to dissect the 
interactions of S. aureus with intact human skin, 3-D organotypic human skin 
tissue models were established to examine the processes of staphylococcal skin 
colonisation and infection (Ridky et al., 2010; Kretz et al., 2013). These models 
fall into two main categories: the ex vivo human skin explant cultures and 
regenerated 3-D organotypic models derived from primary cells and/or human 
cell lines. 
The ex vivo human skin explants are typically acquired from neonatal foreskin, 
surgical or cadaveric tissues, which can be maintained in cell culture media or 
on supports in an air-liquid interface and remain viable in culture for up to two 
weeks (Popov et al., 2014). The advantage of skin explants is that they contain 
all components of the skin tissue, including all resident cell types of the 
168 
 
epidermis and dermis as well as skin appendages. However, there are also 
limitations originating from genetic variations between each individual, and the 
relatively restricted availability of human skin (Popov et al., 2014). 
The 3-D human skin culture models are an informative and tractable 
experimental system for future investigations to dispel the above concern 
(Ridky et al., 2010; Groeber et al., 2011; Song et al., 2012; Kretz et al, 2013, Hogk 
et al., 2013). Organotropic 3-D skin models are generally comprises primary or 
immortalised human keratinocytes, grown at an air-liquid interface on a 
supporting matrix, which can be seeded with fibroblasts (Lebonvallet  et al., 
2010, Gangatirkar et al., 2007; Stark et al., 2004). The matrix can be seeded with 
fibroblasts and other relevant cells including melanocytes, endothelial cells and 
nervous cells (Auxenfans et al., 2009). Moreover, the entire human skin proteins, 
cells and other components including the skin-derived antimicrobials can all be 
involved in the 3-D human organotropic model, to establish a very similar 
thickness and cellular architecture with the human epidermis (Popov et al., 
2014).  
With help of skin models and their further development to be more 
representative, future research studies will be able to provide a deeper 
understanding of the relationship between staphylococci and the epidermal 
lipid sphingosine, together with other skin lipids.  Such studies will help to 
unravel the survival mechanisms and species differences between the different 
staphylococci that successfully colonise our largest organ. 
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Appendix I: Selected SAMMD datasets 
Acid shock 
Regulator : Acid-shock (20min) 
 Growth phase : expression of wild type strain (50583) at exponential phase (OD 
1.0 at 600nm) is compared to the corresponding acid-shocked (450-500 μl of 
6.5 M HCl for 20min) expression of 50583. 
 Stabilising agent used : RNA Protect 
 Fold change cut off :  
 Replicates : Triplicate 
 Strain used : 50583 
 Array type : TIGR-PFGRC S. aureus DNA Microarray 
 Raw data : GEO:GSE7273 
 Software : GeneSpring 
Reference: BORE, E., LANGSRUD, S., LANGSRUD, O., RODE, T. M. & HOLCK, A. 
2007. Acid-shock responses in Staphylococcus aureus investigated by global 
gene expression analysis. Microbiology, 153, 2289-303. 
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Bacitracin 
Regulator : Bacitracin 
 Growth phase : early exponential (OD 0.3 at 600nm) phase wild type (8325-4) 
expression is compared to the Bacitracin treated (6.7 units/ml for 60min) 8325-
4 expression. 
 Stabilising agent used : NONE 
 Fold change cut off : 2 
 Replicates : Duplicate 
 Strain used : 8325-4 
 Array type : S. aureus Affymetrix GeneChip 
 Raw data : NOT AVAILABLE 
 Software : GeneSpring 
Reference: UTAIDA, S., DUNMAN, P. M., MACAPAGAL, D., MURPHY, E., PROJAN, S. 
J., SINGH, V. K., JAYASWAL, R. K. & WILKINSON, B. J. 2003. Genome-wide 
transcriptional profiling of the response of Staphylococcus aureus to cell-wall-
active antibiotics reveals a cell-wall-stress stimulon. Microbiology, 149,  2719-32.  
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Dermaseptin 
Regulator : Antimicrobial peptide (Dermaseptin) 
 Growth phase : expression of early exponential phase (OD 0.6) S. aureus cells 
incubated in the presence of 3 micromolar Dermaseptin for 10min is compared 
to the untreated cells expression. 
 Stabilising agent used : NOT AVAILABLE 
 Fold change cut off : 2 
 Replicates : Triplicate 
 Strain used : Newman 
 Array type : Agilent Chip 
 Raw data : GEO:GSE15800 
 Software : GeneSpring 7.3 
Reference: PIETIAINEN, M., FRANCOIS, P., HYYRYLAINEN, H. L., TANGOMO, M., 
SASS, V., SAHL, H. G., SCHRENZEL, J. & KONTINEN, V. P. 2009. Transcriptome 
analysis of the responses of Staphylococcus aureus to antimicrobial peptides and 
characterization of the roles of vraDE and vraSR in antimicrobial resistance. 
BMC Genomics, 10, 429. 
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Enduracidin 
Regulator : Enduracidin (60min) 
 Growth phase : expression of mid-exponential phase S. aureus cells, added with 
one microgram/ml of enduracidin and incubated for 60min was compared to 
that of the corresponding control cells expression. 
 Stabilising agent used : RNAProtect 
 Fold change cut off : 2 
 Replicates : Triplicate 
 Strain used : ATCC29213 
 Array type : PFGRC Array Version 6 
 Raw data : GEO:GSE37272 
 Software : SAM 
Reference: SONG, Y., LUNDE, C. S., BENTON, B. M. & WILKINSON, B. J. 2012. 
Further insights into the mode of action of the lipoglycopeptide telavancin 
through global gene expression studies. Antimicrob Agents Chemother, 56, 3157-
64. 
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Fosfomycin/murB/murE 
Regulator: Fosfomycin/murB/murE 
Growth phase: expression of murB temperature sensitive mutant grown to OD 
0.25 (600nm) is compared to that of the corresponding wild type cells 
expression. 
 Stabilising agent used : RNAProtect 
Fold change cut off : 2 
 Replicates : Triplicate 
 Strain used : RN4220 
 Array type : Custom array 
 Raw data : ArrayExpress:E-BUGS-71 
 Software : GeneSpring 7.3.1 
Reference: O'NEILL, A. J., LINDSAY, J. A., GOULD, K., HINDS, J. & CHOPRA, I. 2009. 
Transcriptional Signature following Inhibition of Early-Stage Cell Wall 
Biosynthesis in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 
53, 1701-1704. 
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Heat shock 
Regulator : Heat shock 
 Growth phase : mid exponential phase (OD 0.25 at 600nm) wild type (UAMS-1) 
expression is compared to the corresponding cold shocked (42 Degree C for 
30min with aeration) UAMS-1 expression. 
 Stabilising agent used : NONE 
 Fold change cut off : 2 
 Replicates : Duplicate 
 Strain used : UAMS-1 
 Array type : S. aureus Affymetrix GeneChip 
 Raw data : NOT AVAILABLE 
 Software : GeneSpring 
Reference: ANDERSON, K. L., ROBERTS, C., DISZ, T., VONSTEIN, V., HWANG, K., 
OVERBEEK, R., OLSON, P. D., PROJAN, S. J. & DUNMAN, P. M. 2006. 
Characterization of the Staphylococcus aureus heat shock, cold shock, stringent, 
and SOS responses and their effects on log-phase mRNA turnover. J Bacteriol, 
188, 6739-56. 
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Human beta-defensin 3 
Regulator : Human beta-defensin 3 (STE) 
 Growth phase : expression of S. aureus cells grown to an OD of 0.8, added with 2 
micro molar human beta-defensin 3 (short-term exposure) and further 
incubated for 20 min is compared with that of corresponding untreated cells 
expression. 
 Stabilising agent used : RNAProtect 
 Fold change cut off : 2 
 Replicates : Duplicate 
 Strain used : SG511 
 Array type : sciTRACER Custom array 
 Raw data : NOT AVAILABLE 
 Software : SAM 
Reference: SASS, V., PAG, U., TOSSI, A., BIERBAUM, G. & SAHL, H. G. 2008. Mode 
of action of human beta-defensin 3 against Staphylococcus aureus and 
transcriptional analysis of responses to defensin challenge. Int J Med Microbiol,  
298, 619-33. 
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Linoleic acid 
Regulator : Linoleic acid (0.1 mM) 
 Growth phase : expression of late-exponential phase (OD 3.0, 600nm) S. aureus 
cells, added with 0.1 mM of linoleic acid and then grown for 20 min, is compared 
to that of the corresponding untreated cells expression. 
 Stabilising agent used : RNAProtect 
 Fold change cut off : 2 
 Replicates : Triplicate 
 Strain used : MRSA252 
 Array type : BuG@S 
 Raw data : ArrayExpress:E-BUGS-68 
 Software : GeneSpring 7.3.1 
Reference: KENNY, J. G., WARD, D., JOSEFSSON, E., JONSSON, I. M., HINDS, J., 
REES, H. H., LINDSAY, J. A., TARKOWSKI, A. & HORSBURGH, M. J. 2009. The 
Staphylococcus aureus response to unsaturated long chain free fatty acids: 
survival mechanisms and virulence implications. PLoS One, 4, e4344. 
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Nisin 
Regulator : Nisin 
 Growth phase : expression of ATCC 29213 grown to OD 0.4 (600nm) and 
induced with 20 μg/ml nisin for 15min was compared to the expression of the 
untreated ATCC 29213. 
 Stabilising agent used : RNA Protect, Trizon 
 Fold change cut off : 2 
 Replicates : Duplicate 
 Strain used : ATCC29213 
 Array type : TIGR-PFGRC S. aureus DNA Microarrays Version 2 
 Raw data : GEO:GSE9494 
 Software : TIGR-MIDAS, SAM 
Reference: MUTHAIYAN, A., SILVERMAN, J. A., JAYASWAL, R. K. & WILKINSON, B. 
J. 2008. Transcriptional Profiling Reveals that Daptomycin Induces the 
Staphylococcus aureus Cell Wall Stress Stimulon and Genes Responsive to 
Membrane Depolarization. Antimicrobial Agents and Chemotherapy, 52, 980-990. 
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Ovispirin 
Regulator : Antimicrobial peptide (Ovispirin) 
 Growth phase : expression of early exponential phase (OD 0.6) S. aureus cells 
incubated in the presence of 4 micromolar Ovispirin for 10min is compared to 
the untreated cells expression. 
 Stabilising agent used : NOT AVAILABLE 
 Fold change cut off : 2 
 Replicates : Triplicate 
 Strain used : Newman 
 Array type : Agilent Chip 
 Raw data : GEO:GSE15800 
 Software : GeneSpring 7.3 
Reference: PIETIAINEN, M., FRANCOIS, P., HYYRYLAINEN, H. L., TANGOMO, M., 
SASS, V., SAHL, H. G., SCHRENZEL, J. & KONTINEN, V. P. 2009. Transcriptome 
analysis of the responses of Staphylococcus aureus to antimicrobial peptides and 
characterization of the roles of vraDE and vraSR in antimicrobial resistance. 
BMC Genomics, 10, 429. 
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Oxacillin 
Regulator : Oxacillin 
Growth phase : expression of SH1000 grown to OD 0.4 (600nm) and induced 
with 1.2 μg/ml oxacillin for 15min was compared to the expression of the 
untreated SH1000. 
 Stabilising agent used : RNA Protect, Trizon 
 Fold change cut off : 2 
 Replicates : Duplicate 
 Strain used : SH1000 
 Array type : TIGR-PFGRC S. aureus DNA Microarrays Version 2 
 Raw data : GEO:GSE9494 
 Software : TIGR-MIDAS, SAM 
Reference : MUTHAIYAN, A., SILVERMAN, J. A., JAYASWAL, R. K. & WILKINSON, 
B. J. 2008. Transcriptional Profiling Reveals that Daptomycin Induces the 
Staphylococcus aureus Cell Wall Stress Stimulon and Genes Responsive to 
Membrane Depolarization. Antimicrobial Agents and Chemotherapy, 52, 980-990. 
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Teicoplanin 
Regulator : Teicoplanin 
 Growth phase : late exponential phase (grown at 37C for 5hrs without shaking) 
expression of the teicoplanin-susceptible strain MRGR3 is compared to the 
expression of teicoplanin-resistant strain 14-4 expression.  
 Stabilising agent used : Ice-Cold Ethanol-Acetate 
 Fold change cut off : 1.5 
 Replicates : Triplicate 
 Strain used : MRGR3 
 Array type : StaphChip oligoarray from Agilent  
 Raw data : ArrayExpress:E-MEXP-738 
 Software : NOT AVAILABLE 
Reference: RENZONI, A., BARRAS, C., FRANCOIS, P., CHARBONNIER, Y., 
HUGGLER, E., GARZONI, C., KELLEY, W. L., MAJCHERCZYK, P., SCHRENZEL, J., 
LEW, D. P. & VAUDAUX, P. 2006. Transcriptomic and functional analysis of an 
autolysis-deficient, teicoplanin-resistant derivative of methicillin-resistant 
Staphylococcus aureus. Antimicrob Agents Chemother, 50, 3048-61. 
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Telavancin 
Regulator : Telavancin (15min) 
 Growth phase : expression of mid-exponential phase S. aureus cells, added with 
8 microgram/ml of telavancin and incubated for 15min was compared to that of 
the corresponding control cells expression. 
 Stabilising agent used : RNAProtect 
 Fold change cut off : 2 
 Replicates : Triplicate 
 Strain used : ATCC29213 
 Array type : PFGRC Array Version 6 
 Raw data : GEO:GSE37272 
 Software : SAM 
Reference: SONG, Y., LUNDE, C. S., BENTON, B. M. & WILKINSON, B. J. 2012. 
Further insights into the mode of action of the lipoglycopeptide telavancin 
through global gene expression studies. Antimicrob Agents Chemother, 56, 3157-
64. 
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Temporin 
Regulator : Antimicrobial peptide (Temporin) 
 Growth phase : expression of early exponential phase (OD 0.6) S. aureus cells 
incubated in the presence of 3 micromolar Temporin for 10min is compared to 
the untreated cells expression. 
 Stabilising agent used : NOT AVAILABLE 
 Fold change cut off : 2 
 Replicates : Triplicate 
 Strain used : Newman 
 Array type : Agilent Chip 
 Raw data : GEO:GSE15800 
 Software : GeneSpring 7.3 
Reference: PIETIAINEN, M., FRANCOIS, P., HYYRYLAINEN, H. L., TANGOMO, M., 
SASS, V., SAHL, H. G., SCHRENZEL, J. & KONTINEN, V. P. 2009. Transcriptome 
analysis of the responses of Staphylococcus aureus to antimicrobial peptides and 
characterization of the roles of vraDE and vraSR in antimicrobial resistance. 
BMC Genomics, 10, 429. 
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Vancomycin 
Regulator : Vancomycin 
 Growth phase : expression of wild type strain (Newman) (grown to OD 2.0 at 
600nm) is compared to the expression of vancomycin treated (10 μg/ml for 
5min at OD 2.0) Newman. 
 Stabilising agent used : NONE 
 Fold change cut off : 3 
 Replicates : Duplicate 
 Strain used : Newman 
 Array type : S. aureus Affymetrix GeneChip 
 Raw data : NOT AVAILABLE 
 Software: NOT AVAILABLE 
Reference: MCCALLUM, N., SPEHAR, G., BISCHOFF, M. & BERGER-BACHI, B. 
2006. Strain dependence of the cell wall-damage induced stimulon in 
Staphylococcus aureus. Biochim Biophys Acta, 1760, 1475-81. 
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Appendix II: COG scripts 
Script1: counting_cogs 
use strict; 
 
my $all_genes = $ARGV[0];#web mga 
my $list = $ARGV[1];#label cogs output 
my $out = $ARGV[2];#name for output 
 
open (all_genes, "$all_genes"); 
 
my $count = 0; 
my @A = (); 
my @B = (); 
my @C = (); 
my @D = (); 
my @E = (); 
my @F = (); 
my @G = (); 
my @H = (); 
my @I = (); 
my @J = (); 
my @K = (); 
my @L = (); 
my @M = (); 
my @N = (); 
my @O = (); 
my @P = (); 
my @Q = (); 
my @R = (); 
my @S = (); 
my @T = (); 
my @U = (); 
my @V = (); 
my @W = (); 
my @Y = (); 
my @Z = (); 
 
while (my $line = <all_genes>){ 
    if ($count != 0){ 
        my @temp = split (/\t/,$line); 
        if ($temp[4] =~ m/A/){ 
            push (@A, $temp[4]);  
        } 
        if ($temp[4] =~ m/B/){ 
            push (@B, $temp[4]);  
        } 
        if ($temp[4] =~ m/C/){ 
            push (@C, $temp[4]);  
        } 
        if ($temp[4] =~ m/D/){ 
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            push (@D, $temp[4]);  
        } 
        if ($temp[4] =~ m/E/){ 
            push (@E, $temp[4]);  
        } 
        if ($temp[4] =~ m/F/){ 
            push (@F, $temp[4]);  
        } 
        if ($temp[4] =~ m/G/){ 
            push (@G, $temp[4]);  
        } 
        if ($temp[4] =~ m/H/){ 
            push (@H, $temp[4]);  
        } 
        if ($temp[4] =~ m/I/){ 
            push (@I, $temp[4]); 
        } 
        if ($temp[4] =~ m/J/){ 
            push (@J, $temp[4]);  
        } 
        if ($temp[4] =~ m/K/){ 
            push (@K, $temp[4]);  
        } 
        if ($temp[4] =~ m/L/){ 
            push (@L, $temp[4]);  
        } 
        if ($temp[4] =~ m/M/){ 
            push (@M, $temp[4]); 
        } 
        if ($temp[4] =~ m/N/){ 
            push (@N, $temp[4]);  
        } 
        if ($temp[4] =~ m/O/){ 
            push (@O, $temp[4]); 
        } 
        if ($temp[4] =~ m/P/){ 
            push (@P, $temp[4]);  
        } 
        if ($temp[4] =~ m/Q/){ 
            push (@Q, $temp[4]); 
        } 
        if ($temp[4] =~ m/R/){ 
            push (@R, $temp[4]);  
        } 
        if ($temp[4] =~ m/S/){ 
            push (@S, $temp[4]);  
        } 
        if ($temp[4] =~ m/T/){ 
            push (@T, $temp[4]);  
        } 
        if ($temp[4] =~ m/U/){ 
            push (@U, $temp[4]);  
        } 
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        if ($temp[4] =~ m/V/){ 
            push (@V, $temp[4]); 
        } 
        if ($temp[4] =~ m/W/){ 
            push (@W, $temp[4]);  
        } 
        if ($temp[4] =~ m/Y/){ 
            push (@Y, $temp[4]);  
        } 
        if ($temp[4] =~ m/Z/){ 
            push (@Z, $temp[4]);  
        } 
         
    } 
    $count++; 
} 
 
close all_genes; 
 
my $tot_cogs = 
@A+@B+@C+@D+@E+@F+@G+@H+@I+@J+@K+@L+@M+@N+@O+@P+@Q+@R+
@S+@T+@U+@V+@W+@Y+@Z; 
my $pcent_A = (@A/$tot_cogs)*100;  
my $pcent_B = (@B/$tot_cogs)*100; 
my $pcent_C = (@C/$tot_cogs)*100; 
my $pcent_D = (@D/$tot_cogs)*100;  
my $pcent_E = (@E/$tot_cogs)*100;  
my $pcent_F = (@F/$tot_cogs)*100; 
my $pcent_G = (@G/$tot_cogs)*100; 
my $pcent_H = (@H/$tot_cogs)*100;  
my $pcent_I = (@I/$tot_cogs)*100;  
my $pcent_J = (@J/$tot_cogs)*100;  
my $pcent_K = (@K/$tot_cogs)*100; 
my $pcent_L = (@L/$tot_cogs)*100; 
my $pcent_M = (@M/$tot_cogs)*100;  
my $pcent_N = (@N/$tot_cogs)*100;  
my $pcent_O = (@O/$tot_cogs)*100;  
my $pcent_P = (@P/$tot_cogs)*100; 
my $pcent_Q = (@Q/$tot_cogs)*100;  
my $pcent_R = (@R/$tot_cogs)*100; 
my $pcent_S = (@S/$tot_cogs)*100;  
my $pcent_T = (@T/$tot_cogs)*100; 
my $pcent_U = (@U/$tot_cogs)*100; 
my $pcent_V = (@V/$tot_cogs)*100;  
my $pcent_W = (@W/$tot_cogs)*100; 
my $pcent_Y = (@Y/$tot_cogs)*100;  
my $pcent_Z = (@Z/$tot_cogs)*100; 
 
open (list, "$list");  
 
my $counter = 0; 
my @A_up = ();  
my @B_up = ();  
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my @C_up = ();  
my @D_up = ();  
my @E_up = (); 
my @F_up = ();  
my @G_up = ();  
my @H_up = (); 
my @I_up = ();  
my @J_up = ();  
my @K_up = (); 
my @L_up = ();  
my @M_up = ();  
my @N_up = (); 
my @O_up = ();  
my @P_up = (); 
my @Q_up = ();  
my @R_up = ();  
my @S_up = ();  
my @T_up = ();  
my @U_up = ();  
my @V_up = ();  
my @W_up = ();  
my @Y_up = (); 
my @Z_up = ();  
my @A_down = ();  
my @B_down = ();  
my @C_down = ();  
my @D_down = ();  
my @E_down = (); 
my @F_down = ();  
my @G_down = ();  
my @H_down = (); 
my @I_down = ();  
my @J_down = ();  
my @K_down = (); 
my @L_down = ();  
my @M_down = ();  
my @N_down = (); 
my @O_down = ();  
my @P_down = ();  
my @Q_down = ();  
my @R_down = ();  
my @S_down = ();  
my @T_down = ();  
my @U_down = ();  
my @V_down = ();  
my @W_down = ();  
my @Y_down = (); 
my @Z_down = ();  
 
while (my $line = <list>){ 
    if ($counter != 0){ 
        my @temp = split(/\t/, $line); 
        if ($temp[1] <0){ 
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            if ($temp[5] =~ m/A/){ 
                push (@A_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/B/){ 
                push (@B_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/C/){ 
                push (@C_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/D/){ 
                push (@D_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/E/){ 
                push (@E_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/F/){ 
                push (@F_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/G/){ 
                push (@G_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/H/){ 
                push (@H_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/I/){ 
                push (@I_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/J/){ 
                push (@J_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/K/){ 
                push (@K_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/L/){ 
                push (@L_down, $temp[5]); 
            } 
            if ($temp[5] =~ m/M/){ 
                push (@M_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/N/){ 
                push (@N_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/O/){ 
                push (@O_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/P/){ 
                push (@P_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/Q/){ 
                push (@Q_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/R/){ 
                push (@R_down, $temp[5]);  
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            } 
            if ($temp[5] =~ m/S/){ 
                push (@S_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/T/){ 
                push (@T_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/U/){ 
                push (@U_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/V/){ 
                push (@V_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/W/){ 
                push (@W_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/Y/){ 
                push (@Y_down, $temp[5]);  
            } 
            if ($temp[5] =~ m/Z/){ 
                push (@Z_down, $temp[5]);  
            } 
 
        } 
        elsif ($temp[1] >0){ 
            if ($temp[5] =~ m/A/){ 
                push (@A_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/B/){ 
                push (@B_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/C/){ 
                push (@C_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/D/){ 
                push (@D_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/E/){ 
                push (@E_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/F/){ 
                push (@F_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/G/){ 
                push (@G_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/H/){ 
                push (@H_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/I/){ 
                push (@I_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/J/){ 
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                push (@J_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/K/){ 
                push (@K_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/L/){ 
                push (@L_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/M/){ 
                push (@M_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/N/){ 
                push (@N_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/O/){ 
                push (@O_up, $temp[5]); 
            } 
            if ($temp[5] =~ m/P/){ 
                push (@P_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/Q/){ 
                push (@Q_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/R/){ 
                push (@R_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/S/){ 
                push (@S_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/T/){ 
                push (@T_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/U/){ 
                push (@U_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/V/){ 
                push (@V_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/W/){ 
                push (@W_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/Y/){ 
                push (@Y_up, $temp[5]);  
            } 
            if ($temp[5] =~ m/Z/){ 
                push (@Z_up, $temp[5]);  
            } 
 
        } 
    } 
    $counter++; 
} 
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close list; 
 
my $tot_list_cogs = 
@A_up+@B_up+@C_up+@D_up+@E_up+@F_up+@G_up+@H_up+@I_up+@J_up+@K_u
p+@L_up+@M_up+@N_up+@O_up+@P_up+@Q_up+@R_up+@S_up+@T_up+@U_up+
@V_up+@W_up+@Y_up+@Z_up+@A_down+@B_down+@C_down+@D_down+@E_do
wn+@F_down+@G_down+@H_down+@I_down+@J_down+@K_down+@L_down+@M_
down+@N_down+@O_down+@P_down+@Q_down+@R_down+@S_down+@T_down+
@U_down+@V_down+@W_down+@Y_down+@Z_down;  
 
my $pcent_A_tot =((@A_up+@A_down)/$tot_list_cogs)*100; 
my $pcent_B_tot =((@B_up+@B_down)/$tot_list_cogs)*100;  
my $pcent_C_tot =((@C_up+@C_down)/$tot_list_cogs)*100; 
my $pcent_D_tot =((@D_up+@D_down)/$tot_list_cogs)*100; 
my $pcent_E_tot =((@E_up+@E_down)/$tot_list_cogs)*100;  
my $pcent_F_tot =((@F_up+@F_down)/$tot_list_cogs)*100;  
my $pcent_G_tot =((@G_up+@G_down)/$tot_list_cogs)*100;  
my $pcent_H_tot =((@H_up+@H_down)/$tot_list_cogs)*100;  
my $pcent_I_tot =((@I_up+@I_down)/$tot_list_cogs)*100;  
my $pcent_J_tot =((@J_up+@J_down)/$tot_list_cogs)*100;  
my $pcent_K_tot =((@K_up+@K_down)/$tot_list_cogs)*100;  
my $pcent_L_tot =((@L_up+@L_down)/$tot_list_cogs)*100;  
my $pcent_M_tot =((@M_up+@M_down)/$tot_list_cogs)*100;  
my $pcent_N_tot =((@N_up+@N_down)/$tot_list_cogs)*100; 
my $pcent_O_tot =((@O_up+@O_down)/$tot_list_cogs)*100;  
my $pcent_P_tot =((@P_up+@P_down)/$tot_list_cogs)*100; 
my $pcent_Q_tot =((@Q_up+@Q_down)/$tot_list_cogs)*100; 
my $pcent_R_tot =((@R_up+@R_down)/$tot_list_cogs)*100; 
my $pcent_S_tot =((@S_up+@S_down)/$tot_list_cogs)*100; 
my $pcent_T_tot =((@T_up+@T_down)/$tot_list_cogs)*100;  
my $pcent_U_tot =((@U_up+@U_down)/$tot_list_cogs)*100;  
my $pcent_V_tot =((@V_up+@V_down)/$tot_list_cogs)*100; 
my $pcent_W_tot =((@W_up+@W_down)/$tot_list_cogs)*100;  
my $pcent_Y_tot =((@Y_up+@Y_down)/$tot_list_cogs)*100; 
my $pcent_Z_tot =((@Z_up+@Z_down)/$tot_list_cogs)*100;  
 
my $pcent_A_up =(@A_up/$tot_list_cogs)*100;  
my $pcent_B_up =(@B_up/$tot_list_cogs)*100; 
my $pcent_C_up =(@C_up/$tot_list_cogs)*100; 
my $pcent_D_up =(@D_up/$tot_list_cogs)*100; 
my $pcent_E_up =(@E_up/$tot_list_cogs)*100;  
my $pcent_F_up =(@F_up/$tot_list_cogs)*100; 
my $pcent_G_up =(@G_up/$tot_list_cogs)*100; 
my $pcent_H_up =(@H_up/$tot_list_cogs)*100;  
my $pcent_I_up =(@I_up/$tot_list_cogs)*100;  
my $pcent_J_up =(@J_up/$tot_list_cogs)*100; 
my $pcent_K_up =(@K_up/$tot_list_cogs)*100;  
my $pcent_L_up =(@L_up/$tot_list_cogs)*100; 
my $pcent_M_up =(@M_up/$tot_list_cogs)*100;  
my $pcent_N_up =(@N_up/$tot_list_cogs)*100;  
my $pcent_O_up =(@O_up/$tot_list_cogs)*100;  
my $pcent_P_up =(@P_up/$tot_list_cogs)*100;  
my $pcent_Q_up =(@Q_up/$tot_list_cogs)*100;  
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my $pcent_R_up =(@R_up/$tot_list_cogs)*100;  
my $pcent_S_up =(@S_up/$tot_list_cogs)*100; 
my $pcent_T_up =(@T_up/$tot_list_cogs)*100;  
my $pcent_U_up =(@U_up/$tot_list_cogs)*100;  
my $pcent_V_up =(@V_up/$tot_list_cogs)*100;  
my $pcent_W_up =(@W_up/$tot_list_cogs)*100;  
my $pcent_Y_up =(@Y_up/$tot_list_cogs)*100;  
my $pcent_Z_up =(@Z_up/$tot_list_cogs)*100; 
 
my $pcent_A_down =(@A_down/$tot_list_cogs)*100;  
my $pcent_B_down =(@B_down/$tot_list_cogs)*100; 
my $pcent_C_down =(@C_down/$tot_list_cogs)*100; 
my $pcent_D_down =(@D_down/$tot_list_cogs)*100; 
my $pcent_E_down =(@E_down/$tot_list_cogs)*100;  
my $pcent_F_down =(@F_down/$tot_list_cogs)*100; 
my $pcent_G_down =(@G_down/$tot_list_cogs)*100; 
my $pcent_H_down =(@H_down/$tot_list_cogs)*100;  
my $pcent_I_down =(@I_down/$tot_list_cogs)*100;  
my $pcent_J_down =(@J_down/$tot_list_cogs)*100; 
my $pcent_K_down =(@K_down/$tot_list_cogs)*100;  
my $pcent_L_down =(@L_down/$tot_list_cogs)*100; 
my $pcent_M_down =(@M_down/$tot_list_cogs)*100;  
my $pcent_N_down =(@N_down/$tot_list_cogs)*100;  
my $pcent_O_down =(@O_down/$tot_list_cogs)*100;  
my $pcent_P_down =(@P_down/$tot_list_cogs)*100;  
my $pcent_Q_down =(@Q_down/$tot_list_cogs)*100;  
my $pcent_R_down =(@R_down/$tot_list_cogs)*100;  
my $pcent_S_down =(@S_down/$tot_list_cogs)*100;  
my $pcent_T_down =(@T_down/$tot_list_cogs)*100;  
my $pcent_U_down =(@U_down/$tot_list_cogs)*100;  
my $pcent_V_down =(@V_down/$tot_list_cogs)*100;  
my $pcent_W_down =(@W_down/$tot_list_cogs)*100;  
my $pcent_Y_down =(@Y_down/$tot_list_cogs)*100;  
my $pcent_Z_down =(@Z_down/$tot_list_cogs)*100; 
 
my $count_A = @A_up+@A_down ;  
my $count_B = @B_up+@B_down ; 
my $count_C = @C_up+@C_down ;  
my $count_D = @D_up+@D_down ;  
my $count_E = @E_up+@E_down ; 
my $count_F = @F_up+@F_down ; 
my $count_G = @G_up+@G_down ; 
my $count_H = @H_up+@H_down ;  
my $count_I = @I_up+@I_down ;  
my $count_J = @J_up+@J_down ;  
my $count_K = @K_up+@K_down ; 
my $count_L = @L_up+@L_down ; 
my $count_M = @M_up+@M_down ;  
my $count_N = @N_up+@N_down ;  
my $count_O = @O_up+@O_down ;  
my $count_P = @P_up+@P_down ;  
my $count_Q = @Q_up+@Q_down ;  
my $count_R = @R_up+@R_down ;  
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my $count_S = @S_up+@S_down ;  
my $count_T = @T_up+@T_down ; 
my $count_U = @U_up+@U_down ; 
my $count_V = @V_up+@V_down ;  
my $count_W = @W_up+@W_down ; 
my $count_Y = @Y_up+@Y_down ;  
my $count_Z = @Z_up+@Z_down ; 
 
my $count_A_up = @A_up ;  
my $count_B_up = @B_up ; 
my $count_C_up = @C_up ;  
my $count_D_up = @D_up ;  
my $count_E_up = @E_up ;  
my $count_F_up = @F_up ;  
my $count_G_up = @G_up ;  
my $count_H_up = @H_up ;  
my $count_I_up = @I_up ; 
my $count_J_up = @J_up ;  
my $count_K_up = @K_up ;  
my $count_L_up = @L_up ;  
my $count_M_up = @M_up ; 
my $count_N_up = @N_up ; 
my $count_O_up = @O_up ; 
my $count_P_up = @P_up ;  
my $count_Q_up = @Q_up ; 
my $count_R_up = @R_up ;  
my $count_S_up = @S_up ;  
my $count_T_up = @T_up ;  
my $count_U_up = @U_up ;  
my $count_V_up = @V_up ;  
my $count_W_up = @W_up ;  
my $count_Y_up = @Y_up ; 
my $count_Z_up = @Z_up ;  
 
my $count_A_down = @A_down ;  
my $count_B_down = @B_down ;  
my $count_C_down = @C_down ;  
my $count_D_down = @D_down ;  
my $count_E_down = @E_down ;  
my $count_F_down = @F_down ;  
my $count_G_down = @G_down ;  
my $count_H_down = @H_down ;  
my $count_I_down = @I_down ; 
my $count_J_down = @J_down ;  
my $count_K_down = @K_down ;  
my $count_L_down = @L_down ;  
my $count_M_down = @M_down ; 
my $count_N_down = @N_down ; 
my $count_O_down = @O_down ; 
my $count_P_down = @P_down ;  
my $count_Q_down = @Q_down ; 
my $count_R_down = @R_down ;  
my $count_S_down = @S_down ;  
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my $count_T_down = @T_down ;  
my $count_U_down = @U_down ;  
my $count_V_down = @V_down ;  
my $count_W_down = @W_down ;  
my $count_Y_down = @Y_down ; 
my $count_Z_down = @Z_down ;  
 
 
open (out, ">$out");  
 
 
 
print out 
"COG_class\tPercent_of_genome\tPercent_of_gene_list\tpercent_up_of_gene_list\tPerce
nt_down_of_gene_list\ttotal_count\tup_count\tdown_count\nA\t$pcent_A\t$pcent_A_t
ot\t$pcent_A_up\t$pcent_A_down\t$count_A\t$count_A_up\t$count_A_down\nB\t$pc
ent_B\t$pcent_B_tot\t$pcent_B_up\t$pcent_B_down\t$count_B\t$count_B_up\t$count
_B_down\nC\t$pcent_C\t$pcent_C_tot\t$pcent_C_up\t$pcent_C_down\t$count_C\t$co
unt_C_up\t$count_C_down\nD\t$pcent_D\t$pcent_D_tot\t$pcent_D_up\t$pcent_D_dow
n\t$count_D\t$count_D_up\t$count_D_down\nE\t$pcent_E\t$pcent_E_tot\t$pcent_E_u
p\t$pcent_E_down\t$count_E\t$count_E_up\t$count_E_down\nF\t$pcent_F\t$pcent_F
_tot\t$pcent_F_up\t$pcent_F_down\t$count_F\t$count_F_up\t$count_F_down\nG\t$pc
ent_G\t$pcent_G_tot\t$pcent_G_up\t$pcent_G_down\t$count_G\t$count_G_up\t$count
_G_down\nH\t$pcent_H\t$pcent_H_tot\t$pcent_H_up\t$pcent_H_down\t$count_H\t$c
ount_H_up\t$count_H_down\nI\t$pcent_I\t$pcent_I_tot\t$pcent_I_up\t$pcent_I_down
\t$count_I\t$count_I_up\t$count_I_down\nJ\t$pcent_J\t$pcent_J_tot\t$pcent_J_up\t$p
cent_J_down\t$count_J\t$count_J_up\t$count_J_down\nK\t$pcent_K\t$pcent_K_tot\t$
pcent_K_up\t$pcent_K_down\t$count_K\t$count_K_up\t$count_K_down\nL\t$pcent_L
\t$pcent_L_tot\t$pcent_L_up\t$pcent_L_down\t$count_L\t$count_L_up\t$count_L_do
wn\nM\t$pcent_M\t$pcent_M_tot\t$pcent_M_up\t$pcent_M_down\t$count_M\t$count
_M_up\t$count_M_down\nN\t$pcent_N\t$pcent_N_tot\t$pcent_N_up\t$pcent_N_down
\t$count_N\t$count_N_up\t$count_N_down\nO\t$pcent_O\t$pcent_O_tot\t$pcent_O_u
p\t$pcent_O_down\t$count_O\t$count_O_up\t$count_O_down\nP\t$pcent_P\t$pcent_
P_tot\t$pcent_P_up\t$pcent_P_down\t$count_P\t$count_P_up\t$count_P_down\nQ\t$
pcent_Q\t$pcent_Q_tot\t$pcent_Q_up\t$pcent_Q_down\t$count_Q\t$count_Q_up\t$co
unt_Q_down\nR\t$pcent_R\t$pcent_R_tot\t$pcent_R_up\t$pcent_R_down\t$count_R\t
$count_R_up\t$count_R_down\nS\t$pcent_S\t$pcent_S_tot\t$pcent_S_up\t$pcent_S_do
wn\t$count_S\t$count_S_up\t$count_S_down\nT\t$pcent_T\t$pcent_T_tot\t$pcent_T_
up\t$pcent_T_down\t$count_T\t$count_T_up\t$count_T_down\nU\t$pcent_U\t$pcent
_U_tot\t$pcent_U_up\t$pcent_U_down\t$count_U\t$count_U_up\t$count_U_down\nV\
t$pcent_V\t$pcent_V_tot\t$pcent_V_up\t$pcent_V_down\t$count_V\t$count_V_up\t$co
unt_V_down\nW\t$pcent_W\t$pcent_W_tot\t$pcent_W_up\t$pcent_W_down\t$count_
W\t$count_W_up\t$count_W_down\nY\t$pcent_Y\t$pcent_Y_tot\t$pcent_Y_up\t$pcen
t_Y_down\t$count_Y\t$count_Y_up\t$count_Y_down\nZ\t$pcent_Z\t$pcent_Z_tot\t$pc
ent_Z_up\t$pcent_Z_down\t$count_Z\t$count_Z_up\t$count_Z_down\n" 
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Script2: label_cogs 
#usage: gene list, web mga output 2, name 
use strict; 
 
my $gene_list = $ARGV[0];#file 1st collumn ordered gene list 2nd collumn whatever (eg 
Fold change) tab or space delimited 
my $cog_data = $ARGV[1];#output 2 from web MGA cog analysis  
 
open(gene_list, "$gene_list"); 
 
my %list; 
 
my $counter = 0; 
 
while (my $line = <gene_list>){ 
         if ($counter != 0){ 
       $line =~ s/\n//;#substitute newline character with nothing 
       $line =~ s/\r//;#substirute return character with nothing 
       my @temp = split(/\t/,$line); 
        $list{$temp[0]} = $temp[1];  
     } 
    $counter++; 
} 
 
open (cog, "$cog_data"); 
open (out, ">$ARGV[2]");  
 
print out "official_gene_name\tfold_change\tcog_hit\tE-
value\tcog_description\tcog_class\tcog_class_description\n"; 
 
while (my $line = <cog>){ 
    $line =~ s/\n//;#substitute newline character with nothing  
    $line =~ s/\r//;#substirute return character with nothing 
      if ($counter != 0){ 
        my @temp = split (/\t/, $line); 
        my $value = $list{$temp[0]};  
        if ($value =~ m/\w/){ 
             print out 
"$temp[0]\t$list{$temp[0]}\t$temp[1]\t$temp[2]\t$temp[5]\t$temp[6]\t$temp[7]\n"; 
        } 
    } 
    $counter++ 
} 
 
close cog; 
close out; 
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Appendix III: RNA-Seq data 
Appendix Table 1 DE genes of S. aureus Newman in response to 5μM D-sphingosine challenge. The level of fold change (logFC) is based on log2, DE genes shown 
in this table all have more than 2 fold changes. All DE genes have FDR (false discovery rate) ≤ 0.05. 
Gene Gene Description logFC FDR 
NWMN_0006 ADP-dependent (S)-NAD(P)H-hydrate dehydratase -1.959735517 6.32E-30 
serS seryl-tRNA synthetase -0.994123363 1.30E-07 
NWMN_0022 hypothetical protein -1.554251435 7.40E-14 
NWMN_0030 hypothetical protein -1.204553476 9.01E-13 
NWMN_0049 hypothetical protein 1.246338474 7.53E-13 
sarH1 accessory regulator A-like protein -1.62570734 3.98E-23 
sirC siderophore compound ABC transporter permease SirC -1.115350198 4.58E-08 
NWMN_0093 truncated IS200 transposase family protein -1.020927239 1.88E-06 
capA capsular polysaccharide synthesis enzyme CapA -1.021923017 0.001399474 
capB capsular polysaccharide synthesis enzyme CapB -1.144390389 0.000277759 
NWMN_0122 hypothetical protein 1.029174053 1.57E-08 
ipdC indole-3-pyruvate decarboxylase 1.034397132 2.50E-08 
glcA glucose-specific PTS transporter protein IIABC component -1.677084752 2.67E-19 
NWMN_0149 azoreductase -1.23143586 3.91E-12 
NWMN_0150 hypothetical protein 2.135076524 2.79E-11 
NWMN_0157 hypothetical protein -3.266011727 8.22E-86 
pflB Formate acetyltransferase -2.177329331 1.66E-10 
NWMN_0163 hypothetical protein -2.09794827 4.01E-09 
NWMN_0165 hypothetical protein -1.880158903 4.84E-19 
coa staphylocoagulase -5.429586438 8.31E-95 
fadE acyl-CoA synthetase FadE-like protein 1.042241634 2.07E-05 
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NWMN_0171 acetyl-CoA 2Facetoacetyl-CoA transferase 1.722902685 9.84E-17 
ldh1 L-lactate dehydrogenase -1.012596466 0.000947057 
NWMN_0177 similar to PTS transport system 2C IIBC component 1.046168631 9.31E-10 
lytS autolysin sensor histidine kinase -1.097318156 1.37E-09 
lytR two-component response regulator -1.021490425 2.78E-07 
lrgA Antiholin-like protein LrgA -2.273579371 6.46E-08 
lrgB Antiholin-like protein LrgB -1.918354962 0.000175949 
NWMN_0199 PTS system, IIA component 1.960211134 1.55E-22 
bglA 6-phospho-beta-glucosidase 1.752869764 8.35E-24 
lytM peptidoglycan hydrolase 1.204757975 6.62E-09 
NWMN_0249 nucleotidase lipoprotein family protein -1.212881346 3.53E-09 
NWMN_0250 ABC transporter permease -1.05147355 1.79E-08 
NWMN_0262 Truncated triacylglycerol lipase precursor(lipid management) -2.634011837 5.39E-36 
NWMN_0297 hypothetical protein -1.01125955 0.031320192 
NWMN_0298 hypothetical protein -1.054032148 0.037392445 
NWMN_0299 hypothetical protein -1.089734692 0.022583101 
NWMN_0300 hypothetical protein -1.018940659 0.027380805 
NWMN_0301 hypothetical protein -1.039637718 0.011603068 
metE 5-methyltetrahydropteroyltriglutamate--homocysteine S-methyltransferase 1.317212346 4.65E-13 
metH bifunctional homocysteine S-methyltransferase-methylenetetrahydrofolate reductase 1.361349637 8.56E-14 
rpsF 30S ribosomal protein S6 -1.193878896 1.07E-11 
NWMN_0358 single-strand DNA-binding family protein -1.234740397 1.23E-12 
rpsR 30S ribosomal protein S18 -1.278742184 5.87E-13 
NWMN_0362 hypothetical protein -3.127615252 2.45E-78 
NWMN_0363 hypothetical protein -1.756174719 2.58E-21 
NWMN_0364 hypothetical protein -1.293022751 7.08E-09 
NWMN_0366 hypothetical protein -1.569105998 2.81E-11 
ahpC alkyl hydroperoxide reductase subunit C -0.99595264 6.66E-12 
set1nm Staphylococcal enterotoxin-like toxin -2.297534733 3.27E-26 
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set2nm Staphylococcal enterotoxin-like toxin -2.017747072 3.14E-14 
set3nm superantigen-like protein -1.305993877 8.05E-09 
set4nm Staphylococcal enterotoxin-like toxin -2.220637761 1.39E-18 
set5nm superantigen-like protein -1.078733561 1.59E-07 
set6nm superantigen-like protein -1.374610935 1.41E-09 
set7nm superantigen-like protein Staphylococcal enterotoxin-like toxin -4.76024477 1.14E-53 
set8nm Staphylococcal enterotoxin-like toxin -2.29813069 1.21E-16 
set9nm superantigen-like protein -1.502138734 3.84E-08 
set10nm superantigen-like protein -1.569221754 1.63E-13 
set11nm superantigen-like protein Staphylococcal enterotoxin-like toxin -4.600549793 5.51E-76 
NWMN_0401 hypothetical protein -4.642923689 2.45E-78 
NWMN_0402 hypothetical protein -2.129075577 2.08E-21 
lpl4nm tandem lipoprotein 1.190038277 5.32E-06 
lpl5nm tandem lipoprotein 1.042567321 6.87E-06 
ndhF NADH dehydrogenase subunit 5 1.148805408 2.03E-10 
NWMN_0419 hypothetical protein 1.113583438 3.34E-09 
NWMN_0433 hypothetical protein 1.379971109 6.75E-11 
gltC Transcription activator of glutamate synthase operon 1.979457907 7.80E-25 
NWMN_0460 similar to translation initiation inhibitor -1.003180303 6.36E-07 
spoVG regulatory protein SpoVG -1.255908423 1.03E-12 
NWMN_0480 GntR family regulatory protein 1.88388838 2.94E-19 
NWMN_0482 glutamine amidotransferase subunit PdxT -1.024313458 1.05E-08 
nupC pyrimidine nucleoside transport protein -1.057583082 3.21E-10 
ctsR Transcriptional regulator CtsR 2.057606015 3.62E-20 
NWMN_0485 UvrB/UvrC motif domain protein 2.155624124 1.87E-21 
NWMN_0486 Protein-arginine kinase 2.265540933 9.00E-25 
clpC ATP-dependent Clp protease, ATP-binding subunit ClpC 2.306479027 1.15E-23 
rplA 50S ribosomal protein L1 -1.098010133 1.86E-11 
rplJ 50S ribosomal protein L10 -1.142245061 4.29E-10 
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rplL 50S ribosomal protein L7%2FL12 -1.211537488 5.82E-14 
NWMN_0506 putative ribosomal protein L7Ae-like -1.260954425 3.00E-11 
rpsL 30S ribosomal protein S12 -1.218933169 5.43E-10 
rpsG 30S ribosomal protein S7 -1.284511359 3.52E-12 
fus elongation factor G -1.13461012 1.67E-07 
NWMN_0517 haloacid dehalogenase-like hydrolase 1.035553359 6.54E-10 
NWMN_0532 glucosamine-6-phosphate isomerase 1.144687047 2.44E-12 
NWMN_0537 hypothetical protein 4.875464164 2.90E-58 
NWMN_0542 hypothetical protein 6.140607571 1.80E-155 
NWMN_0547 hypothetical protein -1.520115296 1.50E-12 
adh1 similar to zinc-dependent eukaryotic ADH enzymes and distinct from fermentative ADHs -2.342061937 2.43E-15 
NWMN_0587 similar to esterase lipase -1.412253714 3.16E-08 
NWMN_0592 site-specific recombinase -1.579599768 8.21E-09 
mnhA putative monovalent cation antiporter subunit A -1.232160259 1.48E-07 
mnhB putative monovalent cation antiporter subunit B -1.147862434 6.46E-06 
mnhC putative monovalent cation antiporter subunit C -1.313858301 8.68E-08 
mnhD putative monovalent cation antiporter subunit D -1.125509576 3.60E-07 
mnhE putative monovalent cation antiporter subunit E -1.067191092 9.15E-07 
mnhF putative monovalent cation antiporter subunit F -1.033456405 2.69E-06 
mnhG putative monovalent cation antiporter subunit G -1.084455508 2.52E-08 
NWMN_0605 hypothetical protein 2.477199925 3.80E-17 
NWMN_0622 hypothetical protein 1.545048211 3.33E-25 
NWMN_0626 similar to acetyltransferase GNAT family protein 1.098523326 1.54E-09 
NWMN_0653 ABC transporter ATP-binding MsbA family protein 1.023075108 4.21E-10 
NWMN_0654 ABC transporter ATP-binding MsbA family protein 1.112083839 8.13E-12 
NWMN_0667 fructose operon transcriptional regulator -1.197555188 6.68E-07 
fruB fructose 1-phosphate kinase -1.435861494 4.21E-10 
fruA fructose specific permease -1.211811879 4.58E-08 
nagA N-acetylglucosamine-6-phosphate deacetylase 1.05614507 2.25E-09 
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NWMN_0672 aldo-keto reductase family protein 1.613788206 4.39E-19 
NWMN_0673 similar to glycosyl transferase group 2 family protein 1.46986363 6.30E-21 
saeS Histidine protein kinase SaeS -2.957105913 1.03E-43 
saeR DNA-binding response regulator SaeR -3.038304556 7.67E-53 
NWMN_0676 hypothetical protein -3.562638455 4.25E-55 
NWMN_0677 hypothetical protein -3.189158434 2.07E-34 
clpP ATP-dependent Clp protease proteolytic subunit 2.138092999 2.78E-22 
NWMN_0757 secreted von Willebrand factor-binding protein precursor -5.693549252 2.90E-209 
ssp Extracellular matrix protein-binding protein emp -3.011508267 9.75E-21 
NWMN_0759 hypothetical protein -4.553436148 1.30E-101 
NWMN_0760 Thermonuclease -2.452045639 7.62E-27 
cspC cold-shock protein CSD family protein -1.259020411 1.82E-14 
NWMN_0774 similar to thioredoxin 1.014250988 4.75E-08 
NWMN_0783 CsbD-like superfamily protein -1.331348053 7.72E-13 
NWMN_0791 hypothetical protein 1.121371392 7.11E-10 
NWMN_0792 similar to oxidoreductase 2-nitropropane dioxygenase family 1.088059219 4.56E-08 
NWMN_0810 hypothetical protein 1.212439408 7.62E-10 
NWMN_0826 NADH-dependent flavin oxidoreductase 1.633485863 1.66E-13 
glpQ glycerophosphoryl diester phosphodiesterase 1.296975305 1.33E-12 
argH argininosuccinate lyase 1.810650639 6.20E-27 
argG argininosuccinate synthase 1.133195068 3.36E-11 
NWMN_0839 fumarylacetoacetate hydrolase family protein 1.055412058 5.71E-10 
clpB Chaperone protein ClpB 2.110851446 4.79E-14 
NWMN_0875 hypothetical protein 1.34884086 2.43E-14 
NWMN_0876 GTP pyrophosphokinase 1.164831667 2.03E-12 
ppnK inorganic polyphosphate ATP-NAD kinase 1.018022319 8.23E-10 
NWMN_0897 lipoate-protein ligase A 1.390696922 3.64E-13 
NWMN_0900 hypothetical protein 1.145682382 1.59E-07 
NWMN_0920 hypothetical protein 1.375997156 1.44E-09 
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NWMN_0926 autolysis and methicillin resistant-related protein FmtA 1.358601137 1.59E-07 
NWMN_0931 hypothetical protein 1.198111782 1.05E-08 
NWMN_0970 hypothetical protein 1.660139203 1.62E-14 
NWMN_0972 hypothetical protein 1.268860585 4.08E-11 
NWMN_1018 hypothetical protein -1.004805973 0.000302247 
NWMN_1021 hypothetical protein -1.028007424 0.034406639 
NWMN_1066 similar to fibrinogen-binding protein -3.279842274 6.78E-53 
NWMN_1067 formyl peptide receptor-like 1 inhibitory protein FPRL1 inhibitory protein -4.173111334 6.56E-52 
NWMN_1068 hypothetical protein -1.734610178 5.15E-26 
NWMN_1069 hypothetical protein Fibrinogen-binding protein -4.107813329 1.52E-80 
NWMN_1070 similar to fibrinogen-binding protein -4.244328874 1.50E-72 
NWMN_1075 hypothetical protein -2.224229685 1.83E-11 
NWMN_1076 hypothetical protein -2.204473039 1.22E-09 
NWMN_1077 hypothetical protein -2.226084687 2.54E-08 
NWMN_1106 putative transposase;protein 1.461275419 0.038591686 
NWMN_1109 bifunctional pyrimidine regulatory protein PyrR uracil phosphoribosyltransferase;  -1.138913692 4.68E-10 
NWMN_1110 uracil permease -1.829815715 7.47E-18 
NWMN_1111 aspartate carbamoyltransferase catalytic subunit -1.871193982 2.94E-19 
NWMN_1112 dihydroorotase -1.604832669 1.49E-16 
NWMN_1113 carbamoyl phosphate synthase small subunit -1.420033809 1.30E-13 
NWMN_1114 carbamoyl phosphate synthase large subunit -1.286268046 6.52E-14 
NWMN_1115 orotidine 5-phosphate decarboxylase -1.31231274 5.29E-14 
NWMN_1116 orotate phosphoribosyltransferase -1.112818267 9.27E-11 
NWMN_1149 16S rRNA-processing protein RimM -1.224776078 2.79E-09 
NWMN_1150 tRNA guanine methyltransferase -1.167056782 3.54E-09 
NWMN_1151 50S ribosomal protein L19 -1.060698763 7.96E-13 
NWMN_1196 hypothetical protein 1.416965362 2.97E-08 
NWMN_1209 aerobic glycerol-3-phosphate dehydrogenase 1.63003247 1.12E-25 
NWMN_1213 glutathione peroxidase 1.278092794 9.77E-14 
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NWMN_1229 hypothetical protein 1.418662343 0.001776487 
NWMN_1239 Aspartokinase 2.56787952 5.95E-44 
NWMN_1240 Homoserine dehydrogenase 2.465369772 9.82E-55 
NWMN_1241 Threonine synthase 2.380276566 1.64E-47 
NWMN_1242 Homoserine kinase 2.572809134 8.43E-51 
NWMN_1277 prephenate dehydrogenase 1.100969238 5.53E-12 
NWMN_1294 hypothetical protein 1.180369195 3.08E-08 
NWMN_1296 Phosphate-specific transport system accessory protein PhoU 2.716499199 3.19E-30 
NWMN_1297 Phosphate import ATP-binding protein PstB 3.112777021 7.52E-36 
NWMN_1298 Phosphate ABC transporter, permease protein 3.467284479 6.94E-38 
NWMN_1299 phosphate ABC transporter permease 3.752487737 5.70E-45 
NWMN_1300 Phosphate ABC transporter, phosphate-binding protein PstS 4.146614468 6.00E-43 
NWMN_1303 ABC transporter ATP-binding protein -1.372272011 4.76E-18 
NWMN_1304 aspartate kinase 1.295524597 4.99E-10 
NWMN_1305 aspartate semialdehyde dehydrogenase;protein 1.295437181 7.75E-12 
NWMN_1306 dihydrodipicolinate synthase 1.549922577 1.82E-16 
NWMN_1307 dihydrodipicolinate reductase 1.571086702 1.19E-16 
NWMN_1308 tetrahydrodipicolinate acetyltransferase 1.691782184 4.01E-20 
NWMN_1309 hippurate hydrolase 1.86885007 2.24E-20 
alr2 alanine racemase 2 1.679261757 2.43E-16 
lysA diaminopimelate decarboxylase 1.345835367 4.36E-15 
NWMN_1315 acylphosphatase 1.092605988 2.53E-10 
NWMN_1318 putative transposase for IS1272 1.65856771 0.034406639 
ctpA carboxyl-terminal protease 1.205880059 1.77E-07 
NWMN_1333 phosphotransferase system glucose-specific IIA component 1.689672005 1.67E-20 
msrB methionine sulfoxide reductase B 1.787095291 1.48E-20 
msrA methionine sulfoxide reductase A 1.762971686 7.20E-19 
NWMN_1343 hypothetical protein 1.317783667 6.13E-12 
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NWMN_1346 hypothetical protein Quinolone resistance protein NorB -3.716617079 1.70E-33 
NWMN_1347 Amino acid permease -4.60366978 4.28E-50 
NWMN_1348 Threonine dehydratase II -4.862602194 1.74E-60 
NWMN_1349 Alanine dehydrogenase -5.052442908 3.03E-66 
NWMN_1352 hypothetical protein -1.387515314 1.66E-10 
NWMN_1371 hypothetical protein 1.016327243 1.72E-08 
rpsA 30S ribosomal protein S1 1.318567697 3.91E-15 
ebpS elastin binding protein 1.156742096 2.76E-12 
glyS glycyl-tRNA synthetase 1.290077747 2.26E-16 
prmA ribosomal protein L11 methyltransferase 1.13002155 5.82E-12 
dnaJ chaperone protein DnaJ 1.267775971 4.65E-13 
dnaK molecular chaperone DnaK 1.464177138 1.91E-11 
grpE heat shock protein GrpE 1.436016688 1.23E-12 
hrcA heat-inducible transcription repressor 1.464535772 1.52E-12 
NWMN_1503 enterotoxin family protein 1.133471169 8.96E-08 
NWMN_1505 hypothetical protein 1.095810918 1.86E-07 
NWMN_1525 luciferase family protein 1.058806542 9.40E-06 
NWMN_1526 hypothetical protein -1.269804003 3.43E-07 
NWMN_1527 hypothetical protein -1.117633382 6.68E-07 
NWMN_1552 hypothetical protein 2.627725836 6.91E-27 
NWMN_1553 hypothetical protein 2.921500847 1.18E-12 
NWMN_1572 50S ribosomal protein L20 -1.185468435 5.62E-13 
NWMN_1573 50S ribosomal protein L35 -1.170006865 5.05E-13 
NWMN_1602 proline dipeptidase-like protein 1.543263116 2.17E-21 
NWMN_1604 universal stress protein family protein 1.027847187 1.32E-10 
NWMN_1612 hypothetical protein 1.116116969 3.73E-10 
rpsD 30S ribosomal protein S4 -1.016945245 1.43E-09 
NWMN_1615 osmotic stress-related protein 1.492257381 9.26E-15 
NWMN_1616 aminotransferase class V 1.338631756 8.01E-17 
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NWMN_1617 D-3-phosphoglycerate dehydrogenase 1.482780252 1.35E-18 
NWMN_1618 hypothetical protein 1.31804478 4.48E-15 
NWMN_1621 hypothetical protein 2.37434327 8.78E-27 
acuA acetoin utilization 1.040788418 1.64E-06 
acuC acetoin utilization protein AcuC 1.038763722 3.08E-08 
NWMN_1644 dipeptidase PepV 1.016702138 3.33E-12 
NWMN_1655 accessory regulator Rot -1.54475804 5.22E-22 
NWMN_1672 putative translaldolase 1.032054643 1.52E-07 
NWMN_1733 Foldase protein PrsA 2.222675429 1.35E-26 
NWMN_1749 glutamine transport ATP-binding protein 1.015378211 1.75E-06 
NWMN_1766 glycosyltransferase 1.836304776 1.07E-15 
NWMN_1796 hypothetical protein -1.170909748 0.012717705 
NWMN_1821 ribonuclease -1.185211626 8.89E-06 
NWMN_1822 DNA-binding response regulator VraR 2.292267608 2.29E-23 
NWMN_1823 Sensor protein VraS 2.30043501 1.55E-25 
NWMN_1824 hypothetical protein 2.0841714 4.68E-19 
NWMN_1825 hypothetical protein 1.651046352 5.23E-12 
NWMN_1834 hypothetical protein 2.059095789 3.62E-12 
NWMN_1872 65 kDa membrane protein -2.984648365 1.73E-17 
NWMN_1873 Truncated beta-hemolysin -2.273099583 1.57E-20 
NWMN_1876 complement inhibitor SCIN Staphylococcal complement inhibitor -4.318333346 2.05E-94 
NWMN_1877 Chemotaxis inhibitory protein -5.386736207 6.79E-146 
NWMN_1927 Leukocidin/hemolysin toxin family F subunit -3.048172309 4.04E-71 
NWMN_1928 Leukocidin/hemolysin toxin family S subunit -3.188339582 1.98E-70 
NWMN_1937 60 kDa chaperonin 2.11046038 4.62E-26 
NWMN_1938 10 kDa chaperonin 2.069816466 7.11E-25 
ilvC ketol-acid reductoisomerase 1.101061667 1.05E-09 
leuA 2-isopropylmalate synthase 1.191773245 3.01E-10 
253 
 
leuB 3-isopropylmalate dehydrogenase 1.125825129 2.72E-10 
leuC isopropylmalate isomerase large subunit 1.230933208 1.33E-12 
leuD isopropylmalate isomerase small subunit 1.141723039 3.86E-09 
ilvA threonine dehydratase 1.079366752 9.18E-09 
NWMN_1985 ATP-dependent RNA helicase DEAD box family protein -1.002420768 1.94E-06 
NWMN_2022 peptide chain release factor 1 -0.99650741 5.43E-10 
murZ UDP-N-acetylglucosamine 1-carboxyvinyltransferase 1.073235626 3.06E-08 
NWMN_2036 hypothetical protein 1.147341758 3.48E-13 
manA1 mannose-6-phosphate isomerase class I -1.008029596 3.28E-09 
NWMN_2050 cation efflux family protein 1.018631946 2.89E-06 
mtlA mannitol-specific IIA component -1.054554954 5.62E-05 
NWMN_2086 alkaline shock protein 23 -1.739371505 3.00E-12 
NWMN_2087 hypothetical protein -1.841586549 1.50E-11 
NWMN_2088 hypothetical protein -1.73526875 1.06E-10 
alsD alpha-acetolactate decarboxylase 1.706229482 2.60E-13 
alsS acetolactate synthase 1.752311904 3.76E-12 
NWMN_2119 30S ribosomal protein S9 -1.134311223 6.43E-14 
NWMN_2120 50S ribosomal protein L13 -1.049819429 4.66E-11 
rplQ 50S ribosomal protein L17 -1.143545439 5.00E-11 
rpoA DNA-directed RNA polymerase subunit alpha -1.107059355 9.79E-08 
rpsK 30S ribosomal protein S11 -1.068119749 9.20E-09 
rpsM 30S ribosomal protein S13 -1.10204374 1.40E-09 
rpmJ 50S ribosomal protein L36 -1.049868208 9.20E-09 
infA translation initiation factor IF-1 -1.113733924 3.10E-08 
adk adenylate kinase -1.095316744 4.21E-07 
secY preprotein translocase subunit SecY -1.009486742 3.95E-06 
rplO 50S ribosomal protein L15 -1.181508109 8.11E-09 
rpmD 50S ribosomal protein L30 -1.357834476 3.84E-13 
rpsE 30S ribosomal protein S5 -1.247978323 6.96E-10 
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rplR 50S ribosomal protein L18 -1.277414475 4.23E-10 
rplF 50S ribosomal protein L6 -1.253036245 4.22E-10 
rpsH 30S ribosomal protein S8 -1.336877812 2.33E-11 
rpsN 30S ribosomal protein S14 -1.310708673 1.25E-11 
rplE 50S ribosomal protein L5 -1.200276055 1.92E-08 
rplX 50S ribosomal protein L24 -1.235568948 6.39E-10 
rplN 50S ribosomal protein L14 -1.200219593 3.02E-09 
rpsQ 30S ribosomal protein S17 -1.311074765 6.13E-12 
rpmC 50S ribosomal protein L29 -1.36996599 1.86E-14 
rplP 50S ribosomal protein L16 -1.20256782 2.41E-10 
rpsC 30S ribosomal protein S3 -1.199523864 1.23E-10 
rplV 50S ribosomal protein L22 -1.285426785 3.52E-13 
rpsS 30S ribosomal protein S19 -1.212528793 5.07E-12 
rplB 50S ribosomal protein L2 -1.117807376 2.19E-10 
rplW 50S ribosomal protein L23 -1.185874157 1.51E-13 
rplD 50S ribosomal protein L4 -1.173846005 6.29E-12 
rplC 50S ribosomal protein L3 -1.174326276 2.71E-11 
rpsJ 30S ribosomal protein S10 -1.205988948 8.40E-13 
NWMN_2154 hypothetical protein 1.098558799 2.11E-09 
NWMN_2185 iron compound ABC transporter iron compound-binding protein -1.266226727 8.38E-15 
ureA urease subunit gamma 1.190355813 0.000111179 
ureB urease subunit beta 1.315930624 1.32E-10 
ureC urease subunit alpha 1.050994038 2.66E-09 
sarY hypothetical protein -1.04458751 2.97E-09 
NWMN_2198 transcriptional regulator AraC family protein -1.312025809 2.20E-10 
NWMN_2199 secretory antigen precursor SsaA -1.00772592 2.68E-09 
NWMN_2200 Na+/H+ antiporter NhaC -2.297490383 3.02E-45 
NWMN_2201 Dehydrogenase family protein -2.610492379 2.46E-56 
NWMN_2209 hypothetical protein -1.005536816 1.19E-06 
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NWMN_2210 formate dehydrogenase-like protein -1.049464945 2.13E-07 
NWMN_2211 cell envelope-related transcriptional attenuator 1.197015331 9.53E-10 
NWMN_2213 DeoR family regulatory protein 1.010096884 1.06E-08 
NWMN_2223 hypothetical protein 1.820631329 1.07E-17 
NWMN_2246 sodium glutamate symporter -1.135844335 2.32E-12 
NWMN_2258 HTH-type transcriptional regulator TcaR -2.872159254 5.92E-77 
NWMN_2261 ABC transporter ATP-binding protein 1.623274146 1.12E-08 
NWMN_2262 hypothetical protein 1.626608109 1.46E-08 
NWMN_2265 hypothetical protein 2.561818936 2.09E-34 
NWMN_2266 hypothetical protein 2.58144146 4.70E-33 
NWMN_2279 PTS system sucrose-specific IIBC component -1.111842817 4.00E-07 
NWMN_2288 Probable nitrate transporter NarT -2.67261286 1.60E-28 
NWMN_2297 Nitrate reductase, alpha subunit -2.049841392 4.61E-12 
nirB assimilatory nitrite reductase large subunit -1.361887152 1.81E-12 
NWMN_2301 Nitrite reductase transcriptional regulator NirR -2.198425223 3.27E-26 
NWMN_2304 hypothetical protein -1.212103278 0.000344938 
NWMN_2306 Zn-binding lipoprotein adcA-like protein -2.321088679 3.42E-21 
NWMN_2317 immunoglobulin G-binding protein Sbi -3.799191913 8.01E-70 
NWMN_2318 Gamma-hemolysin component A -2.213278172 1.18E-22 
NWMN_2319 gamma-hemolysin component C -1.831420259 1.03E-12 
NWMN_2320 gamma hemolysin component B -1.57392231 2.29E-12 
NWMN_2331 glycerate kinase 1.724823745 9.96E-21 
NWMN_2332 hypothetical protein 1.968987394 4.44E-28 
opp1A oligopeptide permease peptide-binding protein -1.42179085 6.43E-15 
NWMN_2365 hypothetical protein -1.131850385 2.24E-09 
NWMN_2366 hypothetical protein -1.572910656 3.70E-13 
NWMN_2367 hypothetical protein -1.716943302 1.04E-19 
NWMN_2368 hypothetical protein -1.118549557 7.63E-06 
NWMN_2369 short chain dehydrogenase -1.01859753 7.26E-05 
256 
 
NWMN_2377 hypothetical protein -2.436987013 2.11E-19 
NWMN_2396 C-terminal part of fibronectin binding protein B -1.614585231 3.68E-10 
NWMN_2397 fibronectin binding protein B precursor -1.657734574 3.96E-13 
NWMN_2398 C-terminal part of fibronectin binding protein A -3.285334963 5.69E-67 
NWMN_2399 fibronectin binding protein A -3.475875538 1.55E-66 
NWMN_2405 hypothetical protein 1.081733235 4.57E-05 
NWMN_2412 ABC transporter, ATP-binding protein -2.735192865 4.44E-42 
NWMN_2413 hypothetical protein -2.647995265 5.51E-32 
NWMN_2427 acetyltransferase GNAT family protein -1.005816665 5.07E-08 
NWMN_2432 hypothetical protein 2.174951327 2.85E-26 
NWMN_2435 hypothetical protein 1.179182534 1.10E-09 
NWMN_2436 hypothetical protein 1.022013415 2.60E-06 
NWMN_2437 PTS system glucose-specific IIABC component -1.492122527 4.49E-13 
NWMN_2440 Holin-like protein CidA 2.008012308 1.54E-11 
NWMN_2448 ATP-dependent Clp protease, ATP-binding subunit ClpC -3.128756663 1.87E-21 
NWMN_2456 hypothetical protein 2.74672761 1.28E-14 
NWMN_2457 cation-transporting ATPase E1-E2 family protein 1.279479547 1.94E-14 
crtN squalene synthase -1.153962727 1.80E-05 
crtM squalene desaturase -1.322452314 1.25E-06 
NWMN_2463 glycosyl transferase group 2 family protein -1.571953608 3.13E-09 
crtI phytoene dehydrogenase -1.742897474 5.04E-11 
NWMN_2465 hypothetical protein -1.530638256 3.01E-10 
oatA secretory antigen precursor SsaA-like protein -1.122243452 2.02E-09 
NWMN_2467 O-acetyltransferase OatA -1.222191599 3.38E-16 
NWMN_2468 acetyltransferase GNAT family protein -1.068380394 8.18E-09 
NWMN_2490 hypothetical protein -1.039647757 5.92E-10 
NWMN_2502 hypothetical protein -1.252768586 2.24E-05 
NWMN_2510 glycine betaine aldehyde dehydrogenase 1.204437707 9.51E-10 
NWMN_2526 Alkaline phosphatase III 2.021360086 2.26E-18 
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clfB clumping factor B precursor -1.560401321 8.31E-13 
NWMN_2557 hypothetical protein -1.31060434 4.56E-07 
icaD intercellular adhesion protein IcaD 1.428958075 1.56E-05 
icaB intercellular adhesion protein B 1.573773696 6.46E-15 
lip 
bifunctional phosphoribosyl-AMP cyclohydrolase%2Fphosphoribosyl-ATP 
pyrophosphatase 
-1.808216671 2.97E-05 
hisF imidazole glycerol phosphate synthase subunit HisF 1.190622588 5.43E-10 
hisA methylideneamino imidazole-4-carboxamide isomerase 1.394713689 2.72E-08 
hisH imidazole glycerol phosphate synthase subunit HisH 1.535563553 1.43E-06 
hisB imidazoleglycerol-phosphate dehydratase 1.371104273 2.50E-05 
hisC histidinol-phosphate aminotransferase 1.542184524 3.36E-07 
hisD histidinol dehydrogenase 1.240750366 5.63E-05 
hisG ATP phosphoribosyltransferase catalytic subunit 1.088651906 0.000139343 
NWMN_2583 hypothetical protein 1.024945094 7.95E-08 
NWMN_2585 hypothetical protein -1.024637938 1.16E-08 
drp35 Drp35 1.066329774 1.70E-09 
NWMN_2591 hypothetical protein -1.172907571 3.37E-06 
NWMN_2594 hypothetical protein -1.096421507 5.39E-05 
NWMN_2596 N-acetyltransferase family protein 1.142029634 2.17E-07 
cspB cold shock protein CspB -1.531322997 9.20E-14 
NWMN_rRNA02 23S ribosomal RNA -1.191931394 0.007998508 
NWMN_rRNA06 23S ribosomal RNA -0.99524501 0.007037498 
NWMN_rRNA09 23S ribosomal RNA -1.055679329 0.005943289 
NWMN_rRNA10 16S ribosomal RNA -1.062979861 0.015573742 
NWMN_rRNA15 23S ribosomal RNA -1.352823151 0.000482589 
NWMN_tRNA31 tRNA-Thr -1.048489916 0.038451718 
NWMN_tRNA48 tRNA-Ile 1.203381512 0.024067815 
NWMN_tRNA49 tRNA-Gly 1.272918022 0.00038476 
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Appendix Table 2 DE genes of S. epidermidis Tü3298 in response to 5μM D-sphingosine challenge. The level of fold change (logFC) is based on log2, DE genes 
shown in this table all have more than 2 fold changes. All DE genes have FDR (false discovery rate) ≤ 0.05. 
Gene Gene Description logFC FDR 
SETU_00282 secretory antigen SsaA-like protein -2.766344 9.52E-21 
SETU_00070 autolysin (N-acetylmuramoyl-L-alanine amidase -2.745374 1.92E-15 
SETU_00328 lipoprotein -2.700149 0.0014474 
SETU_00327 DoxX family protein -2.563634 0.000945 
SETU_00770 uracil permease -2.454206 5.63E-17 
SETU_01975 secretory antigen SsaA -2.42695 5.82E-15 
SETU_00326 response regulator -2.365861 0.0008135 
SETU_00325 histidine protein kinase -2.270405 0.0019363 
isaA immunodominant antigen A -2.119102 9.83E-06 
SETU_02228 Putative protein-S-isoprenylcysteine methyltransferase -2.110793 1.93E-07 
SETU_00646 N-acetylmuramoyl-L-alanine amidase -2.017126 3.98E-06 
SETU_01355 tRNA-Met -1.958448 1.99E-08 
SETU_01990 ssaA protein -1.912753 0.0005422 
SETU_00316 hypothetical protein -1.725449 9.83E-06 
SETU_00059 hypothetical protein -1.671056 1.93E-07 
SETU_02363 hypothetical protein -1.636509 4.97E-05 
SETU_01252 hypothetical protein -1.576558 7.50E-05 
SETU_02365 Bacitracin transport ATP-binding protein bcrA -1.5743 9.87E-05 
SETU_01757 secretory antigen SsaA -1.485684 0.0269249 
SETU_02085 zinc metalloproteinase aureolysin -1.477159 0.0173582 
SETU_02088 putative lipoprotein -1.47197 0.0020868 
pyrB aspartate carbamoyltransferase -1.463435 3.91E-07 
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SETU_01913 poly (glycerol-phosphate) alpha-glucosyltransferase -1.450237 1.38E-05 
SETU_02205 ABC-2 family transporter protein -1.445553 0.0019363 
SETU_01891 amino acid transporter -1.442578 0.0041218 
SETU_02364 lantibiotic ABC transporter permease -1.422004 0.0007582 
SETU_00024 1,4-beta-N-acetylmuramidase -1.393849 2.76E-05 
SETU_00769 bifunctional pyrimidine regulatory protein PyrR uracil phosphoribosyltransferase -1.379989 8.77E-07 
SETU_01548 tRNA-Leu -1.338624 0.0189738 
SETU_00200 major facilitator family transporter -1.333518 0.0001229 
SETU_02356 Lipid A export ATP-binding/permease MsbA -1.327345 0.0001386 
SETU_01758 SMR-type multidrug efflux transporter -1.306716 0.0002002 
SETU_00272 membrane protein , putative -1.269019 0.0003958 
dltX D-Ala-teichoic acid biosynthesis protein -1.240581 0.0004152 
SETU_02328 hypothetical protein -1.231758 9.28E-05 
SETU_02126 chloramphenicol resistance protein YfhI -1.198924 0.0007701 
infC translation initiation factor IF-3 -1.173646 0.0163621 
SETU_00588 tRNA-Ser -1.1596 0.0248624 
SETU_02341 BsaG protein -1.134193 0.0193139 
SETU_01410 tRNA-Met -1.123722 0.0054929 
rpsD 30S ribosomal protein S4 -1.120808 0.0127396 
SETU_00818 DNA processing Smf protein -1.119019 0.0007701 
rpmI 50S ribosomal protein L35 -1.11505 0.005143 
SETU_00184 Ser-Asp rich fibrinogen-binding, bone sialoprotein-binding protein -1.11254 0.0178877 
SETU_00479 D-alanine--poly(phosphoribitol) ligase subunit 1 -1.097967 0.0277311 
SETU_00029 Transglycosylase associated protein -1.092515 0.0061164 
SETU_01417 tRNA-Ala -1.090776 0.0382581 
SETU_02000 hypothetical protein -1.090436 0.0014996 
SETU_00208 cationic amino acid transporter -1.082609 0.0038271 
SETU_00484 YuzD-like protein -1.076474 0.0146863 
260 
 
SETU_02125 chloramphenicol resistance protein YfhI -1.07263 0.0020864 
SETU_00065 cysteine synthase -1.069987 0.0006181 
SETU_01759 SMR-type multidrug efflux transporter -1.069949 0.0059512 
SETU_00180 deoxypurine kinase -1.060803 0.0002456 
SETU_00925 Large-conductance mechanosensitive channel -1.051639 0.0005432 
SETU_00066 cystathionine gamma-synthase -1.046057 0.0007701 
SETU_01562 ATP-dependent RNA helicase -1.040834 0.0275823 
SETU_01796 DNA-3-methyladenine glycosidase -1.031015 0.0016685 
SETU_00949 ThiJ/PfpI family protein -1.029363 0.0013731 
SETU_01182 caffeoyl-CoA O-methyltransferase -1.027307 0.0005918 
SETU_00067 ABC transporter ATP-binding protein -1.021485 0.0006318 
SETU_02300 Yip1 domain protein -1.00819 0.0039897 
SETU_02264 rRNA large subunit methyltransferase -1.006811 0.0193102 
rplT 50S ribosomal protein L20 -1.002624 0.0100317 
SETU_00424 pathogenicity island protein 1.000794 0.0019516 
SETU_01812 transcriptional regulator 1.0042174 0.0376976 
SETU_02171 dihydroxyacetone kinase subunit DhaK 1.0099166 0.0174084 
SETU_01869 glycerate kinase 1.0152654 0.0112845 
prmA ribosomal protein L11 methyltransferase 1.0163692 0.0247033 
SETU_02045 transcriptional regulator 1.0170919 0.0209625 
SETU_02032 anaerobic ribonucleotide reductase activator protein 1.0180451 0.001756 
SETU_02098 general stress protein 170 1.0195758 0.0106694 
SETU_00528 oligopeptide transport system permease OppC 1.0262721 0.0072479 
SETU_02277 homoserine-o-acetyltransferase 1.0288517 0.0173582 
SETU_00905 homoserine dehydrogenase 1.0484057 0.023533 
SETU_02313 hypothetical protein 1.0608674 0.0008068 
SETU_02092 BigG family transcription antiterminator 1.0631818 0.0196826 
SETU_01536 dihydroxy-acid dehydratase 1.076099 0.029984 
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SETU_01816 Integral membrane protein 1.0779834 0.0250961 
SETU_01152 molecular chaperone DnaJ 1.0874792 0.025926 
SETU_00256 lipoprotein 1.0977566 0.0002391 
SETU_00919 hypothetical protein 1.1014148 0.0427906 
SETU_01383 truncated transposase 1.1069847 0.0250961 
SETU_02315 hypothetical protein 1.1138931 0.0003761 
SETU_02083 arginine deiminase 1.1230474 0.0001039 
SETU_01284 OsmC/Ohr family protein 1.1238116 0.0106694 
SETU_01217 hypothetical protein 1.1265468 0.0209178 
SETU_00491 ComA2 family protein 1.1305507 0.0042598 
SETU_02082 ornithine carbamoyltransferase 1.1493931 6.46E-05 
SETU_02143 hypothetical protein 1.1550498 0.0175604 
SETU_00536 thimet oligopeptidase-like protein 1.1575587 0.0066944 
SETU_00034 alkyl hydroperoxide reductase 1.1800357 0.0379135 
SETU_00240 hypothetical protein 1.1818292 0.0022418 
SETU_01841 NAD(P)H-flavin oxidoreductase 1.1956332 0.0009582 
SETU_00960 negative regulator PhoU 1.1980143 0.0002269 
SETU_02169 phosphotransferase mannnose-specific family component IIA 1.2077496 0.0023493 
SETU_00530 oppF protein 1.2266035 0.0013016 
SETU_00981 5-bromo-4-chloroindolyl phosphate hydrolysis protein XpaC 1.2362432 0.0002391 
SETU_00035 alkyl hydroperoxide reductase 1.2478581 0.0112845 
SETU_00490 Na+/H+ antiporter family protein 1.2523068 0.0011667 
SETU_00982 tellurite resistance protein 1.2610599 0.000214 
SETU_00529 oligopeptide transport ATP-binding protein subunit 1.2729135 0.0007701 
SETU_02170 DAK2 domain-containing protein 1.2774838 0.0007701 
SETU_01288 PTS system N-acetylglucosamine-specific transporter subunit IIBC 1.2811474 9.83E-06 
SETU_01510 helix-turn-helix protein 1.2863653 0.0158079 
SETU_02314 hypothetical protein 1.2879183 0.0105871 
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SETU_01765 truncated transposase 1.294459 0.0173582 
SETU_01874 amino acid ABC transporter-like protein 1.2956636 7.26E-05 
SETU_01987 mercuric ion-binding protein 1.3097681 0.0019363 
SETU_00260 hypothetical protein 1.3112926 0.0045939 
SETU_01768 DeoR family transcriptional regulator 1.3322159 7.26E-05 
SETU_00058 hypothetical protein 1.3450016 1.95E-05 
SETU_00958 hypothetical protein 1.3587182 0.0197906 
SETU_00306 ABC transporter 1.3696359 0.0004788 
SETU_00889 hypothetical protein 1.3984545 0.028688 
SETU_01779 hypothetical protein 1.4044045 0.0146375 
SETU_00305 ABC transporter ATP-binding protein 1.4110045 0.00036 
SETU_01870 hypothetical protein 1.4198953 0.0005614 
dnaK molecular chaperone DnaK 1.4522594 0.0373415 
SETU_01080 alpha-D-1,4-glucosidase 1.4531116 8.77E-07 
SETU_01537 acetolactate synthase large subunit 1.4761263 0.0033671 
SETU_00963 phosphate ABC transporter 1.476965 4.97E-05 
SETU_01499 hypothetical protein 1.4946781 6.94E-06 
SETU_01509 DNA binding domain, excisionase family 1.5171883 0.001168 
SETU_00964 thioredoxine reductase 1.5402013 4.35E-05 
SETU_01498 terminase, superantigen-encoding pathogenicity islands SaPI 1.5550301 3.91E-07 
SETU_00962 phosphate ABC transporter 1.5573509 1.80E-06 
SETU_00989 dihydrolipoamide succinyltransferase 1.5741056 3.82E-07 
SETU_01544 threonine dehydratase 1.5820314 0.0035379 
SETU_02028 glycine betaine aldehyde dehydrogenase gbsA 1.5868653 0.0026235 
SETU_01917 gluconokinase 1.596315 3.45E-05 
SETU_00313 hypothetical protein 1.6023287 0.03631 
SETU_00229 alcohol dehydrogenase 1.6059174 0.0015641 
SETU_00907 homoserine kinase 1.6172107 9.87E-05 
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argG argininosuccinate synthase 1.6318571 0.0379135 
sucA 2-oxoglutarate dehydrogenase E1 1.6332072 7.15E-07 
SETU_00508 argininosuccinate lyase 1.6338 7.26E-05 
clpP ATP-dependent Clp protease proteolytic subunit 1.6345418 0.0032636 
SETU_01513 molecular chaperone GroEL 1.648903 0.0014513 
SETU_01507 pathogenicity island protein 1.6606976 0.0373415 
SETU_01957 ribose transporter RbsU 1.6657941 0.022299 
SETU_00682 cytochrome d ubiquinol oxidase subunit II-like protein 1.6678448 0.0004352 
SETU_00961 phosphate transporter ATP-binding protein 1.6684012 1.02E-07 
SETU_01154 heat shock protein GrpE 1.6923175 0.0010796 
SETU_01955 ribokinase 1.6956079 0.0086072 
SETU_02027 choline dehydrogenase 1.7035408 0.0006958 
SETU_01332 truncated transposase 1.7233683 0.00455 
SETU_01155 heat-inducible transcriptional repressor 1.7513007 0.0015641 
groES co-chaperonin GroES 1.7520444 8.47E-05 
SETU_01340 phosphoenolpyruvate carboxykinase 1.7682791 0.000214 
SETU_00903 hypothetical protein 1.7998051 2.25E-07 
SETU_00673 myosin-cross-reactive antigen 1.8175857 5.64E-07 
SETU_01500 pathogenicity island protein 1.8334579 1.02E-10 
SETU_01542 isopropylmalate isomerase large subunit 1.8388232 0.0009552 
SETU_01956 D-ribose pyranase 1.8475002 0.0158079 
SETU_00681 cytochrome d ubiquinol oxidase subunit 1-like protein 1.8551069 1.20E-05 
SETU_02128 triacylglycerol lipase 1.8974766 1.57E-05 
SETU_00906 threonine synthase 1.9049743 1.35E-05 
SETU_01367 protein export protein PrsA 1.9136543 0.0022179 
SETU_00036 2-oxo-hepta-3-ene-1,7-dioate hydratase 1.9171705 0.0009479 
SETU_02093 PTS system fructose-specific transporter subunit II 1.9371593 0.0214056 
SETU_00230 hypothetical protein 1.9467513 4.63E-05 
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SETU_02090 acetoin reductase 1.9483192 0.0495542 
lacG 6-phospho-beta-galactosidase 1.9697998 1.79E-12 
SETU_00375 ribosomal subunit interface protein 1.9973614 3.61E-07 
hisG ATP phosphoribosyltransferase 2.0198135 0.0001726 
hisZ ATP phosphoribosyltransferase 2.058193 0.0007701 
SETU_01538 acetolactate synthase 1 regulatory subunit 2.0591401 0.0086072 
leuD isopropylmalate isomerase small subunit 2.0828724 5.02E-05 
SETU_01541 3-isopropylmalate dehydrogenase 2.1064437 0.0001229 
SETU_01540 2-isopropylmalate synthase 2.1524792 8.47E-05 
SETU_00057 putative transmembrane protein coupled to NADH-ubiquinone oxidoreductase chain 5 2.1574002 9.27E-09 
isaB immunodominant antigen B 2.1661333 3.12E-09 
SETU_01671 galactose-6-phosphate isomerase subunit LacA 2.1670123 8.93E-13 
SETU_01667 PTS system lactose-specific transporter subunit IIA 2.2158786 8.93E-13 
SETU_00056 NADH dehydrogenase subunit 5 2.2424426 1.27E-12 
lacE PTS system lactose-specific transporter subunit IIBC 2.2521456 6.55E-15 
SETU_00318 transcription repressor of fructose operon 2.291817 0.004395 
SETU_01539 ketol-acid reductoisomerase 2.2982236 4.63E-05 
SETU_01321 proline dehydrogenase 2.3786778 1.25E-15 
SETU_00674 myosin-cross-reactive antigen 2.3993088 1.07E-18 
SETU_01444 hypothetical protein 2.4299707 6.37E-05 
SETU_01670 galactose-6-phosphate isomerase subunit LacB 2.4367947 6.16E-16 
SETU_02150 branched-chain alpha-keto acid dehydrogenase subunit E2 2.4839392 7.22E-15 
clpC endopeptidase Clp ATP-binding subunit C 2.4970218 0.0005794 
SETU_00142 ATP:guanido phosphotransferase 2.5729024 1.62E-05 
SETU_00320 PTS system fructose-specific transporter subunit IIABC 2.5857933 0.000319 
SETU_00140 CtsR family transcriptional regulator 2.5957483 1.39E-05 
SETU_00319 fructose 1-phosphate kinase 2.5995257 0.000702 
SETU_00141 UvrB/UvrC domain-containing protein 2.6018225 1.24E-05 
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SETU_01669 tagatose-6-phosphate kinase 2.6019058 6.83E-20 
SETU_01646 hypothetical protein 2.6274864 1.52E-18 
SETU_01443 transporter associated with VraSR 2.6802737 1.03E-05 
SETU_01668 tagatose 1,6-diphosphate aldolase 2.7019562 6.01E-22 
vraR DNA-binding response regulator VraR 2.7195307 7.66E-06 
SETU_01442 two-component sensor histidine kinase 2.7333151 6.94E-06 
SETU_01983 1-pyrroline-5-carboxylate dehydrogenase 2.7343595 2.90E-22 
SETU_00784 TM2 domain-containing protein 2.7418357 9.83E-06 
SETU_01290 heat-shock protein htrA 2.9920056 4.69E-05 
SETU_02151 branched-chain alpha-keto acid dehydrogenase E1 3.0080045 7.34E-18 
SETU_00522 clpB protein 3.0795585 2.46E-06 
SETU_02153 dihydrolipoamide dehydrogenase 3.2950081 1.22E-27 
SETU_02152 branched-chain alpha-keto acid dehydrogenase E1 3.3326028 2.70E-21 
SETU_01986 copper-transporting ATPase copA （also in Jo's sapi data） 3.6535435 1.17E-07 
pfl formate acetyltransferase 3.6927207 0.0106694 
SETU_01218 hypothetical protein 3.7918843 4.87E-06 
SETU_01985 hypothetical protein (ortholog to NWMN_2456 ?) 4.1056359 3.00E-06 
pflA pyruvate formate-lyase-activating enzyme 4.573273 0.0006202 
SETU_00201 hypothetical protein 5.6249376 2.57E-09 
 
 
 
 
